Background  ||| S:24 E:43 ||| NNP
Chemokines  ||| S:43 E:54 ||| NNPS
are  ||| S:54 E:58 ||| VBP
small ||| S:58 E:63 ||| JJ
,  ||| S:63 E:65 ||| ,
positively  ||| S:65 E:76 ||| RB
charged ||| S:76 E:83 ||| VBN
,  ||| S:83 E:85 ||| ,
secreted  ||| S:85 E:102 ||| JJ
proteins  ||| S:102 E:111 ||| NNS
that  ||| S:111 E:116 ||| WDT
consist  ||| S:116 E:124 ||| VBP
of  ||| S:124 E:127 ||| IN
an  ||| S:127 E:130 ||| DT
N-terminal  ||| S:130 E:141 ||| JJ
region  ||| S:141 E:148 ||| NN
of  ||| S:148 E:151 ||| IN
variable  ||| S:151 E:168 ||| JJ
conformation ||| S:168 E:180 ||| NN
,  ||| S:180 E:182 ||| ,
three  ||| S:182 E:188 ||| CD
antiparallel  ||| S:188 E:201 ||| CD
beta-pleated  ||| S:201 E:214 ||| JJ
sheets  ||| S:214 E:229 ||| NNS
connected  ||| S:229 E:239 ||| VBN
by  ||| S:239 E:242 ||| IN
loops ||| S:242 E:247 ||| NNS
,  ||| S:247 E:249 ||| ,
and  ||| S:249 E:253 ||| CC
a  ||| S:253 E:255 ||| DT
C-terminal  ||| S:255 E:266 ||| JJ
alpha  ||| S:266 E:272 ||| NN
helix  ||| S:272 E:278 ||| NNS
[  ||| S:278 E:280 ||| -LRB-
1  ||| S:280 E:282 ||| LS
]  ||| S:282 E:284 ||| -RRB-
.  ||| S:284 E:294 ||| .
These  ||| S:294 E:300 ||| DT
proteins  ||| S:300 E:309 ||| NNS
are  ||| S:309 E:313 ||| VBP
multifunctional ||| S:313 E:328 ||| VBN
,  ||| S:328 E:330 ||| ,
with  ||| S:330 E:335 ||| IN
different  ||| S:335 E:345 ||| JJ
regions  ||| S:345 E:361 ||| NNS
of  ||| S:361 E:364 ||| IN
the  ||| S:364 E:368 ||| DT
molecules ||| S:368 E:377 ||| NN
,  ||| S:377 E:379 ||| ,
in  ||| S:379 E:382 ||| IN
particular  ||| S:382 E:393 ||| JJ
the  ||| S:393 E:397 ||| DT
N-  ||| S:397 E:400 ||| JJ
and  ||| S:400 E:404 ||| CC
C-termini ||| S:404 E:413 ||| JJ
,  ||| S:413 E:423 ||| ,
performing  ||| S:423 E:434 ||| VBG
specific  ||| S:434 E:443 ||| JJ
functions  ||| S:443 E:453 ||| NNS
[ ||| S:453 E:454 ||| -LRB-
e.g.  ||| S:454 E:459 ||| NNP
[  ||| S:459 E:461 ||| -LRB-
1  ||| S:461 E:463 ||| CD
2  ||| S:463 E:465 ||| CD
3  ||| S:465 E:467 ||| CD
4  ||| S:467 E:469 ||| CD
]  ||| S:469 E:471 ||| CD
] ||| S:471 E:472 ||| -RRB-
.  ||| S:472 E:482 ||| .
Chemokines  ||| S:482 E:493 ||| NNS
are  ||| S:493 E:497 ||| VBP
best  ||| S:497 E:502 ||| RB
known  ||| S:502 E:508 ||| VBN
for  ||| S:508 E:512 ||| IN
their  ||| S:512 E:518 ||| PRP$
functions  ||| S:518 E:528 ||| NNS
in  ||| S:528 E:539 ||| IN
attracting  ||| S:539 E:550 ||| VBG
and  ||| S:550 E:554 ||| CC
activating  ||| S:554 E:565 ||| JJ
leukocytes ||| S:565 E:575 ||| NN
.  ||| S:575 E:577 ||| .
Shortly  ||| S:577 E:585 ||| RB
after  ||| S:585 E:591 ||| IN
injury ||| S:591 E:597 ||| NN
,  ||| S:597 E:607 ||| ,
these  ||| S:607 E:613 ||| DT
small  ||| S:613 E:619 ||| JJ
cytokines  ||| S:619 E:629 ||| NNS
are  ||| S:629 E:633 ||| VBP
primarily  ||| S:633 E:643 ||| RB
produced  ||| S:643 E:652 ||| VBN
by  ||| S:652 E:663 ||| IN
fibroblasts ||| S:663 E:674 ||| NN
,  ||| S:674 E:676 ||| ,
chemoattract  ||| S:676 E:689 ||| JJ
leukocytes  ||| S:689 E:700 ||| NN
and  ||| S:700 E:704 ||| CC
activate  ||| S:704 E:713 ||| VBP
their  ||| S:713 E:727 ||| PRP$
integrins  ||| S:727 E:737 ||| NN
causing  ||| S:737 E:745 ||| VBG
them  ||| S:745 E:750 ||| PRP
to  ||| S:750 E:753 ||| TO
adhere  ||| S:753 E:760 ||| VB
strongly  ||| S:760 E:769 ||| RB
to  ||| S:769 E:772 ||| TO
the  ||| S:772 E:784 ||| DT
endothelial  ||| S:784 E:796 ||| JJ
cells  ||| S:796 E:802 ||| NNS
as  ||| S:802 E:805 ||| IN
a  ||| S:805 E:807 ||| DT
prelude  ||| S:807 E:815 ||| NN
to  ||| S:815 E:818 ||| TO
their  ||| S:818 E:824 ||| PRP$
migration  ||| S:824 E:834 ||| NN
through  ||| S:834 E:850 ||| IN
the  ||| S:850 E:854 ||| DT
blood  ||| S:854 E:860 ||| NN
vessel  ||| S:860 E:867 ||| NN
wall  ||| S:867 E:872 ||| NN
to  ||| S:872 E:875 ||| TO
the  ||| S:875 E:879 ||| DT
underlying  ||| S:879 E:890 ||| JJ
tissue  ||| S:890 E:897 ||| NN
and  ||| S:897 E:901 ||| CC
towards  ||| S:901 E:917 ||| IN
the  ||| S:917 E:921 ||| DT
source  ||| S:921 E:928 ||| NN
of  ||| S:928 E:931 ||| IN
the  ||| S:931 E:935 ||| DT
chemokine  ||| S:935 E:945 ||| NN
[  ||| S:945 E:947 ||| -LRB-
5  ||| S:947 E:949 ||| LS
]  ||| S:949 E:951 ||| -RRB-
.  ||| S:951 E:953 ||| .
In  ||| S:953 E:956 ||| IN
addition  ||| S:956 E:965 ||| NN
to  ||| S:965 E:968 ||| TO
these  ||| S:968 E:982 ||| DT
functions  ||| S:982 E:992 ||| NNS
during  ||| S:992 E:999 ||| IN
the  ||| S:999 E:1003 ||| DT
early  ||| S:1003 E:1009 ||| JJ
stages  ||| S:1009 E:1016 ||| NNS
of  ||| S:1016 E:1019 ||| IN
wound  ||| S:1019 E:1025 ||| JJ
healing ||| S:1025 E:1032 ||| NN
,  ||| S:1032 E:1034 ||| ,
these  ||| S:1034 E:1048 ||| DT
small  ||| S:1048 E:1054 ||| JJ
cytokines  ||| S:1054 E:1064 ||| NNS
are  ||| S:1064 E:1068 ||| VBP
also  ||| S:1068 E:1073 ||| RB
known  ||| S:1073 E:1079 ||| VBN
to  ||| S:1079 E:1082 ||| TO
be  ||| S:1082 E:1085 ||| VB
involved  ||| S:1085 E:1094 ||| VBN
in  ||| S:1094 E:1105 ||| IN
re-epithelialization ||| S:1105 E:1125 ||| NNP
,  ||| S:1125 E:1127 ||| ,
angiogenesis  ||| S:1127 E:1140 ||| NN
and  ||| S:1140 E:1144 ||| CC
granulation  ||| S:1144 E:1156 ||| JJ
tissue  ||| S:1156 E:1171 ||| NN
development  ||| S:1171 E:1183 ||| NN
[  ||| S:1183 E:1185 ||| -LRB-
3  ||| S:1185 E:1187 ||| CD
6  ||| S:1187 E:1189 ||| CD
7  ||| S:1189 E:1191 ||| CD
8  ||| S:1191 E:1193 ||| CD
]  ||| S:1193 E:1195 ||| -RRB-
,  ||| S:1195 E:1197 ||| ,
processes  ||| S:1197 E:1207 ||| NNS
that  ||| S:1207 E:1212 ||| WDT
are  ||| S:1212 E:1216 ||| VBP
critical  ||| S:1216 E:1225 ||| JJ
for  ||| S:1225 E:1237 ||| IN
proper  ||| S:1237 E:1244 ||| JJ
healing ||| S:1244 E:1251 ||| NN
.  ||| S:1251 E:1261 ||| .
The  ||| S:1261 E:1265 ||| DT
first  ||| S:1265 E:1271 ||| JJ
evidence  ||| S:1271 E:1280 ||| NN
that  ||| S:1280 E:1285 ||| IN
chemokines  ||| S:1285 E:1296 ||| NNS
are  ||| S:1296 E:1300 ||| VBP
associated  ||| S:1300 E:1311 ||| VBN
with  ||| S:1311 E:1324 ||| IN
wound  ||| S:1324 E:1330 ||| JJ
healing  ||| S:1330 E:1347 ||| NN
in  ||| S:1347 E:1350 ||| IN
vivo  ||| S:1350 E:1355 ||| NN
was  ||| S:1355 E:1359 ||| VBD
reported  ||| S:1359 E:1368 ||| VBN
in  ||| S:1368 E:1371 ||| IN
1990  ||| S:1371 E:1376 ||| CD
using  ||| S:1376 E:1390 ||| VBG
the  ||| S:1390 E:1394 ||| DT
chemokine  ||| S:1394 E:1404 ||| JJ
cCAF  ||| S:1404 E:1409 ||| NN
( ||| S:1409 E:1410 ||| -LRB-
chicken  ||| S:1410 E:1418 ||| NN
Chemotactic  ||| S:1418 E:1430 ||| NNP
and  ||| S:1430 E:1434 ||| CC
Angiogenic  ||| S:1434 E:1453 ||| NNP
Factor ||| S:1453 E:1459 ||| NNP
;  ||| S:1459 E:1461 ||| :
the  ||| S:1461 E:1465 ||| DT
product  ||| S:1465 E:1473 ||| NN
of  ||| S:1473 E:1476 ||| IN
the  ||| S:1476 E:1480 ||| DT
9E3  ||| S:1480 E:1484 ||| JJ
gene ||| S:1484 E:1488 ||| NN
) ||| S:1488 E:1489 ||| -RRB-
,  ||| S:1489 E:1491 ||| ,
a  ||| S:1491 E:1493 ||| DT
CXC  ||| S:1493 E:1497 ||| NNP
chemokine  ||| S:1497 E:1507 ||| NN
that  ||| S:1507 E:1520 ||| WDT
is  ||| S:1520 E:1523 ||| VBZ
now  ||| S:1523 E:1527 ||| RB
known  ||| S:1527 E:1533 ||| VBN
to  ||| S:1533 E:1536 ||| TO
be  ||| S:1536 E:1539 ||| VB
the  ||| S:1539 E:1543 ||| DT
ortologue  ||| S:1543 E:1553 ||| NN
for  ||| S:1553 E:1557 ||| IN
human  ||| S:1557 E:1563 ||| JJ
IL-8  ||| S:1563 E:1568 ||| NNP
[  ||| S:1568 E:1570 ||| -LRB-
9  ||| S:1570 E:1572 ||| CD
]  ||| S:1572 E:1574 ||| -RRB-
.  ||| S:1574 E:1584 ||| .
cCAF  ||| S:1584 E:1589 ||| SYM
is  ||| S:1589 E:1592 ||| VBZ
expressed  ||| S:1592 E:1602 ||| VBN
to  ||| S:1602 E:1605 ||| TO
high  ||| S:1605 E:1610 ||| JJ
levels  ||| S:1610 E:1617 ||| NNS
very  ||| S:1617 E:1622 ||| RB
shortly  ||| S:1622 E:1630 ||| RB
after  ||| S:1630 E:1644 ||| IN
wounding  ||| S:1644 E:1653 ||| NN
and  ||| S:1653 E:1657 ||| CC
during  ||| S:1657 E:1664 ||| IN
the  ||| S:1664 E:1668 ||| DT
first  ||| S:1668 E:1674 ||| JJ
24-48  ||| S:1674 E:1680 ||| CD
hours  ||| S:1680 E:1686 ||| NNS
after  ||| S:1686 E:1692 ||| IN
injury ||| S:1692 E:1698 ||| NN
,  ||| S:1698 E:1700 ||| ,
and  ||| S:1700 E:1712 ||| CC
remains  ||| S:1712 E:1720 ||| VBZ
elevated  ||| S:1720 E:1729 ||| VBN
for  ||| S:1729 E:1733 ||| IN
at  ||| S:1733 E:1736 ||| IN
least  ||| S:1736 E:1742 ||| JJS
16  ||| S:1742 E:1745 ||| CD
days  ||| S:1745 E:1750 ||| NNS
after  ||| S:1750 E:1756 ||| IN
wounding  ||| S:1756 E:1765 ||| NNS
[  ||| S:1765 E:1767 ||| -LRB-
6  ||| S:1767 E:1769 ||| CD
10  ||| S:1769 E:1780 ||| CD
]  ||| S:1780 E:1782 ||| -RRB-
.  ||| S:1782 E:1784 ||| .
It  ||| S:1784 E:1787 ||| PRP
is  ||| S:1787 E:1790 ||| VBZ
primarily  ||| S:1790 E:1800 ||| RB
expressed  ||| S:1800 E:1810 ||| VBN
by  ||| S:1810 E:1813 ||| IN
the  ||| S:1813 E:1817 ||| DT
fibroblasts  ||| S:1817 E:1829 ||| NN
of  ||| S:1829 E:1832 ||| IN
the  ||| S:1832 E:1844 ||| DT
granulation  ||| S:1844 E:1856 ||| JJ
tissue ||| S:1856 E:1862 ||| NN
,  ||| S:1862 E:1864 ||| ,
especially  ||| S:1864 E:1875 ||| RB
where  ||| S:1875 E:1881 ||| WRB
interstitial  ||| S:1881 E:1894 ||| JJ
collagen  ||| S:1894 E:1911 ||| NN
( ||| S:1911 E:1912 ||| -LRB-
Coll ||| S:1912 E:1916 ||| NNP
)  ||| S:1916 E:1918 ||| -RRB-
is  ||| S:1918 E:1921 ||| VBZ
abundant ||| S:1921 E:1929 ||| JJ
,  ||| S:1929 E:1931 ||| ,
but  ||| S:1931 E:1935 ||| CC
the  ||| S:1935 E:1939 ||| DT
levels  ||| S:1939 E:1946 ||| NNS
are  ||| S:1946 E:1950 ||| VBP
also  ||| S:1950 E:1955 ||| RB
high  ||| S:1955 E:1960 ||| JJ
in  ||| S:1960 E:1963 ||| IN
the  ||| S:1963 E:1975 ||| DT
endothelial  ||| S:1975 E:1987 ||| JJ
cells  ||| S:1987 E:1993 ||| NNS
of  ||| S:1993 E:1996 ||| IN
the  ||| S:1996 E:2000 ||| DT
microvessels ||| S:2000 E:2012 ||| NN
,  ||| S:2012 E:2014 ||| ,
in  ||| S:2014 E:2017 ||| IN
the  ||| S:2017 E:2021 ||| DT
healing  ||| S:2021 E:2037 ||| NN
epidermis  ||| S:2037 E:2047 ||| NNS
and  ||| S:2047 E:2051 ||| CC
in  ||| S:2051 E:2054 ||| IN
the  ||| S:2054 E:2058 ||| DT
connective  ||| S:2058 E:2069 ||| JJ
tissue  ||| S:2069 E:2076 ||| NN
beneath  ||| S:2076 E:2084 ||| IN
the  ||| S:2084 E:2088 ||| DT
skin  ||| S:2088 E:2093 ||| NN
[  ||| S:2093 E:2095 ||| -LRB-
6  ||| S:2095 E:2105 ||| CD
11  ||| S:2105 E:2108 ||| CD
]  ||| S:2108 E:2110 ||| -RRB-
.  ||| S:2110 E:2112 ||| .
In  ||| S:2112 E:2115 ||| IN
the  ||| S:2115 E:2119 ||| DT
chicken  ||| S:2119 E:2127 ||| NN
chorioallantoic  ||| S:2127 E:2143 ||| NN
membrane  ||| S:2143 E:2152 ||| NNS
( ||| S:2152 E:2153 ||| -LRB-
CAM ||| S:2153 E:2156 ||| NNP
)  ||| S:2156 E:2158 ||| -RRB-
assay ||| S:2158 E:2163 ||| NN
,  ||| S:2163 E:2173 ||| ,
low  ||| S:2173 E:2177 ||| JJ
concentration  ||| S:2177 E:2191 ||| NN
of  ||| S:2191 E:2194 ||| IN
cCAF  ||| S:2194 E:2199 ||| JJ
results  ||| S:2199 E:2207 ||| NNS
in  ||| S:2207 E:2210 ||| IN
chemotaxis  ||| S:2210 E:2221 ||| NN
of  ||| S:2221 E:2232 ||| IN
monocyte ||| S:2232 E:2240 ||| CD
/ ||| S:2240 E:2241 ||| CD
macrophages  ||| S:2241 E:2253 ||| NNS
and  ||| S:2253 E:2257 ||| CC
lymphocytes  ||| S:2257 E:2269 ||| NNS
and  ||| S:2269 E:2273 ||| CC
the  ||| S:2273 E:2277 ||| DT
formation  ||| S:2277 E:2287 ||| NN
of  ||| S:2287 E:2290 ||| IN
a  ||| S:2290 E:2300 ||| DT
granulation-like  ||| S:2300 E:2317 ||| JJ
tissue  ||| S:2317 E:2324 ||| NN
beneath  ||| S:2324 E:2332 ||| IN
the  ||| S:2332 E:2336 ||| DT
chemokine-containing  ||| S:2336 E:2365 ||| JJ
pellet  ||| S:2365 E:2372 ||| NNS
[  ||| S:2372 E:2374 ||| -LRB-
3  ||| S:2374 E:2376 ||| LS
]  ||| S:2376 E:2378 ||| -RRB-
.  ||| S:2378 E:2380 ||| .
After  ||| S:2380 E:2386 ||| IN
four  ||| S:2386 E:2391 ||| CD
days  ||| S:2391 E:2396 ||| NNS
of  ||| S:2396 E:2399 ||| IN
exposure  ||| S:2399 E:2408 ||| NN
to  ||| S:2408 E:2411 ||| TO
this  ||| S:2411 E:2424 ||| DT
chemokine ||| S:2424 E:2433 ||| NN
,  ||| S:2433 E:2435 ||| ,
the  ||| S:2435 E:2439 ||| DT
ectoderm  ||| S:2439 E:2448 ||| NN
of  ||| S:2448 E:2451 ||| IN
the  ||| S:2451 E:2455 ||| DT
CAMs  ||| S:2455 E:2460 ||| NN
becomes  ||| S:2460 E:2468 ||| VBZ
thickened  ||| S:2468 E:2478 ||| VBN
and  ||| S:2478 E:2490 ||| CC
the  ||| S:2490 E:2494 ||| DT
amount  ||| S:2494 E:2501 ||| NN
of  ||| S:2501 E:2504 ||| IN
fibrillar  ||| S:2504 E:2514 ||| JJ
collagen  ||| S:2514 E:2523 ||| NN
in  ||| S:2523 E:2526 ||| IN
the  ||| S:2526 E:2530 ||| DT
tissue  ||| S:2530 E:2537 ||| NN
is  ||| S:2537 E:2540 ||| VBZ
markedly  ||| S:2540 E:2557 ||| RB
increased ||| S:2557 E:2566 ||| VBN
,  ||| S:2566 E:2568 ||| ,
strongly  ||| S:2568 E:2577 ||| RB
suggesting  ||| S:2577 E:2588 ||| VBG
that  ||| S:2588 E:2593 ||| IN
cCAF  ||| S:2593 E:2598 ||| NNP
is  ||| S:2598 E:2601 ||| VBZ
able  ||| S:2601 E:2606 ||| JJ
to  ||| S:2606 E:2617 ||| TO
initiate  ||| S:2617 E:2626 ||| VB
some  ||| S:2626 E:2631 ||| DT
of  ||| S:2631 E:2634 ||| IN
the  ||| S:2634 E:2638 ||| DT
primary  ||| S:2638 E:2646 ||| JJ
events  ||| S:2646 E:2653 ||| NNS
that  ||| S:2653 E:2658 ||| WDT
lead  ||| S:2658 E:2663 ||| VBP
to  ||| S:2663 E:2674 ||| TO
granulation  ||| S:2674 E:2686 ||| VB
tissue  ||| S:2686 E:2693 ||| NN
formation  ||| S:2693 E:2703 ||| NN
[  ||| S:2703 E:2705 ||| -LRB-
3  ||| S:2705 E:2707 ||| LS
]  ||| S:2707 E:2709 ||| -RRB-
.  ||| S:2709 E:2719 ||| .
Fibroblasts  ||| S:2719 E:2731 ||| NNS
are  ||| S:2731 E:2735 ||| VBP
important  ||| S:2735 E:2745 ||| JJ
cells  ||| S:2745 E:2751 ||| NNS
in  ||| S:2751 E:2754 ||| IN
the  ||| S:2754 E:2758 ||| DT
healing  ||| S:2758 E:2766 ||| NN
process ||| S:2766 E:2773 ||| NN
.  ||| S:2773 E:2783 ||| .
Upon  ||| S:2783 E:2788 ||| IN
injury ||| S:2788 E:2794 ||| NN
,  ||| S:2794 E:2796 ||| ,
they  ||| S:2796 E:2801 ||| PRP
are  ||| S:2801 E:2805 ||| VBP
activated  ||| S:2805 E:2815 ||| VBN
by  ||| S:2815 E:2818 ||| IN
the  ||| S:2818 E:2822 ||| DT
cytokines  ||| S:2822 E:2832 ||| NN
and  ||| S:2832 E:2836 ||| CC
growth  ||| S:2836 E:2851 ||| NN
factors  ||| S:2851 E:2859 ||| NNS
released  ||| S:2859 E:2868 ||| VBN
during  ||| S:2868 E:2875 ||| IN
the  ||| S:2875 E:2879 ||| DT
coagulation  ||| S:2879 E:2891 ||| JJ
process  ||| S:2891 E:2899 ||| NN
to  ||| S:2899 E:2902 ||| TO
produce  ||| S:2902 E:2918 ||| VB
chemokines  ||| S:2918 E:2929 ||| NNS
and  ||| S:2929 E:2933 ||| CC
additional  ||| S:2933 E:2944 ||| JJ
cytokines  ||| S:2944 E:2954 ||| NN
and  ||| S:2954 E:2958 ||| CC
growth  ||| S:2958 E:2965 ||| NN
factors  ||| S:2965 E:2973 ||| NNS
that  ||| S:2973 E:2986 ||| WDT
are  ||| S:2986 E:2990 ||| VBP
important  ||| S:2990 E:3000 ||| JJ
in  ||| S:3000 E:3003 ||| IN
setting  ||| S:3003 E:3011 ||| VBG
up  ||| S:3011 E:3014 ||| RP
the  ||| S:3014 E:3018 ||| DT
cascade  ||| S:3018 E:3026 ||| NN
of  ||| S:3026 E:3029 ||| IN
events  ||| S:3029 E:3036 ||| NNS
that  ||| S:3036 E:3041 ||| WDT
lead  ||| S:3041 E:3054 ||| VBP
to  ||| S:3054 E:3057 ||| TO
granulation  ||| S:3057 E:3069 ||| VB
tissue  ||| S:3069 E:3076 ||| NN
formation ||| S:3076 E:3085 ||| NN
.  ||| S:3085 E:3087 ||| .
Activated  ||| S:3087 E:3097 ||| JJ
fibroblasts  ||| S:3097 E:3117 ||| JJ
proliferate  ||| S:3117 E:3129 ||| NN
and  ||| S:3129 E:3133 ||| CC
migrate  ||| S:3133 E:3141 ||| VB
across  ||| S:3141 E:3148 ||| IN
the  ||| S:3148 E:3152 ||| DT
provisional  ||| S:3152 E:3164 ||| JJ
matrix  ||| S:3164 E:3179 ||| NNS
formed  ||| S:3179 E:3186 ||| VBN
by  ||| S:3186 E:3189 ||| IN
the  ||| S:3189 E:3193 ||| DT
fibrin-plasma  ||| S:3193 E:3207 ||| JJ
fibronectin  ||| S:3207 E:3219 ||| NNS
( ||| S:3219 E:3220 ||| -LRB-
FN ||| S:3220 E:3222 ||| NNP
)  ||| S:3222 E:3224 ||| -RRB-
clot ||| S:3224 E:3228 ||| NN
.  ||| S:3228 E:3230 ||| .
As  ||| S:3230 E:3233 ||| IN
the  ||| S:3233 E:3245 ||| DT
clot  ||| S:3245 E:3250 ||| NN
is  ||| S:3250 E:3253 ||| VBZ
digested  ||| S:3253 E:3262 ||| VBN
by  ||| S:3262 E:3265 ||| IN
plasmin ||| S:3265 E:3272 ||| NN
,  ||| S:3272 E:3274 ||| ,
fibroblasts  ||| S:3274 E:3286 ||| RB
replace  ||| S:3286 E:3294 ||| VB
it  ||| S:3294 E:3297 ||| PRP
with  ||| S:3297 E:3310 ||| IN
cellular  ||| S:3310 E:3319 ||| JJ
FN ||| S:3319 E:3321 ||| NNP
,  ||| S:3321 E:3323 ||| ,
tenascin  ||| S:3323 E:3332 ||| NNS
( ||| S:3332 E:3333 ||| -LRB-
TN ||| S:3333 E:3335 ||| NNP
)  ||| S:3335 E:3337 ||| -RRB-
and  ||| S:3337 E:3341 ||| CC
Coll  ||| S:3341 E:3346 ||| NNP
III  ||| S:3346 E:3350 ||| NNP
[  ||| S:3350 E:3352 ||| -LRB-
12  ||| S:3352 E:3355 ||| CD
13  ||| S:3355 E:3358 ||| CD
]  ||| S:3358 E:3360 ||| -RRB-
.  ||| S:3360 E:3362 ||| .
These  ||| S:3362 E:3376 ||| DT
extracellular  ||| S:3376 E:3390 ||| JJ
matrix  ||| S:3390 E:3397 ||| JJ
proteins  ||| S:3397 E:3406 ||| NNS
are  ||| S:3406 E:3410 ||| VBP
critical  ||| S:3410 E:3419 ||| JJ
for  ||| S:3419 E:3423 ||| IN
migration  ||| S:3423 E:3433 ||| NN
of  ||| S:3433 E:3444 ||| IN
endothelial  ||| S:3444 E:3456 ||| JJ
cells ||| S:3456 E:3461 ||| NNS
,  ||| S:3461 E:3463 ||| ,
keratinocytes  ||| S:3463 E:3477 ||| NN
and  ||| S:3477 E:3481 ||| CC
additional  ||| S:3481 E:3492 ||| JJ
fibroblasts  ||| S:3492 E:3512 ||| NN
into  ||| S:3512 E:3517 ||| IN
the  ||| S:3517 E:3521 ||| DT
wound  ||| S:3521 E:3527 ||| NN
and  ||| S:3527 E:3531 ||| CC
are  ||| S:3531 E:3535 ||| VBP
important  ||| S:3535 E:3545 ||| JJ
for  ||| S:3545 E:3549 ||| IN
proper  ||| S:3549 E:3556 ||| JJ
generation  ||| S:3556 E:3567 ||| NN
of  ||| S:3567 E:3578 ||| IN
healthy  ||| S:3578 E:3586 ||| JJ
healing  ||| S:3586 E:3594 ||| NN
tissue ||| S:3594 E:3600 ||| NN
.  ||| S:3600 E:3602 ||| .
Some  ||| S:3602 E:3607 ||| DT
of  ||| S:3607 E:3610 ||| IN
the  ||| S:3610 E:3614 ||| DT
fibroblasts  ||| S:3614 E:3634 ||| JJ
differentiate  ||| S:3634 E:3648 ||| NN
into  ||| S:3648 E:3653 ||| IN
myofibroblasts ||| S:3653 E:3667 ||| NN
,  ||| S:3667 E:3669 ||| ,
which  ||| S:3669 E:3675 ||| WDT
contract  ||| S:3675 E:3684 ||| NN
to  ||| S:3684 E:3687 ||| TO
close  ||| S:3687 E:3701 ||| VB
the  ||| S:3701 E:3705 ||| DT
wound  ||| S:3705 E:3711 ||| NN
[  ||| S:3711 E:3713 ||| -LRB-
4  ||| S:3713 E:3715 ||| CD
14  ||| S:3715 E:3718 ||| CD
15  ||| S:3718 E:3721 ||| CD
]  ||| S:3721 E:3723 ||| -RRB-
.  ||| S:3723 E:3725 ||| .
Myofibroblasts  ||| S:3725 E:3740 ||| NNS
are  ||| S:3740 E:3744 ||| VBP
fibrogenic ||| S:3744 E:3754 ||| VBN
,  ||| S:3754 E:3764 ||| ,
showing  ||| S:3764 E:3772 ||| VBG
elevated  ||| S:3772 E:3781 ||| JJ
expression  ||| S:3781 E:3792 ||| NN
of  ||| S:3792 E:3795 ||| IN
interstitial  ||| S:3795 E:3808 ||| JJ
collagens ||| S:3808 E:3817 ||| NN
,  ||| S:3817 E:3827 ||| ,
laminin ||| S:3827 E:3834 ||| NN
,  ||| S:3834 E:3836 ||| ,
FN  ||| S:3836 E:3839 ||| NNP
and  ||| S:3839 E:3843 ||| CC
TN ||| S:3843 E:3845 ||| NNP
,  ||| S:3845 E:3847 ||| ,
and  ||| S:3847 E:3851 ||| CC
inhibitors  ||| S:3851 E:3862 ||| NN
of  ||| S:3862 E:3865 ||| IN
matrix  ||| S:3865 E:3880 ||| JJ
metalloproteinases  ||| S:3880 E:3899 ||| JJ
such  ||| S:3899 E:3904 ||| JJ
as  ||| S:3904 E:3907 ||| IN
TIMP-1  ||| S:3907 E:3914 ||| NNP
[  ||| S:3914 E:3916 ||| -LRB-
15  ||| S:3916 E:3919 ||| CD
16  ||| S:3919 E:3922 ||| CD
17  ||| S:3922 E:3925 ||| CD
18  ||| S:3925 E:3928 ||| CD
19  ||| S:3928 E:3931 ||| CD
]  ||| S:3931 E:3933 ||| -RRB-
.  ||| S:3933 E:3943 ||| .
Because  ||| S:3943 E:3951 ||| IN
cCAF  ||| S:3951 E:3956 ||| NNP
is  ||| S:3956 E:3959 ||| VBZ
expressed  ||| S:3959 E:3969 ||| VBN
highly  ||| S:3969 E:3976 ||| RB
in  ||| S:3976 E:3979 ||| IN
the  ||| S:3979 E:3983 ||| DT
granulation  ||| S:3983 E:3995 ||| JJ
tissue  ||| S:3995 E:4010 ||| NN
of  ||| S:4010 E:4013 ||| IN
wounds  ||| S:4013 E:4020 ||| NNS
in  ||| S:4020 E:4023 ||| IN
areas  ||| S:4023 E:4029 ||| NNS
where  ||| S:4029 E:4035 ||| WRB
ECM  ||| S:4035 E:4039 ||| NNP
is  ||| S:4039 E:4042 ||| VBZ
abundant  ||| S:4042 E:4051 ||| JJ
[  ||| S:4051 E:4053 ||| -LRB-
3  ||| S:4053 E:4055 ||| CD
6  ||| S:4055 E:4057 ||| CD
11  ||| S:4057 E:4060 ||| CD
]  ||| S:4060 E:4062 ||| -RRB-
,  ||| S:4062 E:4064 ||| ,
and  ||| S:4064 E:4076 ||| CC
it  ||| S:4076 E:4079 ||| PRP
stimulates  ||| S:4079 E:4090 ||| VBP
fibroblasts  ||| S:4090 E:4102 ||| VBN
to  ||| S:4102 E:4105 ||| TO
differentiate  ||| S:4105 E:4119 ||| VB
into  ||| S:4119 E:4132 ||| IN
myofibroblasts  ||| S:4132 E:4147 ||| NNS
[  ||| S:4147 E:4149 ||| -LRB-
4  ||| S:4149 E:4151 ||| LS
]  ||| S:4151 E:4153 ||| -RRB-
,  ||| S:4153 E:4155 ||| ,
we  ||| S:4155 E:4158 ||| PRP
investigated  ||| S:4158 E:4171 ||| VBD
whether  ||| S:4171 E:4179 ||| IN
this  ||| S:4179 E:4192 ||| DT
chemokine  ||| S:4192 E:4202 ||| NN
stimulates  ||| S:4202 E:4213 ||| VBD
the  ||| S:4213 E:4217 ||| DT
production  ||| S:4217 E:4228 ||| NN
of  ||| S:4228 E:4231 ||| IN
the  ||| S:4231 E:4235 ||| DT
four  ||| S:4235 E:4240 ||| CD
major  ||| S:4240 E:4246 ||| JJ
ECM  ||| S:4246 E:4258 ||| NNP
molecules  ||| S:4258 E:4268 ||| VBD
mentioned  ||| S:4268 E:4278 ||| VBN
above ||| S:4278 E:4283 ||| IN
,  ||| S:4283 E:4285 ||| ,
interstitial  ||| S:4285 E:4298 ||| VBG
Colls  ||| S:4298 E:4304 ||| NNP
I  ||| S:4304 E:4306 ||| NNP
and  ||| S:4306 E:4310 ||| CC
III ||| S:4310 E:4313 ||| NNP
,  ||| S:4313 E:4315 ||| ,
TN  ||| S:4315 E:4326 ||| NNP
and  ||| S:4326 E:4330 ||| CC
cellular  ||| S:4330 E:4339 ||| JJ
FN ||| S:4339 E:4341 ||| NNP
.  ||| S:4341 E:4343 ||| .
Here  ||| S:4343 E:4348 ||| RB
we  ||| S:4348 E:4351 ||| PRP
show  ||| S:4351 E:4356 ||| VBP
that  ||| S:4356 E:4361 ||| IN
cCAF  ||| S:4361 E:4366 ||| JJ
stimulates  ||| S:4366 E:4377 ||| JJ
cultures  ||| S:4377 E:4394 ||| NNS
of  ||| S:4394 E:4397 ||| IN
fibroblasts  ||| S:4397 E:4409 ||| VBG
to  ||| S:4409 E:4412 ||| TO
produce  ||| S:4412 E:4420 ||| VB
TN ||| S:4420 E:4422 ||| NNP
,  ||| S:4422 E:4424 ||| ,
FN ||| S:4424 E:4426 ||| NNP
,  ||| S:4426 E:4428 ||| ,
and  ||| S:4428 E:4432 ||| CC
Coll  ||| S:4432 E:4437 ||| NNP
I ||| S:4437 E:4438 ||| NNP
,  ||| S:4438 E:4440 ||| ,
albeit  ||| S:4440 E:4447 ||| VBG
with  ||| S:4447 E:4460 ||| IN
different  ||| S:4460 E:4470 ||| JJ
dynamics  ||| S:4470 E:4479 ||| NNS
and  ||| S:4479 E:4483 ||| CC
that  ||| S:4483 E:4488 ||| IN
these  ||| S:4488 E:4494 ||| DT
ECM  ||| S:4494 E:4498 ||| NNP
molecules  ||| S:4498 E:4508 ||| NNS
are  ||| S:4508 E:4512 ||| VBP
also  ||| S:4512 E:4525 ||| RB
increased  ||| S:4525 E:4535 ||| VBN
in  ||| S:4535 E:4538 ||| IN
wounded  ||| S:4538 E:4546 ||| JJ
tissues  ||| S:4546 E:4554 ||| NNS
treated  ||| S:4554 E:4562 ||| VBN
with  ||| S:4562 E:4567 ||| IN
cCAF ||| S:4567 E:4571 ||| JJ
.  ||| S:4571 E:4595 ||| .
Results  ||| S:4595 E:4622 ||| NNP
Effects  ||| S:4622 E:4630 ||| NNPS
of  ||| S:4630 E:4633 ||| IN
cCAF  ||| S:4633 E:4638 ||| JJ
and  ||| S:4638 E:4642 ||| CC
its  ||| S:4642 E:4646 ||| PRP$
peptides  ||| S:4646 E:4655 ||| NN
on  ||| S:4655 E:4658 ||| IN
the  ||| S:4658 E:4662 ||| DT
production  ||| S:4662 E:4683 ||| NN
of  ||| S:4683 E:4686 ||| IN
TN  ||| S:4686 E:4699 ||| NNP
In  ||| S:4699 E:4702 ||| IN
adults ||| S:4702 E:4708 ||| NNS
,  ||| S:4708 E:4710 ||| ,
TN ||| S:4710 E:4712 ||| NNP
,  ||| S:4712 E:4714 ||| ,
specifically  ||| S:4714 E:4727 ||| RB
TN  ||| S:4727 E:4730 ||| NNP
C ||| S:4730 E:4731 ||| NNP
,  ||| S:4731 E:4733 ||| ,
is  ||| S:4733 E:4736 ||| VBZ
present  ||| S:4736 E:4744 ||| RB
almost  ||| S:4744 E:4761 ||| RB
exclusively  ||| S:4761 E:4773 ||| RB
in  ||| S:4773 E:4776 ||| IN
the  ||| S:4776 E:4780 ||| DT
granulation  ||| S:4780 E:4792 ||| JJ
tissue  ||| S:4792 E:4799 ||| NN
of  ||| S:4799 E:4802 ||| IN
healing  ||| S:4802 E:4810 ||| JJ
wounds  ||| S:4810 E:4817 ||| NNS
[  ||| S:4817 E:4829 ||| -LRB-
12  ||| S:4829 E:4832 ||| CD
24  ||| S:4832 E:4835 ||| CD
]  ||| S:4835 E:4837 ||| -RRB-
.  ||| S:4837 E:4839 ||| .
In  ||| S:4839 E:4842 ||| IN
addition  ||| S:4842 E:4851 ||| NN
to  ||| S:4851 E:4854 ||| TO
providing  ||| S:4854 E:4864 ||| VBG
a  ||| S:4864 E:4866 ||| DT
matrix  ||| S:4866 E:4873 ||| NN
for  ||| S:4873 E:4877 ||| IN
rapid  ||| S:4877 E:4893 ||| JJ
migration  ||| S:4893 E:4903 ||| NN
of  ||| S:4903 E:4906 ||| IN
cells  ||| S:4906 E:4912 ||| NNS
during  ||| S:4912 E:4919 ||| IN
wound  ||| S:4919 E:4925 ||| JJ
repair ||| S:4925 E:4931 ||| NN
,  ||| S:4931 E:4933 ||| ,
TN  ||| S:4933 E:4936 ||| NNP
supports  ||| S:4936 E:4955 ||| VBZ
differentiation  ||| S:4955 E:4971 ||| VBN
of  ||| S:4971 E:4974 ||| IN
fibroblasts  ||| S:4974 E:4986 ||| NN
into  ||| S:4986 E:4991 ||| IN
myofibroblasts  ||| S:4991 E:5006 ||| NNS
[  ||| S:5006 E:5008 ||| -LRB-
25  ||| S:5008 E:5011 ||| CD
]  ||| S:5011 E:5023 ||| -RRB-
,  ||| S:5023 E:5025 ||| ,
which  ||| S:5025 E:5031 ||| WDT
then  ||| S:5031 E:5036 ||| RB
produce  ||| S:5036 E:5044 ||| VB
more  ||| S:5044 E:5049 ||| JJR
TN  ||| S:5049 E:5052 ||| NN
than  ||| S:5052 E:5057 ||| IN
do  ||| S:5057 E:5060 ||| VBP
normal  ||| S:5060 E:5067 ||| JJ
fibroblasts  ||| S:5067 E:5079 ||| NNS
[  ||| S:5079 E:5091 ||| -LRB-
15  ||| S:5091 E:5094 ||| CD
18  ||| S:5094 E:5097 ||| CD
]  ||| S:5097 E:5099 ||| -RRB-
.  ||| S:5099 E:5101 ||| .
Because  ||| S:5101 E:5109 ||| IN
cCAF  ||| S:5109 E:5114 ||| JJ
stimulates  ||| S:5114 E:5125 ||| JJ
fibroblasts  ||| S:5125 E:5137 ||| NN
to  ||| S:5137 E:5150 ||| TO
differentiate  ||| S:5150 E:5164 ||| VB
into  ||| S:5164 E:5169 ||| IN
myofibroblasts ||| S:5169 E:5183 ||| NN
,  ||| S:5183 E:5185 ||| ,
we  ||| S:5185 E:5188 ||| PRP
tested  ||| S:5188 E:5195 ||| VBD
the  ||| S:5195 E:5209 ||| DT
possibility  ||| S:5209 E:5221 ||| NN
that  ||| S:5221 E:5226 ||| IN
this  ||| S:5226 E:5231 ||| DT
chemokine  ||| S:5231 E:5241 ||| NN
also  ||| S:5241 E:5246 ||| RB
affects  ||| S:5246 E:5254 ||| VBZ
TN  ||| S:5254 E:5267 ||| NNP
production ||| S:5267 E:5277 ||| NN
.  ||| S:5277 E:5279 ||| .
Immunolabeling  ||| S:5279 E:5294 ||| NNP
of  ||| S:5294 E:5297 ||| IN
cells  ||| S:5297 E:5303 ||| NNS
treated  ||| S:5303 E:5311 ||| VBN
daily  ||| S:5311 E:5317 ||| RB
for  ||| S:5317 E:5331 ||| IN
four  ||| S:5331 E:5336 ||| CD
days  ||| S:5336 E:5341 ||| NNS
with  ||| S:5341 E:5346 ||| IN
750  ||| S:5346 E:5350 ||| CD
ng ||| S:5350 E:5352 ||| CD
/ ||| S:5352 E:5353 ||| CD
ml  ||| S:5353 E:5356 ||| NN
of  ||| S:5356 E:5359 ||| IN
the  ||| S:5359 E:5363 ||| DT
chemokine  ||| S:5363 E:5373 ||| NN
showed  ||| S:5373 E:5380 ||| VBD
that  ||| S:5380 E:5395 ||| DT
cCAF  ||| S:5395 E:5400 ||| JJ
stimulates  ||| S:5400 E:5411 ||| NNS
the  ||| S:5411 E:5415 ||| DT
cells  ||| S:5415 E:5421 ||| NNS
to  ||| S:5421 E:5424 ||| TO
produce  ||| S:5424 E:5432 ||| VB
more  ||| S:5432 E:5437 ||| JJR
TN  ||| S:5437 E:5440 ||| NN
than  ||| S:5440 E:5445 ||| IN
the  ||| S:5445 E:5459 ||| DT
control  ||| S:5459 E:5467 ||| NN
cells  ||| S:5467 E:5473 ||| NNS
( ||| S:5473 E:5474 ||| -LRB-
Fig.  ||| S:5474 E:5479 ||| NNP
1A ||| S:5479 E:5481 ||| NNP
&  ||| S:5481 E:5483 ||| CC
1B ||| S:5483 E:5485 ||| CD
) ||| S:5485 E:5486 ||| -RRB-
.  ||| S:5486 E:5488 ||| .
We  ||| S:5488 E:5491 ||| PRP
have  ||| S:5491 E:5496 ||| VBP
previously  ||| S:5496 E:5517 ||| RB
determined ||| S:5517 E:5527 ||| VBN
,  ||| S:5527 E:5529 ||| ,
using  ||| S:5529 E:5535 ||| VBG
dose-dependent  ||| S:5535 E:5550 ||| JJ
studies ||| S:5550 E:5557 ||| NNS
,  ||| S:5557 E:5559 ||| ,
that  ||| S:5559 E:5564 ||| IN
this  ||| S:5564 E:5579 ||| DT
concentration  ||| S:5579 E:5593 ||| NN
is  ||| S:5593 E:5596 ||| VBZ
optimal  ||| S:5596 E:5604 ||| VBN
for  ||| S:5604 E:5608 ||| IN
functions  ||| S:5608 E:5618 ||| NNS
of  ||| S:5618 E:5621 ||| IN
this  ||| S:5621 E:5626 ||| DT
chemokine  ||| S:5626 E:5646 ||| NN
on  ||| S:5646 E:5649 ||| IN
these  ||| S:5649 E:5655 ||| DT
embryonic  ||| S:5655 E:5665 ||| JJ
fibroblasts  ||| S:5665 E:5677 ||| NN
and  ||| S:5677 E:5681 ||| CC
in  ||| S:5681 E:5684 ||| IN
processes  ||| S:5684 E:5694 ||| NNS
of  ||| S:5694 E:5707 ||| IN
granulation  ||| S:5707 E:5719 ||| JJ
tissue  ||| S:5719 E:5726 ||| NN
formation  ||| S:5726 E:5736 ||| NN
[  ||| S:5736 E:5738 ||| -LRB-
3  ||| S:5738 E:5740 ||| CD
4  ||| S:5740 E:5742 ||| CD
]  ||| S:5742 E:5744 ||| CD
) ||| S:5744 E:5745 ||| -RRB-
.  ||| S:5745 E:5747 ||| .
Although  ||| S:5747 E:5766 ||| IN
chemokine  ||| S:5766 E:5776 ||| JJ
concentrations  ||| S:5776 E:5791 ||| NNS
of  ||| S:5791 E:5794 ||| IN
10  ||| S:5794 E:5797 ||| CD
-2-10  ||| S:5797 E:5803 ||| CD
ng ||| S:5803 E:5805 ||| CD
/ ||| S:5805 E:5806 ||| CD
ml  ||| S:5806 E:5809 ||| NNS
can  ||| S:5809 E:5823 ||| MD
chemoattract  ||| S:5823 E:5836 ||| VB
and  ||| S:5836 E:5840 ||| CC
activate  ||| S:5840 E:5849 ||| JJ
leukocytes ||| S:5849 E:5859 ||| NN
,  ||| S:5859 E:5861 ||| ,
chemokines  ||| S:5861 E:5872 ||| VBZ
acting  ||| S:5872 E:5889 ||| VBG
on  ||| S:5889 E:5892 ||| IN
other  ||| S:5892 E:5898 ||| JJ
cell  ||| S:5898 E:5903 ||| NN
types  ||| S:5903 E:5909 ||| NNS
such  ||| S:5909 E:5914 ||| JJ
as  ||| S:5914 E:5917 ||| IN
endothelial  ||| S:5917 E:5929 ||| JJ
cells ||| S:5929 E:5934 ||| NNS
,  ||| S:5934 E:5936 ||| ,
smooth  ||| S:5936 E:5953 ||| JJ
muscle  ||| S:5953 E:5960 ||| NN
cells  ||| S:5960 E:5966 ||| NNS
and  ||| S:5966 E:5970 ||| CC
fibroblasts  ||| S:5970 E:5982 ||| NNS
require  ||| S:5982 E:5990 ||| VBP
concentrations  ||| S:5990 E:6005 ||| VBN
in  ||| S:6005 E:6018 ||| IN
the  ||| S:6018 E:6022 ||| DT
range  ||| S:6022 E:6028 ||| NN
of  ||| S:6028 E:6031 ||| IN
10  ||| S:6031 E:6034 ||| CD
2ng ||| S:6034 E:6037 ||| CD
/ ||| S:6037 E:6038 ||| CD
ml  ||| S:6038 E:6041 ||| NNS
and  ||| S:6041 E:6045 ||| CC
higher  ||| S:6045 E:6052 ||| JJR
[  ||| S:6052 E:6054 ||| -LRB-
4  ||| S:6054 E:6056 ||| CD
26  ||| S:6056 E:6059 ||| CD
27  ||| S:6059 E:6062 ||| CD
28  ||| S:6062 E:6065 ||| CD
]  ||| S:6065 E:6067 ||| -RRB-
.  ||| S:6067 E:6069 ||| .
This  ||| S:6069 E:6084 ||| DT
is  ||| S:6084 E:6087 ||| VBZ
within  ||| S:6087 E:6094 ||| IN
physiological  ||| S:6094 E:6108 ||| JJ
range ||| S:6108 E:6113 ||| NN
;  ||| S:6113 E:6115 ||| :
for  ||| S:6115 E:6119 ||| IN
example  ||| S:6119 E:6127 ||| NN
wound  ||| S:6127 E:6133 ||| VBD
fluid  ||| S:6133 E:6149 ||| VBN
from  ||| S:6149 E:6154 ||| IN
burn  ||| S:6154 E:6159 ||| JJ
patients  ||| S:6159 E:6168 ||| NNS
contain  ||| S:6168 E:6176 ||| VBP
MGSA  ||| S:6176 E:6181 ||| NNP
( ||| S:6181 E:6182 ||| -LRB-
a  ||| S:6182 E:6184 ||| DT
chemokine  ||| S:6184 E:6194 ||| NN
that  ||| S:6194 E:6199 ||| WDT
is  ||| S:6199 E:6212 ||| VBZ
highly  ||| S:6212 E:6219 ||| RB
homologous  ||| S:6219 E:6230 ||| VBN
to  ||| S:6230 E:6233 ||| TO
cCAF ||| S:6233 E:6237 ||| NNP
)  ||| S:6237 E:6239 ||| -RRB-
concentrations  ||| S:6239 E:6254 ||| NNS
of  ||| S:6254 E:6257 ||| IN
10  ||| S:6257 E:6260 ||| CD
2-10  ||| S:6260 E:6275 ||| CD
3ng ||| S:6275 E:6278 ||| CD
/ ||| S:6278 E:6279 ||| CD
ml  ||| S:6279 E:6282 ||| NNS
[  ||| S:6282 E:6284 ||| -LRB-
29  ||| S:6284 E:6287 ||| CD
]  ||| S:6287 E:6289 ||| -RRB-
.  ||| S:6289 E:6291 ||| .
Because  ||| S:6291 E:6299 ||| IN
both  ||| S:6299 E:6304 ||| PDT
the  ||| S:6304 E:6308 ||| DT
N-terminal  ||| S:6308 E:6319 ||| JJ
and  ||| S:6319 E:6333 ||| CC
C-terminal  ||| S:6333 E:6344 ||| JJ
peptides  ||| S:6344 E:6353 ||| NN
of  ||| S:6353 E:6356 ||| IN
cCAF  ||| S:6356 E:6361 ||| NNS
have  ||| S:6361 E:6366 ||| VBP
been  ||| S:6366 E:6371 ||| VBN
shown  ||| S:6371 E:6377 ||| VBN
to  ||| S:6377 E:6380 ||| TO
be  ||| S:6380 E:6393 ||| VB
functional  ||| S:6393 E:6404 ||| VBN
in  ||| S:6404 E:6407 ||| IN
culture  ||| S:6407 E:6415 ||| NN
and  ||| S:6415 E:6430 ||| CC
in  ||| S:6430 E:6433 ||| IN
vivo  ||| S:6433 E:6438 ||| NNS
( ||| S:6438 E:6439 ||| -LRB-
1-4 ||| S:6439 E:6442 ||| NNP
,  ||| S:6442 E:6444 ||| ,
30 ||| S:6444 E:6446 ||| CD
) ||| S:6446 E:6447 ||| -RRB-
,  ||| S:6447 E:6449 ||| ,
we  ||| S:6449 E:6452 ||| PRP
also  ||| S:6452 E:6457 ||| RB
tested  ||| S:6457 E:6474 ||| VBN
these  ||| S:6474 E:6480 ||| DT
two  ||| S:6480 E:6484 ||| CD
peptides  ||| S:6484 E:6493 ||| NNS
( ||| S:6493 E:6494 ||| -LRB-
Fig.  ||| S:6494 E:6499 ||| CD
1 ||| S:6499 E:6500 ||| CD
) ||| S:6500 E:6501 ||| -RRB-
.  ||| S:6501 E:6503 ||| .
The  ||| S:6503 E:6507 ||| DT
N-terminal  ||| S:6507 E:6518 ||| JJ
15aa  ||| S:6518 E:6523 ||| CD
peptide  ||| S:6523 E:6541 ||| NNS
produced  ||| S:6541 E:6550 ||| VBD
an  ||| S:6550 E:6553 ||| DT
effect  ||| S:6553 E:6560 ||| NN
at  ||| S:6560 E:6563 ||| IN
least  ||| S:6563 E:6569 ||| JJS
as  ||| S:6569 E:6572 ||| IN
strong  ||| S:6572 E:6579 ||| JJ
as  ||| S:6579 E:6582 ||| IN
the  ||| S:6582 E:6586 ||| DT
whole  ||| S:6586 E:6602 ||| JJ
molecule  ||| S:6602 E:6611 ||| NN
( ||| S:6611 E:6612 ||| -LRB-
Fig.  ||| S:6612 E:6617 ||| NNP
1C ||| S:6617 E:6619 ||| NNP
)  ||| S:6619 E:6621 ||| -RRB-
whereas  ||| S:6621 E:6629 ||| IN
the  ||| S:6629 E:6633 ||| DT
effects  ||| S:6633 E:6641 ||| NNS
of  ||| S:6641 E:6644 ||| IN
the  ||| S:6644 E:6648 ||| DT
C-terminal  ||| S:6648 E:6669 ||| JJ
peptide  ||| S:6669 E:6677 ||| NNS
( ||| S:6677 E:6678 ||| -LRB-
28aa ||| S:6678 E:6682 ||| NNP
)  ||| S:6682 E:6684 ||| -RRB-
was  ||| S:6684 E:6688 ||| VBD
closer  ||| S:6688 E:6695 ||| JJR
to  ||| S:6695 E:6698 ||| TO
those  ||| S:6698 E:6704 ||| DT
of  ||| S:6704 E:6707 ||| IN
the  ||| S:6707 E:6711 ||| DT
control  ||| S:6711 E:6719 ||| NN
( ||| S:6719 E:6720 ||| -LRB-
Fig.  ||| S:6720 E:6735 ||| NNP
1D ||| S:6735 E:6737 ||| NNP
) ||| S:6737 E:6738 ||| -RRB-
.  ||| S:6738 E:6740 ||| .
Western  ||| S:6740 E:6748 ||| JJ
blot  ||| S:6748 E:6753 ||| JJ
analysis  ||| S:6753 E:6762 ||| NN
of  ||| S:6762 E:6765 ||| IN
extracts  ||| S:6765 E:6774 ||| NN
from  ||| S:6774 E:6779 ||| IN
treated  ||| S:6779 E:6797 ||| JJ
fibroblasts  ||| S:6797 E:6809 ||| NN
confirmed  ||| S:6809 E:6819 ||| VBD
that  ||| S:6819 E:6824 ||| DT
cCAF  ||| S:6824 E:6829 ||| JJ
increases  ||| S:6829 E:6839 ||| NNS
production  ||| S:6839 E:6850 ||| NN
of  ||| S:6850 E:6863 ||| IN
TN  ||| S:6863 E:6866 ||| NNP
in  ||| S:6866 E:6869 ||| IN
culture ||| S:6869 E:6876 ||| NN
,  ||| S:6876 E:6878 ||| ,
that  ||| S:6878 E:6883 ||| IN
this  ||| S:6883 E:6888 ||| DT
effect  ||| S:6888 E:6895 ||| NN
also  ||| S:6895 E:6900 ||| RB
can  ||| S:6900 E:6904 ||| MD
be  ||| S:6904 E:6907 ||| VB
accomplished  ||| S:6907 E:6930 ||| VBN
effectively  ||| S:6930 E:6942 ||| RB
by  ||| S:6942 E:6945 ||| IN
the  ||| S:6945 E:6949 ||| DT
N-peptide ||| S:6949 E:6958 ||| JJ
,  ||| S:6958 E:6960 ||| ,
but  ||| S:6960 E:6964 ||| CC
that  ||| S:6964 E:6969 ||| IN
the  ||| S:6969 E:6973 ||| DT
C-peptide  ||| S:6973 E:6993 ||| NN
produced  ||| S:6993 E:7002 ||| VBD
an  ||| S:7002 E:7005 ||| DT
elevated ||| S:7005 E:7013 ||| NN
,  ||| S:7013 E:7015 ||| ,
but  ||| S:7015 E:7019 ||| CC
substantially  ||| S:7019 E:7033 ||| RB
smaller ||| S:7033 E:7040 ||| JJR
,  ||| S:7040 E:7042 ||| ,
response  ||| S:7042 E:7061 ||| NN
than  ||| S:7061 E:7066 ||| IN
either  ||| S:7066 E:7073 ||| RB
the  ||| S:7073 E:7077 ||| DT
N-peptide  ||| S:7077 E:7087 ||| JJ
or  ||| S:7087 E:7090 ||| CC
the  ||| S:7090 E:7094 ||| DT
whole  ||| S:7094 E:7100 ||| JJ
cCAF  ||| S:7100 E:7105 ||| JJ
molecule  ||| S:7105 E:7124 ||| NN
( ||| S:7124 E:7125 ||| -LRB-
Fig.  ||| S:7125 E:7130 ||| NNP
1E ||| S:7130 E:7132 ||| NNP
) ||| S:7132 E:7133 ||| -RRB-
.  ||| S:7133 E:7135 ||| .
To  ||| S:7135 E:7138 ||| TO
determine  ||| S:7138 E:7148 ||| VB
whether  ||| S:7148 E:7156 ||| IN
cCAF  ||| S:7156 E:7161 ||| JJ
stimulates  ||| S:7161 E:7172 ||| JJ
TN  ||| S:7172 E:7185 ||| NNP
expression  ||| S:7185 E:7196 ||| NN
we  ||| S:7196 E:7199 ||| PRP
examined  ||| S:7199 E:7208 ||| VBD
the  ||| S:7208 E:7212 ||| DT
levels  ||| S:7212 E:7219 ||| NNS
of  ||| S:7219 E:7222 ||| IN
mRNA  ||| S:7222 E:7227 ||| JJ
for  ||| S:7227 E:7231 ||| IN
this  ||| S:7231 E:7236 ||| DT
ECM  ||| S:7236 E:7250 ||| NNP
molecule ||| S:7250 E:7258 ||| NN
.  ||| S:7258 E:7260 ||| .
RT-PCR  ||| S:7260 E:7267 ||| JJ
analysis  ||| S:7267 E:7276 ||| NN
showed  ||| S:7276 E:7283 ||| VBD
significant  ||| S:7283 E:7295 ||| JJ
increased  ||| S:7295 E:7315 ||| JJ
levels  ||| S:7315 E:7322 ||| NNS
of  ||| S:7322 E:7325 ||| IN
mRNA  ||| S:7325 E:7330 ||| JJ
for  ||| S:7330 E:7334 ||| IN
TN  ||| S:7334 E:7337 ||| NNP
after  ||| S:7337 E:7343 ||| IN
treatment  ||| S:7343 E:7353 ||| NN
with  ||| S:7353 E:7358 ||| IN
either  ||| S:7358 E:7365 ||| DT
cCAF  ||| S:7365 E:7370 ||| JJ
or  ||| S:7370 E:7383 ||| CC
its  ||| S:7383 E:7387 ||| PRP$
N-peptide  ||| S:7387 E:7397 ||| JJ
( ||| S:7397 E:7398 ||| -LRB-
Fig.  ||| S:7398 E:7403 ||| NNP
1F ||| S:7403 E:7405 ||| NNP
)  ||| S:7405 E:7407 ||| -RRB-
but  ||| S:7407 E:7411 ||| CC
the  ||| S:7411 E:7415 ||| DT
increase  ||| S:7415 E:7424 ||| NN
stimulated  ||| S:7424 E:7435 ||| VBN
by  ||| S:7435 E:7448 ||| IN
the  ||| S:7448 E:7452 ||| DT
C-terminus  ||| S:7452 E:7463 ||| NN
is  ||| S:7463 E:7466 ||| VBZ
much  ||| S:7466 E:7471 ||| RB
smaller  ||| S:7471 E:7479 ||| JJR
correlating  ||| S:7479 E:7491 ||| NN
with  ||| S:7491 E:7496 ||| IN
the  ||| S:7496 E:7500 ||| DT
small  ||| S:7500 E:7516 ||| JJ
increase  ||| S:7516 E:7525 ||| NN
in  ||| S:7525 E:7528 ||| IN
protein  ||| S:7528 E:7536 ||| NN
levels ||| S:7536 E:7542 ||| NNS
.  ||| S:7542 E:7554 ||| .
To  ||| S:7554 E:7557 ||| TO
determine  ||| S:7557 E:7567 ||| VB
whether  ||| S:7567 E:7575 ||| IN
this  ||| S:7575 E:7580 ||| DT
effect  ||| S:7580 E:7587 ||| NN
is  ||| S:7587 E:7590 ||| VBZ
also  ||| S:7590 E:7595 ||| RB
observed  ||| S:7595 E:7615 ||| VBN
in  ||| S:7615 E:7618 ||| IN
vivo  ||| S:7618 E:7623 ||| NN
,  ||| S:7623 E:7625 ||| ,
excision  ||| S:7625 E:7634 ||| JJ
wounds  ||| S:7634 E:7641 ||| NNS
were  ||| S:7641 E:7646 ||| VBD
made  ||| S:7646 E:7661 ||| VBN
on  ||| S:7661 E:7664 ||| IN
the  ||| S:7664 E:7668 ||| DT
underside  ||| S:7668 E:7678 ||| NN
of  ||| S:7678 E:7681 ||| IN
wings  ||| S:7681 E:7687 ||| NNS
of  ||| S:7687 E:7690 ||| IN
2  ||| S:7690 E:7692 ||| CD
week-old  ||| S:7692 E:7701 ||| JJ
chicks ||| S:7701 E:7707 ||| NN
.  ||| S:7707 E:7709 ||| .
To  ||| S:7709 E:7712 ||| TO
avoid  ||| S:7712 E:7728 ||| VB
variations  ||| S:7728 E:7739 ||| NNS
in  ||| S:7739 E:7742 ||| IN
genetic  ||| S:7742 E:7750 ||| JJ
background ||| S:7750 E:7760 ||| NN
,  ||| S:7760 E:7762 ||| ,
for  ||| S:7762 E:7766 ||| IN
each  ||| S:7766 E:7771 ||| DT
bird  ||| S:7771 E:7776 ||| NN
one  ||| S:7776 E:7780 ||| CD
wing  ||| S:7780 E:7795 ||| NN
was  ||| S:7795 E:7799 ||| VBD
treated  ||| S:7799 E:7807 ||| VBN
with  ||| S:7807 E:7812 ||| IN
vehicle  ||| S:7812 E:7820 ||| NN
and  ||| S:7820 E:7824 ||| CC
the  ||| S:7824 E:7828 ||| DT
other  ||| S:7828 E:7834 ||| JJ
with  ||| S:7834 E:7839 ||| IN
cCAF ||| S:7839 E:7843 ||| NNP
,  ||| S:7843 E:7845 ||| ,
and  ||| S:7845 E:7859 ||| CC
treatments  ||| S:7859 E:7870 ||| NNS
were  ||| S:7870 E:7875 ||| VBD
applied  ||| S:7875 E:7883 ||| VBN
every  ||| S:7883 E:7889 ||| DT
other  ||| S:7889 E:7895 ||| JJ
day  ||| S:7895 E:7899 ||| NN
for  ||| S:7899 E:7903 ||| IN
5  ||| S:7903 E:7905 ||| CD
days ||| S:7905 E:7909 ||| NNS
.  ||| S:7909 E:7911 ||| .
In  ||| S:7911 E:7924 ||| IN
normal  ||| S:7924 E:7931 ||| JJ
wound  ||| S:7931 E:7937 ||| NN
healing ||| S:7937 E:7944 ||| NN
,  ||| S:7944 E:7946 ||| ,
TN  ||| S:7946 E:7949 ||| NNP
appeared  ||| S:7949 E:7958 ||| VBD
at  ||| S:7958 E:7961 ||| IN
days  ||| S:7961 E:7966 ||| NNS
2-3  ||| S:7966 E:7970 ||| CD
and  ||| S:7970 E:7984 ||| CC
disappeared  ||| S:7984 E:7996 ||| VBD
during  ||| S:7996 E:8003 ||| IN
remodeling  ||| S:8003 E:8014 ||| NN
which  ||| S:8014 E:8020 ||| WDT
begins  ||| S:8020 E:8027 ||| VBZ
around  ||| S:8027 E:8034 ||| IN
day  ||| S:8034 E:8038 ||| NN
10  ||| S:8038 E:8051 ||| CD
after  ||| S:8051 E:8057 ||| IN
wounding ||| S:8057 E:8065 ||| NN
.  ||| S:8065 E:8067 ||| .
Therefore ||| S:8067 E:8076 ||| RB
,  ||| S:8076 E:8078 ||| ,
tissues  ||| S:8078 E:8086 ||| NNS
were  ||| S:8086 E:8091 ||| VBD
collected  ||| S:8091 E:8101 ||| VBN
at  ||| S:8101 E:8104 ||| IN
days  ||| S:8104 E:8119 ||| NNS
3  ||| S:8119 E:8121 ||| CD
and  ||| S:8121 E:8125 ||| CC
7  ||| S:8125 E:8127 ||| CD
after  ||| S:8127 E:8133 ||| IN
wounding  ||| S:8133 E:8142 ||| NN
and  ||| S:8142 E:8146 ||| CC
analyzed  ||| S:8146 E:8155 ||| VBD
for  ||| S:8155 E:8159 ||| IN
TN  ||| S:8159 E:8162 ||| NNP
by  ||| S:8162 E:8175 ||| IN
immunostaining  ||| S:8175 E:8190 ||| NN
and  ||| S:8190 E:8194 ||| CC
western  ||| S:8194 E:8202 ||| JJ
blot  ||| S:8202 E:8207 ||| JJ
analysis  ||| S:8207 E:8216 ||| NN
( ||| S:8216 E:8217 ||| -LRB-
Fig.  ||| S:8217 E:8222 ||| NNP
2A ||| S:8222 E:8224 ||| NNP
&  ||| S:8224 E:8236 ||| CC
2B ||| S:8236 E:8238 ||| CD
) ||| S:8238 E:8239 ||| -RRB-
.  ||| S:8239 E:8241 ||| .
Immunoblot  ||| S:8241 E:8252 ||| JJ
analysis  ||| S:8252 E:8261 ||| NN
of  ||| S:8261 E:8264 ||| IN
protein  ||| S:8264 E:8272 ||| NN
extracted  ||| S:8272 E:8282 ||| VBN
from  ||| S:8282 E:8297 ||| IN
control  ||| S:8297 E:8305 ||| NN
wounds  ||| S:8305 E:8312 ||| NNS
confirmed  ||| S:8312 E:8322 ||| VBD
that  ||| S:8322 E:8327 ||| IN
TN  ||| S:8327 E:8330 ||| NNP
deposition  ||| S:8330 E:8341 ||| VBD
begun  ||| S:8341 E:8347 ||| VBN
by  ||| S:8347 E:8350 ||| IN
3  ||| S:8350 E:8362 ||| CD
days  ||| S:8362 E:8367 ||| NNS
and  ||| S:8367 E:8371 ||| CC
that  ||| S:8371 E:8376 ||| IN
it  ||| S:8376 E:8379 ||| PRP
increased  ||| S:8379 E:8389 ||| VBD
dramatically  ||| S:8389 E:8402 ||| RB
by  ||| S:8402 E:8405 ||| IN
7  ||| S:8405 E:8407 ||| CD
days  ||| S:8407 E:8412 ||| NNS
( ||| S:8412 E:8413 ||| -LRB-
Fig.  ||| S:8413 E:8428 ||| NNP
2C ||| S:8428 E:8430 ||| NNP
,  ||| S:8430 E:8432 ||| ,
Control ||| S:8432 E:8439 ||| NNP
) ||| S:8439 E:8440 ||| -RRB-
.  ||| S:8440 E:8442 ||| .
In  ||| S:8442 E:8445 ||| IN
contrast ||| S:8445 E:8453 ||| NN
,  ||| S:8453 E:8455 ||| ,
by  ||| S:8455 E:8458 ||| IN
3  ||| S:8458 E:8460 ||| CD
days ||| S:8460 E:8464 ||| NNS
,  ||| S:8464 E:8466 ||| ,
cCAF-treated  ||| S:8466 E:8479 ||| JJ
wounds  ||| S:8479 E:8496 ||| NNS
already  ||| S:8496 E:8504 ||| RB
contained  ||| S:8504 E:8514 ||| VBN
as  ||| S:8514 E:8517 ||| IN
much  ||| S:8517 E:8522 ||| JJ
TN  ||| S:8522 E:8525 ||| NN
as  ||| S:8525 E:8528 ||| IN
the  ||| S:8528 E:8532 ||| DT
control  ||| S:8532 E:8540 ||| NN
at  ||| S:8540 E:8543 ||| IN
7  ||| S:8543 E:8545 ||| CD
days  ||| S:8545 E:8550 ||| NNS
and  ||| S:8550 E:8564 ||| CC
that  ||| S:8564 E:8569 ||| IN
by  ||| S:8569 E:8572 ||| IN
7  ||| S:8572 E:8574 ||| CD
days ||| S:8574 E:8578 ||| NNS
,  ||| S:8578 E:8580 ||| ,
the  ||| S:8580 E:8584 ||| DT
TN  ||| S:8584 E:8587 ||| NNP
is  ||| S:8587 E:8590 ||| VBZ
dramatically  ||| S:8590 E:8603 ||| RB
reduced  ||| S:8603 E:8611 ||| VBN
by  ||| S:8611 E:8614 ||| IN
the  ||| S:8614 E:8628 ||| DT
ongoing  ||| S:8628 E:8636 ||| JJ
processes  ||| S:8636 E:8646 ||| NNS
of  ||| S:8646 E:8649 ||| IN
repair  ||| S:8649 E:8656 ||| NN
( ||| S:8656 E:8657 ||| -LRB-
Fig  ||| S:8657 E:8661 ||| NNP
2C ||| S:8661 E:8663 ||| NNP
,  ||| S:8663 E:8665 ||| ,
cCAF ||| S:8665 E:8669 ||| NNP
) ||| S:8669 E:8670 ||| -RRB-
.  ||| S:8670 E:8672 ||| .
Thus ||| S:8672 E:8676 ||| RB
,  ||| S:8676 E:8678 ||| ,
the  ||| S:8678 E:8692 ||| DT
addition  ||| S:8692 E:8701 ||| NN
of  ||| S:8701 E:8704 ||| IN
the  ||| S:8704 E:8708 ||| DT
chemokine  ||| S:8708 E:8718 ||| NN
to  ||| S:8718 E:8721 ||| TO
wounds  ||| S:8721 E:8728 ||| VB
shifts  ||| S:8728 E:8735 ||| NNS
the  ||| S:8735 E:8739 ||| DT
peak  ||| S:8739 E:8744 ||| NN
of  ||| S:8744 E:8747 ||| IN
TN  ||| S:8747 E:8760 ||| NNP
in  ||| S:8760 E:8763 ||| IN
the  ||| S:8763 E:8767 ||| DT
wound  ||| S:8767 E:8773 ||| JJ
tissues  ||| S:8773 E:8781 ||| NNS
to  ||| S:8781 E:8784 ||| TO
earlier  ||| S:8784 E:8792 ||| JJR
stages  ||| S:8792 E:8799 ||| NNS
of  ||| S:8799 E:8802 ||| IN
wound  ||| S:8802 E:8808 ||| JJ
healing  ||| S:8808 E:8826 ||| NN
than  ||| S:8826 E:8831 ||| IN
in  ||| S:8831 E:8834 ||| IN
control  ||| S:8834 E:8842 ||| NN
wounds ||| S:8842 E:8848 ||| NNS
.  ||| S:8848 E:8878 ||| .
Effects  ||| S:8878 E:8886 ||| NNS
of  ||| S:8886 E:8889 ||| IN
cCAF  ||| S:8889 E:8894 ||| JJ
and  ||| S:8894 E:8898 ||| CC
its  ||| S:8898 E:8902 ||| PRP$
peptides  ||| S:8902 E:8911 ||| NN
on  ||| S:8911 E:8914 ||| IN
the  ||| S:8914 E:8918 ||| DT
production  ||| S:8918 E:8939 ||| NN
of  ||| S:8939 E:8942 ||| IN
FN  ||| S:8942 E:8955 ||| NNP
Cellular  ||| S:8955 E:8964 ||| NNP
FN  ||| S:8964 E:8967 ||| NNP
is  ||| S:8967 E:8970 ||| VBZ
abundantly  ||| S:8970 E:8981 ||| RB
present  ||| S:8981 E:8989 ||| VB
in  ||| S:8989 E:8992 ||| IN
granulation  ||| S:8992 E:9014 ||| JJ
tissue ||| S:9014 E:9020 ||| NN
,  ||| S:9020 E:9022 ||| ,
is  ||| S:9022 E:9025 ||| VBZ
produced  ||| S:9025 E:9034 ||| VBN
primarily  ||| S:9034 E:9044 ||| RB
by  ||| S:9044 E:9047 ||| IN
the  ||| S:9047 E:9051 ||| DT
wound  ||| S:9051 E:9057 ||| JJ
fibroblasts  ||| S:9057 E:9079 ||| NN
and  ||| S:9079 E:9083 ||| CC
myofibroblasts ||| S:9083 E:9097 ||| NN
.  ||| S:9097 E:9099 ||| .
Fibroblast  ||| S:9099 E:9110 ||| JJ
cultures  ||| S:9110 E:9119 ||| NNS
treated  ||| S:9119 E:9127 ||| VBN
as  ||| S:9127 E:9130 ||| IN
for  ||| S:9130 E:9144 ||| IN
TN ||| S:9144 E:9146 ||| NNP
,  ||| S:9146 E:9148 ||| ,
produced  ||| S:9148 E:9157 ||| VBD
much  ||| S:9157 E:9162 ||| RB
more  ||| S:9162 E:9167 ||| JJR
FN ||| S:9167 E:9169 ||| NNP
,  ||| S:9169 E:9171 ||| ,
as  ||| S:9171 E:9174 ||| RB
shown  ||| S:9174 E:9180 ||| VBN
by  ||| S:9180 E:9183 ||| IN
immunolabeling  ||| S:9183 E:9208 ||| NNS
( ||| S:9208 E:9209 ||| -LRB-
Figs.  ||| S:9209 E:9215 ||| NNP
3A ||| S:9215 E:9217 ||| NNP
&  ||| S:9217 E:9219 ||| CC
3B ||| S:9219 E:9221 ||| CD
)  ||| S:9221 E:9223 ||| -RRB-
and  ||| S:9223 E:9227 ||| CC
immunoblot  ||| S:9227 E:9238 ||| JJ
analysis  ||| S:9238 E:9247 ||| NN
( ||| S:9247 E:9248 ||| -LRB-
Fig.  ||| S:9248 E:9253 ||| NNP
3E ||| S:9253 E:9255 ||| NNP
) ||| S:9255 E:9256 ||| -RRB-
.  ||| S:9256 E:9268 ||| .
Unlike  ||| S:9268 E:9275 ||| IN
TN ||| S:9275 E:9277 ||| NNP
,  ||| S:9277 E:9279 ||| ,
this  ||| S:9279 E:9284 ||| DT
effect  ||| S:9284 E:9291 ||| NN
can  ||| S:9291 E:9295 ||| MD
only  ||| S:9295 E:9300 ||| RB
be  ||| S:9300 E:9303 ||| VB
accomplished  ||| S:9303 E:9316 ||| VBN
by  ||| S:9316 E:9319 ||| IN
the  ||| S:9319 E:9333 ||| DT
whole  ||| S:9333 E:9339 ||| JJ
cCAF  ||| S:9339 E:9344 ||| JJ
molecule ||| S:9344 E:9352 ||| NN
;  ||| S:9352 E:9354 ||| :
immunolabeling  ||| S:9354 E:9369 ||| NNS
and  ||| S:9369 E:9373 ||| CC
immunoblot  ||| S:9373 E:9394 ||| JJ
analysis  ||| S:9394 E:9403 ||| NN
of  ||| S:9403 E:9406 ||| IN
cells  ||| S:9406 E:9412 ||| NNS
treated  ||| S:9412 E:9420 ||| VBN
with  ||| S:9420 E:9425 ||| IN
the  ||| S:9425 E:9429 ||| DT
N-peptide  ||| S:9429 E:9439 ||| JJ
( ||| S:9439 E:9440 ||| -LRB-
Fig.  ||| S:9440 E:9455 ||| NNP
3C ||| S:9455 E:9457 ||| NNP
&  ||| S:9457 E:9459 ||| CC
3E ||| S:9459 E:9461 ||| CD
)  ||| S:9461 E:9463 ||| -RRB-
or  ||| S:9463 E:9466 ||| CC
C-peptide  ||| S:9466 E:9476 ||| NNP
( ||| S:9476 E:9477 ||| -LRB-
Fig.  ||| S:9477 E:9482 ||| NNP
3D ||| S:9482 E:9484 ||| NNP
&  ||| S:9484 E:9486 ||| CC
3E ||| S:9486 E:9488 ||| CD
)  ||| S:9488 E:9490 ||| -RRB-
revealed  ||| S:9490 E:9509 ||| VBD
similar  ||| S:9509 E:9517 ||| JJ
FN  ||| S:9517 E:9520 ||| NN
levels  ||| S:9520 E:9527 ||| NNS
to  ||| S:9527 E:9530 ||| TO
control ||| S:9530 E:9537 ||| VB
.  ||| S:9537 E:9539 ||| .
Unlike  ||| S:9539 E:9546 ||| IN
TN ||| S:9546 E:9548 ||| NNP
,  ||| S:9548 E:9550 ||| ,
cCAF  ||| S:9550 E:9555 ||| NNP
did  ||| S:9555 E:9559 ||| VBD
not  ||| S:9559 E:9573 ||| RB
affect  ||| S:9573 E:9580 ||| VB
FN  ||| S:9580 E:9583 ||| JJ
mRNA  ||| S:9583 E:9588 ||| JJ
levels  ||| S:9588 E:9595 ||| NNS
( ||| S:9595 E:9596 ||| -LRB-
Fig.  ||| S:9596 E:9601 ||| NNP
3F ||| S:9601 E:9603 ||| NNP
) ||| S:9603 E:9604 ||| -RRB-
.  ||| S:9604 E:9617 ||| .
In  ||| S:9617 E:9620 ||| IN
vivo  ||| S:9620 E:9625 ||| NN
,  ||| S:9625 E:9627 ||| ,
immunostaining  ||| S:9627 E:9642 ||| VBG
for  ||| S:9642 E:9646 ||| IN
FN ||| S:9646 E:9648 ||| NNP
,  ||| S:9648 E:9650 ||| ,
3  ||| S:9650 E:9662 ||| CD
days  ||| S:9662 E:9667 ||| NNS
after  ||| S:9667 E:9673 ||| IN
making  ||| S:9673 E:9680 ||| VBG
excision  ||| S:9680 E:9689 ||| NN
wounds ||| S:9689 E:9695 ||| NNS
,  ||| S:9695 E:9697 ||| ,
showed  ||| S:9697 E:9704 ||| VBD
that  ||| S:9704 E:9709 ||| IN
levels  ||| S:9709 E:9716 ||| NNS
of  ||| S:9716 E:9729 ||| IN
this  ||| S:9729 E:9734 ||| DT
protein  ||| S:9734 E:9742 ||| NN
are  ||| S:9742 E:9746 ||| VBP
high  ||| S:9746 E:9751 ||| JJ
in  ||| S:9751 E:9754 ||| IN
the  ||| S:9754 E:9758 ||| DT
healing  ||| S:9758 E:9766 ||| NN
tissues  ||| S:9766 E:9774 ||| NNS
and  ||| S:9774 E:9778 ||| CC
that  ||| S:9778 E:9793 ||| DT
treatment  ||| S:9793 E:9803 ||| NN
with  ||| S:9803 E:9808 ||| IN
cCAF  ||| S:9808 E:9813 ||| NNP
increased  ||| S:9813 E:9823 ||| VBD
FN  ||| S:9823 E:9826 ||| NNP
accumulation  ||| S:9826 E:9839 ||| NN
in  ||| S:9839 E:9842 ||| IN
the  ||| S:9842 E:9856 ||| DT
granulation  ||| S:9856 E:9868 ||| JJ
tissue  ||| S:9868 E:9875 ||| NN
( ||| S:9875 E:9876 ||| -LRB-
Fig.  ||| S:9876 E:9881 ||| NNP
4A ||| S:9881 E:9883 ||| NNP
&  ||| S:9883 E:9885 ||| CC
4B ||| S:9885 E:9887 ||| CD
) ||| S:9887 E:9888 ||| -RRB-
.  ||| S:9888 E:9890 ||| .
Immunoblot  ||| S:9890 E:9901 ||| JJ
analysis  ||| S:9901 E:9920 ||| NN
for  ||| S:9920 E:9924 ||| IN
FN  ||| S:9924 E:9927 ||| NNP
extracted  ||| S:9927 E:9937 ||| VBD
from  ||| S:9937 E:9942 ||| IN
excision  ||| S:9942 E:9951 ||| JJ
wounds  ||| S:9951 E:9958 ||| NNS
showed  ||| S:9958 E:9965 ||| VBD
that  ||| S:9965 E:9970 ||| IN
by  ||| S:9970 E:9973 ||| IN
3  ||| S:9973 E:9985 ||| CD
days  ||| S:9985 E:9990 ||| NNS
after  ||| S:9990 E:9996 ||| IN
injury  ||| S:9996 E:10003 ||| VBG
the  ||| S:10003 E:10007 ||| DT
cCAF-treated  ||| S:10007 E:10020 ||| JJ
wounds  ||| S:10020 E:10027 ||| NNS
contained  ||| S:10027 E:10037 ||| VBD
more  ||| S:10037 E:10052 ||| JJR
FN  ||| S:10052 E:10055 ||| NN
than  ||| S:10055 E:10060 ||| IN
the  ||| S:10060 E:10064 ||| DT
control  ||| S:10064 E:10072 ||| NN
wounds  ||| S:10072 E:10079 ||| NNS
but  ||| S:10079 E:10083 ||| CC
that  ||| S:10083 E:10088 ||| IN
the  ||| S:10088 E:10092 ||| DT
levels  ||| S:10092 E:10099 ||| NNS
by  ||| S:10099 E:10102 ||| IN
7  ||| S:10102 E:10104 ||| CD
days  ||| S:10104 E:10119 ||| NNS
are  ||| S:10119 E:10123 ||| VBP
similar  ||| S:10123 E:10131 ||| JJ
to  ||| S:10131 E:10134 ||| TO
those  ||| S:10134 E:10140 ||| DT
of  ||| S:10140 E:10143 ||| IN
the  ||| S:10143 E:10147 ||| DT
control  ||| S:10147 E:10155 ||| NN
( ||| S:10155 E:10156 ||| -LRB-
Fig.  ||| S:10156 E:10161 ||| NNP
4C ||| S:10161 E:10163 ||| NNP
) ||| S:10163 E:10164 ||| -RRB-
.  ||| S:10164 E:10176 ||| .
Taken  ||| S:10176 E:10182 ||| VBN
together  ||| S:10182 E:10191 ||| RP
the  ||| S:10191 E:10195 ||| DT
results  ||| S:10195 E:10203 ||| NNS
in  ||| S:10203 E:10206 ||| IN
culture  ||| S:10206 E:10214 ||| NN
and  ||| S:10214 E:10229 ||| CC
in  ||| S:10229 E:10232 ||| IN
vivo  ||| S:10232 E:10237 ||| NNS
suggest  ||| S:10237 E:10245 ||| VBP
that  ||| S:10245 E:10250 ||| IN
the  ||| S:10250 E:10254 ||| DT
chemokine  ||| S:10254 E:10274 ||| NN
does  ||| S:10274 E:10279 ||| VBZ
not  ||| S:10279 E:10283 ||| RB
stimulate  ||| S:10283 E:10293 ||| VB
FN  ||| S:10293 E:10296 ||| JJ
gene  ||| S:10296 E:10301 ||| NN
expression  ||| S:10301 E:10312 ||| NN
but  ||| S:10312 E:10316 ||| CC
rather  ||| S:10316 E:10323 ||| RB
may  ||| S:10323 E:10337 ||| MD
directly  ||| S:10337 E:10346 ||| RB
or  ||| S:10346 E:10349 ||| CC
indirectly  ||| S:10349 E:10360 ||| RB
affect  ||| S:10360 E:10367 ||| VB
stability  ||| S:10367 E:10377 ||| NN
of  ||| S:10377 E:10380 ||| IN
this  ||| S:10380 E:10385 ||| DT
protein ||| S:10385 E:10392 ||| NN
.  ||| S:10392 E:10404 ||| .
Therefore ||| S:10404 E:10413 ||| RB
,  ||| S:10413 E:10415 ||| ,
we  ||| S:10415 E:10418 ||| PRP
tested  ||| S:10418 E:10425 ||| VBD
the  ||| S:10425 E:10429 ||| DT
possibility  ||| S:10429 E:10441 ||| NN
that  ||| S:10441 E:10446 ||| IN
cCAF  ||| S:10446 E:10451 ||| JJ
treatment  ||| S:10451 E:10471 ||| NN
leads  ||| S:10471 E:10477 ||| VBZ
to  ||| S:10477 E:10480 ||| TO
stability  ||| S:10480 E:10490 ||| NN
of  ||| S:10490 E:10493 ||| IN
the  ||| S:10493 E:10497 ||| DT
protein  ||| S:10497 E:10505 ||| NN
by  ||| S:10505 E:10508 ||| IN
stimulating  ||| S:10508 E:10520 ||| VBG
decrease  ||| S:10520 E:10539 ||| NN
in  ||| S:10539 E:10542 ||| IN
matrix  ||| S:10542 E:10549 ||| JJ
degrading  ||| S:10549 E:10559 ||| JJ
enzymes ||| S:10559 E:10566 ||| NN
.  ||| S:10566 E:10568 ||| .
In  ||| S:10568 E:10571 ||| IN
chickens ||| S:10571 E:10579 ||| NNS
,  ||| S:10579 E:10581 ||| ,
plasmin  ||| S:10581 E:10599 ||| VBD
generated  ||| S:10599 E:10609 ||| VBN
from  ||| S:10609 E:10614 ||| IN
plasminogen  ||| S:10614 E:10626 ||| NN
by  ||| S:10626 E:10629 ||| IN
plasminogen  ||| S:10629 E:10641 ||| JJ
activator  ||| S:10641 E:10651 ||| NNS
( ||| S:10651 E:10652 ||| -LRB-
PA ||| S:10652 E:10654 ||| NNP
)  ||| S:10654 E:10666 ||| -RRB-
degrades  ||| S:10666 E:10675 ||| VBZ
much  ||| S:10675 E:10680 ||| RB
of  ||| S:10680 E:10683 ||| IN
the  ||| S:10683 E:10687 ||| DT
FN ||| S:10687 E:10689 ||| NNP
.  ||| S:10689 E:10691 ||| .
To  ||| S:10691 E:10694 ||| TO
investigate  ||| S:10694 E:10706 ||| VB
whether  ||| S:10706 E:10714 ||| IN
activity  ||| S:10714 E:10733 ||| NN
of  ||| S:10733 E:10736 ||| IN
PA  ||| S:10736 E:10739 ||| NNP
might  ||| S:10739 E:10745 ||| MD
be  ||| S:10745 E:10748 ||| VB
decreased  ||| S:10748 E:10758 ||| VBN
with  ||| S:10758 E:10763 ||| IN
cCAF  ||| S:10763 E:10768 ||| JJ
treatment  ||| S:10768 E:10778 ||| NN
leading  ||| S:10778 E:10786 ||| VBG
to  ||| S:10786 E:10799 ||| TO
accumulation  ||| S:10799 E:10812 ||| VB
of  ||| S:10812 E:10815 ||| IN
FN ||| S:10815 E:10817 ||| NNP
,  ||| S:10817 E:10819 ||| ,
we  ||| S:10819 E:10822 ||| PRP
examined  ||| S:10822 E:10831 ||| VBD
the  ||| S:10831 E:10835 ||| DT
levels  ||| S:10835 E:10842 ||| NNS
of  ||| S:10842 E:10845 ||| IN
PA  ||| S:10845 E:10858 ||| NNP
activity ||| S:10858 E:10866 ||| NN
.  ||| S:10866 E:10868 ||| .
Our  ||| S:10868 E:10872 ||| PRP$
results  ||| S:10872 E:10880 ||| NNS
showed  ||| S:10880 E:10887 ||| VBD
that  ||| S:10887 E:10892 ||| IN
there  ||| S:10892 E:10898 ||| EX
is  ||| S:10898 E:10901 ||| VBZ
no  ||| S:10901 E:10904 ||| DT
detectable  ||| S:10904 E:10925 ||| JJ
PA  ||| S:10925 E:10928 ||| NNP
activity  ||| S:10928 E:10937 ||| NN
in  ||| S:10937 E:10940 ||| IN
untreated  ||| S:10940 E:10950 ||| NN
or  ||| S:10950 E:10953 ||| CC
treated  ||| S:10953 E:10961 ||| JJ
fibroblasts  ||| S:10961 E:10973 ||| NN
whereas  ||| S:10973 E:10991 ||| IN
the  ||| S:10991 E:10995 ||| DT
activity  ||| S:10995 E:11004 ||| NN
is  ||| S:11004 E:11007 ||| VBZ
high  ||| S:11007 E:11012 ||| JJ
in  ||| S:11012 E:11015 ||| IN
RSV-transformed  ||| S:11015 E:11031 ||| JJ
CEFs  ||| S:11031 E:11036 ||| NN
( ||| S:11036 E:11037 ||| -LRB-
tCEFs ||| S:11037 E:11042 ||| NNP
;  ||| S:11042 E:11044 ||| :
Fig.  ||| S:11044 E:11059 ||| CD
5A ||| S:11059 E:11061 ||| CD
)  ||| S:11061 E:11063 ||| -RRB-
which  ||| S:11063 E:11069 ||| WDT
are  ||| S:11069 E:11073 ||| VBP
known  ||| S:11073 E:11079 ||| VBN
to  ||| S:11079 E:11082 ||| TO
produce  ||| S:11082 E:11090 ||| VB
high  ||| S:11090 E:11095 ||| JJ
levels  ||| S:11095 E:11102 ||| NNS
of  ||| S:11102 E:11105 ||| IN
PA  ||| S:11105 E:11108 ||| NNP
[  ||| S:11108 E:11110 ||| -LRB-
31  ||| S:11110 E:11113 ||| CD
]  ||| S:11113 E:11115 ||| -RRB-
.  ||| S:11115 E:11127 ||| .
Because  ||| S:11127 E:11135 ||| IN
PA  ||| S:11135 E:11138 ||| NNP
does  ||| S:11138 E:11143 ||| VBZ
not  ||| S:11143 E:11147 ||| RB
appear  ||| S:11147 E:11154 ||| VB
to  ||| S:11154 E:11157 ||| TO
be  ||| S:11157 E:11160 ||| VB
activated  ||| S:11160 E:11170 ||| VBN
by  ||| S:11170 E:11173 ||| IN
cCAF ||| S:11173 E:11177 ||| NNP
,  ||| S:11177 E:11179 ||| ,
we  ||| S:11179 E:11192 ||| PRP
tested  ||| S:11192 E:11199 ||| VBD
the  ||| S:11199 E:11203 ||| DT
possibility  ||| S:11203 E:11215 ||| NN
that  ||| S:11215 E:11220 ||| IN
the  ||| S:11220 E:11224 ||| DT
stability  ||| S:11224 E:11234 ||| NN
of  ||| S:11234 E:11237 ||| IN
FN  ||| S:11237 E:11240 ||| NNP
is  ||| S:11240 E:11243 ||| VBZ
due  ||| S:11243 E:11247 ||| JJ
to  ||| S:11247 E:11260 ||| TO
a  ||| S:11260 E:11262 ||| DT
decrease  ||| S:11262 E:11271 ||| NN
in  ||| S:11271 E:11274 ||| IN
MMP  ||| S:11274 E:11278 ||| NNP
production ||| S:11278 E:11288 ||| NN
/ ||| S:11288 E:11289 ||| CD
activation ||| S:11289 E:11299 ||| NNS
.  ||| S:11299 E:11301 ||| .
In  ||| S:11301 E:11304 ||| IN
humans ||| S:11304 E:11310 ||| NNS
,  ||| S:11310 E:11322 ||| ,
MMP-3 ||| S:11322 E:11327 ||| NNP
,  ||| S:11327 E:11329 ||| ,
MMP-7  ||| S:11329 E:11335 ||| NNP
and  ||| S:11335 E:11339 ||| CC
MMP-10  ||| S:11339 E:11346 ||| NNP
( ||| S:11346 E:11347 ||| -LRB-
stromelysins ||| S:11347 E:11359 ||| LS
)  ||| S:11359 E:11361 ||| -RRB-
are  ||| S:11361 E:11365 ||| VBP
the  ||| S:11365 E:11369 ||| DT
most  ||| S:11369 E:11384 ||| RBS
active  ||| S:11384 E:11391 ||| JJ
proteases  ||| S:11391 E:11401 ||| NN
for  ||| S:11401 E:11405 ||| IN
FN ||| S:11405 E:11407 ||| NNP
,  ||| S:11407 E:11409 ||| ,
but  ||| S:11409 E:11413 ||| CC
these  ||| S:11413 E:11419 ||| DT
molecules  ||| S:11419 E:11429 ||| NNS
have  ||| S:11429 E:11434 ||| VBP
not  ||| S:11434 E:11448 ||| RB
been  ||| S:11448 E:11453 ||| VBN
isolated  ||| S:11453 E:11462 ||| VBN
in  ||| S:11462 E:11465 ||| IN
chickens ||| S:11465 E:11473 ||| NNS
.  ||| S:11473 E:11475 ||| .
However ||| S:11475 E:11482 ||| RB
,  ||| S:11482 E:11484 ||| ,
we  ||| S:11484 E:11487 ||| PRP
can  ||| S:11487 E:11491 ||| MD
test  ||| S:11491 E:11496 ||| VB
for  ||| S:11496 E:11510 ||| IN
general  ||| S:11510 E:11518 ||| JJ
activity  ||| S:11518 E:11527 ||| NN
of  ||| S:11527 E:11530 ||| IN
these  ||| S:11530 E:11536 ||| DT
MMPs  ||| S:11536 E:11541 ||| JJ
in  ||| S:11541 E:11544 ||| IN
the  ||| S:11544 E:11548 ||| DT
chicken  ||| S:11548 E:11556 ||| NN
system  ||| S:11556 E:11563 ||| NN
by  ||| S:11563 E:11576 ||| IN
zymography  ||| S:11576 E:11587 ||| NNS
using  ||| S:11587 E:11593 ||| VBG
casein  ||| S:11593 E:11600 ||| NN
as  ||| S:11600 E:11603 ||| IN
substrate  ||| S:11603 E:11613 ||| NNS
( ||| S:11613 E:11614 ||| -LRB-
Fig.  ||| S:11614 E:11619 ||| NNP
5B ||| S:11619 E:11621 ||| NNP
) ||| S:11621 E:11622 ||| -RRB-
.  ||| S:11622 E:11624 ||| .
Whereas  ||| S:11624 E:11642 ||| IN
the  ||| S:11642 E:11646 ||| DT
positive  ||| S:11646 E:11655 ||| JJ
control  ||| S:11655 E:11663 ||| NN
( ||| S:11663 E:11664 ||| -LRB-
trypsin ||| S:11664 E:11671 ||| LS
)  ||| S:11671 E:11673 ||| -RRB-
was  ||| S:11673 E:11677 ||| VBD
able  ||| S:11677 E:11682 ||| JJ
to  ||| S:11682 E:11685 ||| TO
digest  ||| S:11685 E:11692 ||| VB
the  ||| S:11692 E:11706 ||| DT
substrate  ||| S:11706 E:11716 ||| NN
at  ||| S:11716 E:11719 ||| IN
specific  ||| S:11719 E:11728 ||| JJ
sites  ||| S:11728 E:11734 ||| NNS
in  ||| S:11734 E:11737 ||| IN
the  ||| S:11737 E:11741 ||| DT
gel ||| S:11741 E:11744 ||| NN
,  ||| S:11744 E:11746 ||| ,
the  ||| S:11746 E:11750 ||| DT
supernatants  ||| S:11750 E:11773 ||| NN
of  ||| S:11773 E:11776 ||| IN
our  ||| S:11776 E:11780 ||| PRP$
treated  ||| S:11780 E:11788 ||| JJ
fibroblasts  ||| S:11788 E:11800 ||| NN
did  ||| S:11800 E:11804 ||| VBD
not ||| S:11804 E:11807 ||| RB
.  ||| S:11807 E:11809 ||| .
This  ||| S:11809 E:11814 ||| DT
suggests  ||| S:11814 E:11823 ||| VBZ
that  ||| S:11823 E:11838 ||| IN
the  ||| S:11838 E:11842 ||| DT
stromelysins  ||| S:11842 E:11855 ||| NNS
are  ||| S:11855 E:11859 ||| VBP
not  ||| S:11859 E:11863 ||| RB
active  ||| S:11863 E:11870 ||| JJ
in  ||| S:11870 E:11873 ||| IN
this  ||| S:11873 E:11878 ||| DT
system  ||| S:11878 E:11885 ||| NN
or  ||| S:11885 E:11888 ||| CC
that  ||| S:11888 E:11903 ||| IN
our  ||| S:11903 E:11907 ||| PRP$
test  ||| S:11907 E:11912 ||| NN
is  ||| S:11912 E:11915 ||| VBZ
not  ||| S:11915 E:11919 ||| RB
sensitive  ||| S:11919 E:11929 ||| JJ
enough ||| S:11929 E:11935 ||| NN
.  ||| S:11935 E:11937 ||| .
To  ||| S:11937 E:11940 ||| TO
further  ||| S:11940 E:11948 ||| RB
investigate  ||| S:11948 E:11970 ||| VB
whether  ||| S:11970 E:11978 ||| IN
MMPs  ||| S:11978 E:11983 ||| NNS
are  ||| S:11983 E:11987 ||| VBP
involved  ||| S:11987 E:11996 ||| VBN
in  ||| S:11996 E:11999 ||| IN
the  ||| S:11999 E:12003 ||| DT
cCAF  ||| S:12003 E:12008 ||| JJ
induced  ||| S:12008 E:12016 ||| JJ
high  ||| S:12016 E:12021 ||| JJ
levels  ||| S:12021 E:12038 ||| NNS
of  ||| S:12038 E:12041 ||| IN
FN  ||| S:12041 E:12044 ||| NNP
will  ||| S:12044 E:12049 ||| MD
require  ||| S:12049 E:12057 ||| VB
evaluation  ||| S:12057 E:12068 ||| NN
of  ||| S:12068 E:12071 ||| IN
matrix-degrading  ||| S:12071 E:12088 ||| JJ
enzymes  ||| S:12088 E:12106 ||| JJ
specific  ||| S:12106 E:12115 ||| JJ
for  ||| S:12115 E:12119 ||| IN
chickens  ||| S:12119 E:12128 ||| NNS
and  ||| S:12128 E:12132 ||| CC
is  ||| S:12132 E:12135 ||| VBZ
an  ||| S:12135 E:12138 ||| DT
ongoing  ||| S:12138 E:12146 ||| JJ
project  ||| S:12146 E:12154 ||| NN
in  ||| S:12154 E:12157 ||| IN
our  ||| S:12157 E:12171 ||| PRP$
laboratory  ||| S:12171 E:12182 ||| NN
as  ||| S:12182 E:12185 ||| IN
we  ||| S:12185 E:12188 ||| PRP
obtain ||| S:12188 E:12194 ||| VBP
/ ||| S:12194 E:12195 ||| RB
develop  ||| S:12195 E:12203 ||| VB
probes  ||| S:12203 E:12210 ||| NNS
for  ||| S:12210 E:12214 ||| IN
theses  ||| S:12214 E:12221 ||| JJ
MMPs ||| S:12221 E:12225 ||| NN
.  ||| S:12225 E:12237 ||| .
However ||| S:12237 E:12244 ||| RB
,  ||| S:12244 E:12246 ||| ,
another  ||| S:12246 E:12254 ||| DT
possible  ||| S:12254 E:12263 ||| JJ
mechanism  ||| S:12263 E:12273 ||| NN
for  ||| S:12273 E:12277 ||| IN
the  ||| S:12277 E:12281 ||| DT
cCAF-induced  ||| S:12281 E:12304 ||| JJ
FN  ||| S:12304 E:12307 ||| NNP
accumulation  ||| S:12307 E:12320 ||| NN
could  ||| S:12320 E:12326 ||| MD
be  ||| S:12326 E:12329 ||| VB
linked  ||| S:12329 E:12336 ||| VBN
to  ||| S:12336 E:12339 ||| TO
an  ||| S:12339 E:12342 ||| DT
increase  ||| S:12342 E:12351 ||| NN
in  ||| S:12351 E:12354 ||| IN
TN ||| S:12354 E:12356 ||| NNP
.  ||| S:12356 E:12368 ||| .
TN-C  ||| S:12368 E:12373 ||| JJ
knockout  ||| S:12373 E:12382 ||| NN
mice  ||| S:12382 E:12387 ||| NNS
show  ||| S:12387 E:12392 ||| VBP
decreased  ||| S:12392 E:12402 ||| VBN
accumulation  ||| S:12402 E:12415 ||| NN
of  ||| S:12415 E:12418 ||| IN
FN  ||| S:12418 E:12421 ||| NNP
in  ||| S:12421 E:12434 ||| IN
wounded  ||| S:12434 E:12442 ||| JJ
tissue  ||| S:12442 E:12449 ||| NN
and  ||| S:12449 E:12453 ||| CC
this  ||| S:12453 E:12458 ||| DT
decrease  ||| S:12458 E:12467 ||| NN
has  ||| S:12467 E:12471 ||| VBZ
been  ||| S:12471 E:12476 ||| VBN
hypothesized  ||| S:12476 E:12489 ||| VBN
to  ||| S:12489 E:12502 ||| TO
be  ||| S:12502 E:12505 ||| VB
due  ||| S:12505 E:12509 ||| JJ
to  ||| S:12509 E:12512 ||| TO
disrupted  ||| S:12512 E:12522 ||| VB
incorporation  ||| S:12522 E:12536 ||| VBN
of  ||| S:12536 E:12539 ||| IN
FN  ||| S:12539 E:12542 ||| NNP
into  ||| S:12542 E:12547 ||| IN
the  ||| S:12547 E:12551 ||| DT
matrix  ||| S:12551 E:12568 ||| NN
in  ||| S:12568 E:12571 ||| IN
the  ||| S:12571 E:12575 ||| DT
absence  ||| S:12575 E:12583 ||| NN
of  ||| S:12583 E:12586 ||| IN
TN-C  ||| S:12586 E:12591 ||| NNP
[  ||| S:12591 E:12593 ||| -LRB-
32  ||| S:12593 E:12596 ||| CD
33  ||| S:12596 E:12599 ||| CD
]  ||| S:12599 E:12601 ||| -RRB-
.  ||| S:12601 E:12603 ||| .
To  ||| S:12603 E:12606 ||| TO
determine  ||| S:12606 E:12616 ||| VB
whether  ||| S:12616 E:12634 ||| IN
cCAF-induced  ||| S:12634 E:12647 ||| NNP
TN  ||| S:12647 E:12650 ||| NNP
production  ||| S:12650 E:12661 ||| NN
is  ||| S:12661 E:12664 ||| VBZ
involved  ||| S:12664 E:12673 ||| VBN
in  ||| S:12673 E:12676 ||| IN
the  ||| S:12676 E:12680 ||| DT
increase  ||| S:12680 E:12689 ||| NN
in  ||| S:12689 E:12702 ||| IN
FN  ||| S:12702 E:12705 ||| NNP
observed  ||| S:12705 E:12714 ||| VBD
after  ||| S:12714 E:12720 ||| IN
cCAF  ||| S:12720 E:12725 ||| JJ
treatment ||| S:12725 E:12734 ||| NN
,  ||| S:12734 E:12736 ||| ,
we  ||| S:12736 E:12739 ||| PRP
used  ||| S:12739 E:12744 ||| VBD
antisense  ||| S:12744 E:12764 ||| JJ
phosphothioated  ||| S:12764 E:12780 ||| JJ
oligonucleotides  ||| S:12780 E:12797 ||| NN
to  ||| S:12797 E:12800 ||| TO
inhibit  ||| S:12800 E:12808 ||| VB
TN  ||| S:12808 E:12821 ||| JJ
production ||| S:12821 E:12831 ||| NN
.  ||| S:12831 E:12833 ||| .
Sense  ||| S:12833 E:12839 ||| NN
oligonucleotides  ||| S:12839 E:12856 ||| NNS
did  ||| S:12856 E:12860 ||| VBD
not  ||| S:12860 E:12864 ||| RB
have  ||| S:12864 E:12869 ||| VB
an  ||| S:12869 E:12872 ||| DT
effect  ||| S:12872 E:12889 ||| NN
on  ||| S:12889 E:12892 ||| IN
cCAF-induced  ||| S:12892 E:12905 ||| NNP
TN  ||| S:12905 E:12908 ||| NNP
or  ||| S:12908 E:12911 ||| CC
FN  ||| S:12911 E:12914 ||| NNP
production ||| S:12914 E:12924 ||| NN
.  ||| S:12924 E:12926 ||| .
However ||| S:12926 E:12933 ||| RB
,  ||| S:12933 E:12935 ||| ,
the  ||| S:12935 E:12949 ||| DT
antisense  ||| S:12949 E:12959 ||| JJ
oligonucleotides  ||| S:12959 E:12976 ||| NN
were  ||| S:12976 E:12981 ||| VBD
able  ||| S:12981 E:12986 ||| JJ
to  ||| S:12986 E:12989 ||| TO
significantly  ||| S:12989 E:13013 ||| RB
decrease  ||| S:13013 E:13022 ||| VB
the  ||| S:13022 E:13026 ||| DT
production  ||| S:13026 E:13037 ||| NN
of  ||| S:13037 E:13040 ||| IN
both  ||| S:13040 E:13045 ||| DT
TN  ||| S:13045 E:13048 ||| NNP
and  ||| S:13048 E:13052 ||| CC
FN  ||| S:13052 E:13055 ||| NNP
( ||| S:13055 E:13056 ||| -LRB-
Fig.  ||| S:13056 E:13061 ||| NNP
5C ||| S:13061 E:13063 ||| NNP
) ||| S:13063 E:13064 ||| -RRB-
.  ||| S:13064 E:13094 ||| .
Effects  ||| S:13094 E:13102 ||| NNS
of  ||| S:13102 E:13105 ||| IN
cCAF  ||| S:13105 E:13110 ||| JJ
and  ||| S:13110 E:13114 ||| CC
its  ||| S:13114 E:13118 ||| PRP$
peptides  ||| S:13118 E:13127 ||| NN
on  ||| S:13127 E:13130 ||| IN
the  ||| S:13130 E:13134 ||| DT
production  ||| S:13134 E:13155 ||| NN
of  ||| S:13155 E:13158 ||| IN
Colls  ||| S:13158 E:13164 ||| NNP
I  ||| S:13164 E:13166 ||| NNP
and  ||| S:13166 E:13170 ||| CC
III  ||| S:13170 E:13184 ||| NNP
To  ||| S:13184 E:13187 ||| TO
determine  ||| S:13187 E:13197 ||| VB
whether  ||| S:13197 E:13205 ||| IN
cCAF  ||| S:13205 E:13210 ||| JJ
stimulates  ||| S:13210 E:13221 ||| JJ
fibroblasts  ||| S:13221 E:13233 ||| NN
to  ||| S:13233 E:13246 ||| TO
produce  ||| S:13246 E:13254 ||| VB
increased  ||| S:13254 E:13264 ||| VBN
levels  ||| S:13264 E:13271 ||| NNS
of  ||| S:13271 E:13274 ||| IN
Colls  ||| S:13274 E:13280 ||| NNP
I  ||| S:13280 E:13282 ||| NNP
and  ||| S:13282 E:13286 ||| CC
III ||| S:13286 E:13289 ||| NNP
,  ||| S:13289 E:13291 ||| ,
we  ||| S:13291 E:13294 ||| PRP
treated  ||| S:13294 E:13312 ||| VBD
cultures  ||| S:13312 E:13321 ||| NNS
as  ||| S:13321 E:13324 ||| IN
for  ||| S:13324 E:13328 ||| IN
TN ||| S:13328 E:13330 ||| NNP
.  ||| S:13330 E:13332 ||| .
Immunoblot  ||| S:13332 E:13343 ||| JJ
analysis  ||| S:13343 E:13352 ||| NN
for  ||| S:13352 E:13356 ||| IN
Coll  ||| S:13356 E:13361 ||| NNP
I  ||| S:13361 E:13363 ||| PRP
showed  ||| S:13363 E:13380 ||| VBD
that  ||| S:13380 E:13385 ||| IN
cCAF ||| S:13385 E:13389 ||| NNP
,  ||| S:13389 E:13391 ||| ,
but  ||| S:13391 E:13395 ||| CC
not  ||| S:13395 E:13399 ||| RB
the  ||| S:13399 E:13403 ||| DT
N-  ||| S:13403 E:13406 ||| JJ
or  ||| S:13406 E:13409 ||| CC
C-peptides ||| S:13409 E:13419 ||| JJ
,  ||| S:13419 E:13421 ||| ,
caused  ||| S:13421 E:13428 ||| VBD
a  ||| S:13428 E:13430 ||| DT
small  ||| S:13430 E:13446 ||| JJ
increase  ||| S:13446 E:13455 ||| NN
in  ||| S:13455 E:13458 ||| IN
Coll  ||| S:13458 E:13463 ||| NNP
I  ||| S:13463 E:13465 ||| NNP
protein  ||| S:13465 E:13473 ||| NN
levels  ||| S:13473 E:13480 ||| NNS
( ||| S:13480 E:13481 ||| -LRB-
Fig.  ||| S:13481 E:13486 ||| NNP
6A ||| S:13486 E:13488 ||| NNP
) ||| S:13488 E:13489 ||| -RRB-
.  ||| S:13489 E:13491 ||| .
Probing  ||| S:13491 E:13499 ||| VBG
the  ||| S:13499 E:13513 ||| DT
same  ||| S:13513 E:13518 ||| JJ
blots  ||| S:13518 E:13524 ||| NN
for  ||| S:13524 E:13528 ||| IN
Coll  ||| S:13528 E:13533 ||| NNP
III  ||| S:13533 E:13537 ||| NNP
revealed  ||| S:13537 E:13546 ||| VBD
no  ||| S:13546 E:13549 ||| DT
cCAF-induced  ||| S:13549 E:13572 ||| JJ
difference  ||| S:13572 E:13583 ||| NN
in  ||| S:13583 E:13586 ||| IN
the  ||| S:13586 E:13590 ||| DT
level  ||| S:13590 E:13596 ||| NN
of  ||| S:13596 E:13599 ||| IN
production  ||| S:13599 E:13610 ||| NN
of  ||| S:13610 E:13613 ||| IN
this  ||| S:13613 E:13618 ||| DT
protein  ||| S:13618 E:13636 ||| NN
( ||| S:13636 E:13637 ||| -LRB-
Fig.  ||| S:13637 E:13642 ||| NNP
6B ||| S:13642 E:13644 ||| NNP
) ||| S:13644 E:13645 ||| -RRB-
.  ||| S:13645 E:13658 ||| .
In  ||| S:13658 E:13661 ||| IN
vivo ||| S:13661 E:13665 ||| NN
,  ||| S:13665 E:13667 ||| ,
Coll  ||| S:13667 E:13672 ||| NNP
I  ||| S:13672 E:13674 ||| PRP
was  ||| S:13674 E:13678 ||| VBD
also  ||| S:13678 E:13683 ||| RB
slightly  ||| S:13683 E:13702 ||| RB
increased  ||| S:13702 E:13712 ||| VBN
by  ||| S:13712 E:13715 ||| IN
treatment  ||| S:13715 E:13725 ||| NN
with  ||| S:13725 E:13730 ||| IN
the  ||| S:13730 E:13734 ||| DT
chemokine  ||| S:13734 E:13744 ||| NN
at  ||| S:13744 E:13747 ||| IN
3  ||| S:13747 E:13749 ||| CD
days  ||| S:13749 E:13754 ||| NNS
after  ||| S:13754 E:13770 ||| IN
wounding  ||| S:13770 E:13779 ||| NN
but  ||| S:13779 E:13783 ||| CC
did  ||| S:13783 E:13787 ||| VBD
not  ||| S:13787 E:13791 ||| RB
increase  ||| S:13791 E:13800 ||| VB
to  ||| S:13800 E:13803 ||| TO
higher  ||| S:13803 E:13810 ||| JJR
levels  ||| S:13810 E:13817 ||| NNS
than  ||| S:13817 E:13822 ||| IN
the  ||| S:13822 E:13836 ||| DT
control  ||| S:13836 E:13844 ||| NN
at  ||| S:13844 E:13847 ||| IN
7  ||| S:13847 E:13849 ||| CD
days ||| S:13849 E:13853 ||| NNS
,  ||| S:13853 E:13855 ||| ,
whereas  ||| S:13855 E:13863 ||| IN
the  ||| S:13863 E:13867 ||| DT
same  ||| S:13867 E:13872 ||| JJ
blots  ||| S:13872 E:13878 ||| JJ
probed  ||| S:13878 E:13885 ||| NN
for  ||| S:13885 E:13889 ||| IN
Coll  ||| S:13889 E:13904 ||| NNP
III  ||| S:13904 E:13908 ||| NNP
showed  ||| S:13908 E:13915 ||| VBD
similar  ||| S:13915 E:13923 ||| JJ
levels  ||| S:13923 E:13930 ||| NNS
in  ||| S:13930 E:13933 ||| IN
treated  ||| S:13933 E:13941 ||| VBN
and  ||| S:13941 E:13945 ||| CC
control  ||| S:13945 E:13953 ||| NN
at  ||| S:13953 E:13956 ||| IN
both  ||| S:13956 E:13971 ||| DT
3  ||| S:13971 E:13973 ||| CD
and  ||| S:13973 E:13977 ||| CC
7  ||| S:13977 E:13979 ||| CD
days  ||| S:13979 E:13984 ||| NNS
( ||| S:13984 E:13985 ||| -LRB-
Figure  ||| S:13985 E:13992 ||| NNP
6C ||| S:13992 E:13994 ||| NNP
) ||| S:13994 E:13995 ||| -RRB-
.  ||| S:13995 E:14007 ||| .
The  ||| S:14007 E:14011 ||| DT
effect  ||| S:14011 E:14018 ||| NN
on  ||| S:14018 E:14021 ||| IN
Coll  ||| S:14021 E:14026 ||| NNP
I  ||| S:14026 E:14028 ||| PRP
could  ||| S:14028 E:14034 ||| MD
be  ||| S:14034 E:14037 ||| VB
due  ||| S:14037 E:14041 ||| JJ
to  ||| S:14041 E:14044 ||| TO
remodeling  ||| S:14044 E:14055 ||| VB
of  ||| S:14055 E:14068 ||| IN
this  ||| S:14068 E:14073 ||| DT
protein  ||| S:14073 E:14081 ||| NN
by  ||| S:14081 E:14084 ||| IN
proteases  ||| S:14084 E:14094 ||| JJ
induced  ||| S:14094 E:14102 ||| NN
by  ||| S:14102 E:14105 ||| IN
the  ||| S:14105 E:14109 ||| DT
chemokine ||| S:14109 E:14118 ||| NN
.  ||| S:14118 E:14130 ||| .
Therefore ||| S:14130 E:14139 ||| RB
,  ||| S:14139 E:14141 ||| ,
we  ||| S:14141 E:14144 ||| PRP
tested  ||| S:14144 E:14151 ||| VBD
whether  ||| S:14151 E:14159 ||| IN
cCAF  ||| S:14159 E:14164 ||| NNP
affects  ||| S:14164 E:14172 ||| VBZ
the  ||| S:14172 E:14176 ||| DT
production  ||| S:14176 E:14197 ||| NN
or  ||| S:14197 E:14200 ||| CC
activity  ||| S:14200 E:14209 ||| NN
of  ||| S:14209 E:14212 ||| IN
the  ||| S:14212 E:14216 ||| DT
gelatinases  ||| S:14216 E:14228 ||| JJ
MMP-2  ||| S:14228 E:14234 ||| NN
or  ||| S:14234 E:14237 ||| CC
MMP-9 ||| S:14237 E:14242 ||| NNP
,  ||| S:14242 E:14244 ||| ,
or  ||| S:14244 E:14247 ||| CC
the  ||| S:14247 E:14261 ||| DT
collagenase  ||| S:14261 E:14273 ||| JJ
MMP-1 ||| S:14273 E:14278 ||| NN
,  ||| S:14278 E:14280 ||| ,
all  ||| S:14280 E:14284 ||| DT
of  ||| S:14284 E:14287 ||| IN
which  ||| S:14287 E:14293 ||| WDT
digest  ||| S:14293 E:14300 ||| VBP
collagens  ||| S:14300 E:14310 ||| VBG
I  ||| S:14310 E:14312 ||| PRP
and  ||| S:14312 E:14326 ||| CC
III ||| S:14326 E:14329 ||| NNP
.  ||| S:14329 E:14331 ||| .
Using  ||| S:14331 E:14337 ||| VBG
zymography ||| S:14337 E:14347 ||| NN
,  ||| S:14347 E:14349 ||| ,
we  ||| S:14349 E:14352 ||| PRP
found  ||| S:14352 E:14358 ||| VBD
that  ||| S:14358 E:14363 ||| DT
treatment  ||| S:14363 E:14373 ||| NN
with  ||| S:14373 E:14378 ||| IN
cCAF  ||| S:14378 E:14393 ||| JJ
or  ||| S:14393 E:14396 ||| CC
the  ||| S:14396 E:14400 ||| DT
peptides  ||| S:14400 E:14409 ||| NN
does  ||| S:14409 E:14414 ||| VBZ
not  ||| S:14414 E:14418 ||| RB
alter  ||| S:14418 E:14424 ||| VB
the  ||| S:14424 E:14428 ||| DT
levels  ||| S:14428 E:14435 ||| NNS
of  ||| S:14435 E:14438 ||| IN
proMMP-2  ||| S:14438 E:14447 ||| NNP
and  ||| S:14447 E:14461 ||| CC
there  ||| S:14461 E:14467 ||| EX
was  ||| S:14467 E:14471 ||| VBD
no  ||| S:14471 E:14474 ||| DT
detectable  ||| S:14474 E:14485 ||| JJ
levels  ||| S:14485 E:14492 ||| NNS
of  ||| S:14492 E:14495 ||| IN
proMMP-9  ||| S:14495 E:14504 ||| NNP
( ||| S:14504 E:14505 ||| -LRB-
Fig.  ||| S:14505 E:14510 ||| NNP
7A ||| S:14510 E:14512 ||| NNP
) ||| S:14512 E:14513 ||| -RRB-
.  ||| S:14513 E:14525 ||| .
However ||| S:14525 E:14532 ||| RB
,  ||| S:14532 E:14534 ||| ,
immunoblot  ||| S:14534 E:14545 ||| JJ
analysis  ||| S:14545 E:14554 ||| NN
using  ||| S:14554 E:14560 ||| VBG
a  ||| S:14560 E:14562 ||| DT
polyclonal  ||| S:14562 E:14573 ||| JJ
antibody  ||| S:14573 E:14592 ||| NN
to  ||| S:14592 E:14595 ||| TO
human  ||| S:14595 E:14601 ||| JJ
MMP-1  ||| S:14601 E:14607 ||| NNP
( ||| S:14607 E:14608 ||| -LRB-
this  ||| S:14608 E:14613 ||| DT
reagent  ||| S:14613 E:14621 ||| NN
is  ||| S:14621 E:14624 ||| VBZ
not  ||| S:14624 E:14628 ||| RB
available  ||| S:14628 E:14638 ||| JJ
for  ||| S:14638 E:14642 ||| IN
the  ||| S:14642 E:14656 ||| DT
chicken  ||| S:14656 E:14664 ||| NN
homologue  ||| S:14664 E:14674 ||| NN
of  ||| S:14674 E:14677 ||| IN
this  ||| S:14677 E:14682 ||| DT
matrix  ||| S:14682 E:14689 ||| JJ
metalloproteinase ||| S:14689 E:14706 ||| NN
)  ||| S:14706 E:14718 ||| -RRB-
showed  ||| S:14718 E:14725 ||| VBD
that  ||| S:14725 E:14730 ||| DT
cCAF  ||| S:14730 E:14735 ||| JJ
treatment  ||| S:14735 E:14745 ||| NN
caused  ||| S:14745 E:14752 ||| VBD
a  ||| S:14752 E:14754 ||| DT
decrease  ||| S:14754 E:14763 ||| NN
in  ||| S:14763 E:14766 ||| IN
the  ||| S:14766 E:14780 ||| DT
amount  ||| S:14780 E:14787 ||| NN
of  ||| S:14787 E:14790 ||| IN
the  ||| S:14790 E:14794 ||| DT
collagenase  ||| S:14794 E:14806 ||| JJ
MMP-1  ||| S:14806 E:14812 ||| NN
detected ||| S:14812 E:14820 ||| VBD
,  ||| S:14820 E:14822 ||| ,
but  ||| S:14822 E:14826 ||| CC
neither  ||| S:14826 E:14844 ||| DT
TIMP-1  ||| S:14844 E:14851 ||| NNP
nor  ||| S:14851 E:14855 ||| CC
TIMP-2  ||| S:14855 E:14862 ||| NNP
( ||| S:14862 E:14863 ||| -LRB-
two  ||| S:14863 E:14867 ||| CD
natural  ||| S:14867 E:14875 ||| JJ
inhibitors  ||| S:14875 E:14886 ||| NN
of  ||| S:14886 E:14889 ||| IN
these  ||| S:14889 E:14895 ||| DT
MMPs ||| S:14895 E:14899 ||| JJ
)  ||| S:14899 E:14911 ||| -RRB-
levels  ||| S:14911 E:14918 ||| NNS
were  ||| S:14918 E:14923 ||| VBD
changed ||| S:14923 E:14930 ||| VBN
,  ||| S:14930 E:14932 ||| ,
as  ||| S:14932 E:14935 ||| RB
evaluated  ||| S:14935 E:14945 ||| VBN
by  ||| S:14945 E:14948 ||| IN
immunoblot  ||| S:14948 E:14959 ||| JJ
analysis  ||| S:14959 E:14978 ||| NN
with  ||| S:14978 E:14983 ||| IN
a  ||| S:14983 E:14985 ||| DT
monoclonal  ||| S:14985 E:14996 ||| JJ
antibody  ||| S:14996 E:15005 ||| NN
to  ||| S:15005 E:15008 ||| TO
the  ||| S:15008 E:15012 ||| DT
corresponding  ||| S:15012 E:15026 ||| JJ
human  ||| S:15026 E:15042 ||| JJ
proteins  ||| S:15042 E:15051 ||| NNS
( ||| S:15051 E:15052 ||| -LRB-
Fig.  ||| S:15052 E:15057 ||| NNP
7B ||| S:15057 E:15059 ||| NNP
) ||| S:15059 E:15060 ||| -RRB-
.  ||| S:15060 E:15090 ||| .
Effects  ||| S:15090 E:15098 ||| NNS
of  ||| S:15098 E:15101 ||| IN
cCAF  ||| S:15101 E:15106 ||| JJ
on  ||| S:15106 E:15109 ||| IN
migration  ||| S:15109 E:15119 ||| NN
of  ||| S:15119 E:15122 ||| IN
fibroblasts  ||| S:15122 E:15144 ||| NN
During  ||| S:15144 E:15151 ||| IN
healing ||| S:15151 E:15158 ||| NN
,  ||| S:15158 E:15160 ||| ,
fibroblasts  ||| S:15160 E:15172 ||| JJ
migrate  ||| S:15172 E:15180 ||| NN
into  ||| S:15180 E:15185 ||| IN
and  ||| S:15185 E:15189 ||| CC
within  ||| S:15189 E:15206 ||| IN
the  ||| S:15206 E:15210 ||| DT
wounded  ||| S:15210 E:15218 ||| JJ
tissue  ||| S:15218 E:15225 ||| NN
and  ||| S:15225 E:15229 ||| CC
lay  ||| S:15229 E:15233 ||| VB
down  ||| S:15233 E:15238 ||| RP
the  ||| S:15238 E:15242 ||| DT
extracellular  ||| S:15242 E:15256 ||| JJ
matrix  ||| S:15256 E:15273 ||| NN
that  ||| S:15273 E:15278 ||| WDT
forms  ||| S:15278 E:15284 ||| VBZ
the  ||| S:15284 E:15288 ||| DT
granulation  ||| S:15288 E:15300 ||| JJ
tissue ||| S:15300 E:15306 ||| NN
.  ||| S:15306 E:15308 ||| .
These  ||| S:15308 E:15314 ||| DT
ECM  ||| S:15314 E:15318 ||| NNP
molecules ||| S:15318 E:15327 ||| NNS
,  ||| S:15327 E:15339 ||| ,
especially  ||| S:15339 E:15350 ||| RB
TN  ||| S:15350 E:15353 ||| NNP
and  ||| S:15353 E:15357 ||| CC
FN  ||| S:15357 E:15360 ||| NNP
together ||| S:15360 E:15368 ||| RB
,  ||| S:15368 E:15370 ||| ,
stimulate  ||| S:15370 E:15380 ||| JJ
cell  ||| S:15380 E:15385 ||| NN
migration ||| S:15385 E:15394 ||| NN
,  ||| S:15394 E:15406 ||| ,
thereby  ||| S:15406 E:15414 ||| RB
facilitating  ||| S:15414 E:15427 ||| VBG
the  ||| S:15427 E:15431 ||| DT
entrance  ||| S:15431 E:15440 ||| NN
and  ||| S:15440 E:15444 ||| CC
movement  ||| S:15444 E:15453 ||| NN
of  ||| S:15453 E:15466 ||| IN
additional  ||| S:15466 E:15477 ||| JJ
fibroblasts  ||| S:15477 E:15489 ||| NN
and  ||| S:15489 E:15493 ||| CC
of  ||| S:15493 E:15496 ||| IN
endothelial  ||| S:15496 E:15508 ||| JJ
cells  ||| S:15508 E:15514 ||| NNS
into  ||| S:15514 E:15519 ||| IN
the  ||| S:15519 E:15533 ||| DT
wound  ||| S:15533 E:15539 ||| JJ
tissue ||| S:15539 E:15545 ||| NN
.  ||| S:15545 E:15547 ||| .
Because  ||| S:15547 E:15555 ||| IN
tissues  ||| S:15555 E:15563 ||| NNS
treated  ||| S:15563 E:15571 ||| VBN
with  ||| S:15571 E:15576 ||| IN
cCAF  ||| S:15576 E:15581 ||| NNS
have  ||| S:15581 E:15586 ||| VBP
more  ||| S:15586 E:15601 ||| JJR
FN  ||| S:15601 E:15604 ||| NNP
and  ||| S:15604 E:15608 ||| CC
TN  ||| S:15608 E:15611 ||| NNP
at  ||| S:15611 E:15614 ||| IN
the  ||| S:15614 E:15618 ||| DT
time  ||| S:15618 E:15623 ||| NN
that  ||| S:15623 E:15628 ||| IN
these  ||| S:15628 E:15634 ||| DT
cells  ||| S:15634 E:15640 ||| NNS
are  ||| S:15640 E:15644 ||| VBP
entering  ||| S:15644 E:15653 ||| VBG
the  ||| S:15653 E:15667 ||| DT
wound  ||| S:15667 E:15673 ||| NN
and  ||| S:15673 E:15677 ||| CC
chemokines  ||| S:15677 E:15688 ||| NNS
are  ||| S:15688 E:15692 ||| VBP
well  ||| S:15692 E:15697 ||| RB
known  ||| S:15697 E:15703 ||| VBN
for  ||| S:15703 E:15707 ||| IN
their  ||| S:15707 E:15723 ||| PRP$
chemoattractant  ||| S:15723 E:15739 ||| JJ
properties  ||| S:15739 E:15750 ||| NNS
[  ||| S:15750 E:15752 ||| -LRB-
34  ||| S:15752 E:15755 ||| CD
35  ||| S:15755 E:15758 ||| CD
]  ||| S:15758 E:15760 ||| -RRB-
,  ||| S:15760 E:15762 ||| ,
we  ||| S:15762 E:15765 ||| PRP
tested  ||| S:15765 E:15772 ||| VBD
whether  ||| S:15772 E:15790 ||| IN
cCAF  ||| S:15790 E:15795 ||| JJ
stimulates  ||| S:15795 E:15806 ||| JJ
chemotaxis  ||| S:15806 E:15817 ||| NN
of  ||| S:15817 E:15820 ||| IN
fibroblasts  ||| S:15820 E:15832 ||| NNS
using  ||| S:15832 E:15838 ||| VBG
transwell  ||| S:15838 E:15858 ||| JJ
assays ||| S:15858 E:15864 ||| NN
.  ||| S:15864 E:15866 ||| .
To  ||| S:15866 E:15869 ||| TO
avoid  ||| S:15869 E:15875 ||| VB
effects  ||| S:15875 E:15883 ||| NNS
of  ||| S:15883 E:15886 ||| IN
gravity  ||| S:15886 E:15894 ||| NN
on  ||| S:15894 E:15897 ||| IN
cell  ||| S:15897 E:15902 ||| NN
migration ||| S:15902 E:15911 ||| NN
,  ||| S:15911 E:15923 ||| ,
the  ||| S:15923 E:15927 ||| DT
top  ||| S:15927 E:15931 ||| JJ
chamber  ||| S:15931 E:15939 ||| NN
was  ||| S:15939 E:15943 ||| VBD
inverted ||| S:15943 E:15951 ||| VBN
,  ||| S:15951 E:15953 ||| ,
the  ||| S:15953 E:15957 ||| DT
cells  ||| S:15957 E:15963 ||| NNS
were  ||| S:15963 E:15968 ||| VBD
plated  ||| S:15968 E:15975 ||| VBN
on  ||| S:15975 E:15988 ||| IN
the  ||| S:15988 E:15992 ||| DT
underside  ||| S:15992 E:16002 ||| NN
of  ||| S:16002 E:16005 ||| IN
the  ||| S:16005 E:16009 ||| DT
membrane ||| S:16009 E:16017 ||| NN
,  ||| S:16017 E:16019 ||| ,
allowed  ||| S:16019 E:16027 ||| VBN
to  ||| S:16027 E:16030 ||| TO
adhere  ||| S:16030 E:16037 ||| VB
to  ||| S:16037 E:16040 ||| TO
it  ||| S:16040 E:16053 ||| PRP
and  ||| S:16053 E:16057 ||| CC
then  ||| S:16057 E:16062 ||| RB
the  ||| S:16062 E:16066 ||| DT
chamber  ||| S:16066 E:16074 ||| NN
was  ||| S:16074 E:16078 ||| VBD
turned  ||| S:16078 E:16085 ||| VBN
right  ||| S:16085 E:16091 ||| JJ
side  ||| S:16091 E:16096 ||| NN
up ||| S:16096 E:16098 ||| RB
.  ||| S:16098 E:16100 ||| .
The  ||| S:16100 E:16104 ||| DT
cells  ||| S:16104 E:16120 ||| NNS
were  ||| S:16120 E:16125 ||| VBD
incubated  ||| S:16125 E:16135 ||| JJ
overnight  ||| S:16135 E:16145 ||| JJ
in  ||| S:16145 E:16148 ||| IN
standard  ||| S:16148 E:16157 ||| JJ
medium  ||| S:16157 E:16164 ||| NN
to  ||| S:16164 E:16167 ||| TO
allow  ||| S:16167 E:16183 ||| VB
expression  ||| S:16183 E:16194 ||| NN
of  ||| S:16194 E:16197 ||| IN
the  ||| S:16197 E:16201 ||| DT
cCAF  ||| S:16201 E:16206 ||| JJ
receptor ||| S:16206 E:16214 ||| NN
( ||| S:16214 E:16215 ||| -LRB-
s ||| S:16215 E:16216 ||| LS
)  ||| S:16216 E:16218 ||| -RRB-
and  ||| S:16218 E:16222 ||| CC
the  ||| S:16222 E:16226 ||| DT
following  ||| S:16226 E:16236 ||| JJ
day  ||| S:16236 E:16250 ||| NN
cCAF  ||| S:16250 E:16255 ||| NN
was  ||| S:16255 E:16259 ||| VBD
applied  ||| S:16259 E:16267 ||| VBN
at  ||| S:16267 E:16270 ||| IN
increasing  ||| S:16270 E:16281 ||| VBG
doses  ||| S:16281 E:16287 ||| NNS
( ||| S:16287 E:16288 ||| -LRB-
100-1000  ||| S:16288 E:16297 ||| FW
ng ||| S:16297 E:16299 ||| FW
/ ||| S:16299 E:16300 ||| FW
ml ||| S:16300 E:16302 ||| FW
)  ||| S:16302 E:16304 ||| -RRB-
to  ||| S:16304 E:16317 ||| TO
the  ||| S:16317 E:16321 ||| DT
top  ||| S:16321 E:16325 ||| JJ
chamber  ||| S:16325 E:16333 ||| NN
only ||| S:16333 E:16337 ||| RB
.  ||| S:16337 E:16339 ||| .
The  ||| S:16339 E:16343 ||| DT
migration  ||| S:16343 E:16353 ||| JJ
assays  ||| S:16353 E:16360 ||| NN
were  ||| S:16360 E:16365 ||| VBD
carried  ||| S:16365 E:16383 ||| VBN
out  ||| S:16383 E:16387 ||| RP
for  ||| S:16387 E:16391 ||| IN
24  ||| S:16391 E:16394 ||| CD
hrs ||| S:16394 E:16397 ||| NNS
.  ||| S:16397 E:16399 ||| .
We  ||| S:16399 E:16402 ||| PRP
found  ||| S:16402 E:16408 ||| VBD
that  ||| S:16408 E:16413 ||| DT
cCAF  ||| S:16413 E:16418 ||| JJ
stimulated  ||| S:16418 E:16429 ||| JJ
migration  ||| S:16429 E:16449 ||| NN
of  ||| S:16449 E:16452 ||| IN
the  ||| S:16452 E:16456 ||| DT
fibroblasts  ||| S:16456 E:16468 ||| NN
up  ||| S:16468 E:16471 ||| IN
the  ||| S:16471 E:16475 ||| DT
concentration  ||| S:16475 E:16489 ||| NN
gradient  ||| S:16489 E:16498 ||| NN
in  ||| S:16498 E:16501 ||| IN
a  ||| S:16501 E:16513 ||| DT
dose-dependent  ||| S:16513 E:16528 ||| JJ
manner  ||| S:16528 E:16535 ||| NN
( ||| S:16535 E:16536 ||| -LRB-
Fig.  ||| S:16536 E:16541 ||| NNP
8A ||| S:16541 E:16543 ||| NNP
) ||| S:16543 E:16544 ||| -RRB-
.  ||| S:16544 E:16546 ||| .
To  ||| S:16546 E:16549 ||| TO
test  ||| S:16549 E:16554 ||| VB
whether  ||| S:16554 E:16562 ||| IN
the  ||| S:16562 E:16576 ||| DT
cCAF-induced  ||| S:16576 E:16589 ||| JJ
effect  ||| S:16589 E:16596 ||| NN
is  ||| S:16596 E:16599 ||| VBZ
due  ||| S:16599 E:16603 ||| JJ
to  ||| S:16603 E:16606 ||| TO
chemotaxis ||| S:16606 E:16616 ||| VB
,  ||| S:16616 E:16618 ||| ,
we  ||| S:16618 E:16621 ||| PRP
repeated  ||| S:16621 E:16630 ||| VBD
the  ||| S:16630 E:16644 ||| DT
transwell  ||| S:16644 E:16654 ||| JJ
assay  ||| S:16654 E:16660 ||| NN
and  ||| S:16660 E:16664 ||| CC
compared  ||| S:16664 E:16673 ||| VBN
cell  ||| S:16673 E:16678 ||| NN
migration  ||| S:16678 E:16688 ||| NN
when  ||| S:16688 E:16693 ||| WRB
cCAF  ||| S:16693 E:16698 ||| NNP
is  ||| S:16698 E:16711 ||| VBZ
added  ||| S:16711 E:16717 ||| VBN
to  ||| S:16717 E:16720 ||| TO
both  ||| S:16720 E:16725 ||| DT
wells ||| S:16725 E:16730 ||| NNS
.  ||| S:16730 E:16732 ||| .
Placing  ||| S:16732 E:16740 ||| VBG
cCAF  ||| S:16740 E:16745 ||| JJ
in  ||| S:16745 E:16748 ||| IN
both  ||| S:16748 E:16753 ||| DT
wells  ||| S:16753 E:16759 ||| NNS
abrogated  ||| S:16759 E:16779 ||| JJ
cell  ||| S:16779 E:16784 ||| NN
migration ||| S:16784 E:16793 ||| NN
,  ||| S:16793 E:16795 ||| ,
strongly  ||| S:16795 E:16804 ||| RB
suggesting  ||| S:16804 E:16815 ||| VBG
that  ||| S:16815 E:16820 ||| IN
this  ||| S:16820 E:16825 ||| DT
protein  ||| S:16825 E:16843 ||| NN
chemoattracts  ||| S:16843 E:16857 ||| NN
fibroblasts  ||| S:16857 E:16869 ||| NNS
( ||| S:16869 E:16870 ||| -LRB-
Fig  ||| S:16870 E:16874 ||| NNP
8B ||| S:16874 E:16876 ||| NNP
) ||| S:16876 E:16877 ||| -RRB-
.  ||| S:16877 E:16879 ||| .
We  ||| S:16879 E:16882 ||| PRP
also  ||| S:16882 E:16887 ||| RB
tested  ||| S:16887 E:16894 ||| VBN
the  ||| S:16894 E:16908 ||| DT
effects  ||| S:16908 E:16916 ||| NNS
of  ||| S:16916 E:16919 ||| IN
the  ||| S:16919 E:16923 ||| DT
chemokine  ||| S:16923 E:16933 ||| NN
on  ||| S:16933 E:16936 ||| IN
migration  ||| S:16936 E:16946 ||| NN
by  ||| S:16946 E:16949 ||| IN
using  ||| S:16949 E:16955 ||| VBG
the  ||| S:16955 E:16969 ||| DT
cloning  ||| S:16969 E:16977 ||| JJ
ring  ||| S:16977 E:16982 ||| NN
assay ||| S:16982 E:16987 ||| NN
.  ||| S:16987 E:16989 ||| .
In  ||| S:16989 E:16992 ||| IN
a  ||| S:16992 E:16994 ||| DT
specified  ||| S:16994 E:17004 ||| JJ
length  ||| S:17004 E:17011 ||| NN
of  ||| S:17011 E:17014 ||| IN
time ||| S:17014 E:17018 ||| NN
,  ||| S:17018 E:17020 ||| ,
cells  ||| S:17020 E:17036 ||| NNS
treated  ||| S:17036 E:17044 ||| VBN
with  ||| S:17044 E:17049 ||| IN
cCAF  ||| S:17049 E:17054 ||| NNP
moved  ||| S:17054 E:17060 ||| VBD
a  ||| S:17060 E:17062 ||| DT
longer  ||| S:17062 E:17069 ||| JJR
distance  ||| S:17069 E:17078 ||| NN
than  ||| S:17078 E:17083 ||| IN
did  ||| S:17083 E:17097 ||| JJ
control  ||| S:17097 E:17105 ||| NN
cells ||| S:17105 E:17110 ||| NNS
,  ||| S:17110 E:17112 ||| ,
corroborating  ||| S:17112 E:17126 ||| VBG
the  ||| S:17126 E:17130 ||| DT
previous  ||| S:17130 E:17139 ||| JJ
results  ||| S:17139 E:17147 ||| NNS
that  ||| S:17147 E:17162 ||| IN
the  ||| S:17162 E:17166 ||| DT
chemokine  ||| S:17166 E:17176 ||| FW
stimulates  ||| S:17176 E:17187 ||| FW
cell  ||| S:17187 E:17192 ||| FW
motility  ||| S:17192 E:17201 ||| FW
( ||| S:17201 E:17202 ||| -LRB-
Fig.  ||| S:17202 E:17207 ||| NNP
8C ||| S:17207 E:17209 ||| NNP
) ||| S:17209 E:17210 ||| -RRB-
.  ||| S:17210 E:17223 ||| .
In  ||| S:17223 E:17226 ||| IN
situ  ||| S:17226 E:17231 ||| JJ
hybridization  ||| S:17231 E:17245 ||| NN
for  ||| S:17245 E:17249 ||| IN
cCAF  ||| S:17249 E:17264 ||| NNP
showed  ||| S:17264 E:17271 ||| VBD
that  ||| S:17271 E:17276 ||| IN
the  ||| S:17276 E:17280 ||| DT
migrating  ||| S:17280 E:17290 ||| JJ
fibroblasts  ||| S:17290 E:17302 ||| NNS
also  ||| S:17302 E:17307 ||| RB
express  ||| S:17307 E:17315 ||| VB
higher  ||| S:17315 E:17332 ||| JJR
levels  ||| S:17332 E:17339 ||| NNS
of  ||| S:17339 E:17342 ||| IN
cCAF  ||| S:17342 E:17347 ||| NNP
( ||| S:17347 E:17348 ||| -LRB-
Fig.  ||| S:17348 E:17353 ||| NNP
8D ||| S:17353 E:17355 ||| NNP
&  ||| S:17355 E:17357 ||| CC
8E ||| S:17357 E:17359 ||| NNP
;  ||| S:17359 E:17361 ||| :
see  ||| S:17361 E:17365 ||| VBP
also  ||| S:17365 E:17370 ||| RB
ref.  ||| S:17370 E:17375 ||| CD
[  ||| S:17375 E:17377 ||| -LRB-
36  ||| S:17377 E:17380 ||| CD
]  ||| S:17380 E:17392 ||| CD
) ||| S:17392 E:17393 ||| -RRB-
.  ||| S:17393 E:17426 ||| .
Discussion  ||| S:17426 E:17445 ||| NN
The  ||| S:17445 E:17449 ||| DT
work  ||| S:17449 E:17454 ||| NN
presented  ||| S:17454 E:17464 ||| VBD
here  ||| S:17464 E:17469 ||| RB
shows  ||| S:17469 E:17475 ||| VBZ
that  ||| S:17475 E:17480 ||| DT
cCAF ||| S:17480 E:17484 ||| JJ
,  ||| S:17484 E:17486 ||| ,
the  ||| S:17486 E:17490 ||| DT
IL-8  ||| S:17490 E:17495 ||| NN
of  ||| S:17495 E:17506 ||| IN
chickens ||| S:17506 E:17514 ||| NNS
,  ||| S:17514 E:17516 ||| ,
stimulates  ||| S:17516 E:17527 ||| JJ
expression  ||| S:17527 E:17538 ||| NN
of  ||| S:17538 E:17541 ||| IN
several  ||| S:17541 E:17549 ||| JJ
ECM  ||| S:17549 E:17553 ||| NNP
molecules  ||| S:17553 E:17571 ||| VBD
important  ||| S:17571 E:17581 ||| JJ
in  ||| S:17581 E:17584 ||| IN
development  ||| S:17584 E:17596 ||| NN
of  ||| S:17596 E:17599 ||| IN
the  ||| S:17599 E:17603 ||| DT
granulation  ||| S:17603 E:17615 ||| JJ
tissue ||| S:17615 E:17621 ||| NN
.  ||| S:17621 E:17623 ||| .
We  ||| S:17623 E:17626 ||| PRP
show  ||| S:17626 E:17639 ||| VBP
that ||| S:17639 E:17643 ||| IN
:  ||| S:17643 E:17654 ||| :
( ||| S:17654 E:17655 ||| -LRB-
i ||| S:17655 E:17656 ||| FW
)  ||| S:17656 E:17658 ||| -RRB-
cCAF  ||| S:17658 E:17663 ||| FW
stimulates  ||| S:17663 E:17674 ||| FW
TN  ||| S:17674 E:17677 ||| FW
expression  ||| S:17677 E:17688 ||| FW
and  ||| S:17688 E:17700 ||| CC
that  ||| S:17700 E:17705 ||| IN
a  ||| S:17705 E:17707 ||| DT
15  ||| S:17707 E:17710 ||| CD
aa  ||| S:17710 E:17713 ||| NNS
peptide  ||| S:17713 E:17721 ||| VBP
containing  ||| S:17721 E:17732 ||| VBG
the  ||| S:17732 E:17736 ||| DT
N-terminal  ||| S:17736 E:17747 ||| JJ
sequence  ||| S:17747 E:17764 ||| NN
causes  ||| S:17764 E:17771 ||| VBZ
the  ||| S:17771 E:17775 ||| DT
same  ||| S:17775 E:17780 ||| JJ
effects  ||| S:17780 E:17788 ||| NNS
as  ||| S:17788 E:17791 ||| IN
the  ||| S:17791 E:17795 ||| DT
whole  ||| S:17795 E:17801 ||| JJ
molecule ||| S:17801 E:17809 ||| NN
;  ||| S:17809 E:17820 ||| :
( ||| S:17820 E:17821 ||| -LRB-
ii ||| S:17821 E:17823 ||| LS
)  ||| S:17823 E:17825 ||| -RRB-
in  ||| S:17825 E:17828 ||| IN
contrast  ||| S:17828 E:17837 ||| NN
to  ||| S:17837 E:17840 ||| TO
its  ||| S:17840 E:17844 ||| PRP$
effects  ||| S:17844 E:17852 ||| NNS
on  ||| S:17852 E:17855 ||| IN
TN  ||| S:17855 E:17866 ||| NNP
production ||| S:17866 E:17876 ||| NN
,  ||| S:17876 E:17878 ||| ,
cCAF-induced  ||| S:17878 E:17891 ||| JJ
increase  ||| S:17891 E:17900 ||| NN
in  ||| S:17900 E:17903 ||| IN
FN  ||| S:17903 E:17906 ||| NNP
and  ||| S:17906 E:17910 ||| CC
Coll  ||| S:17910 E:17915 ||| NNP
I  ||| S:17915 E:17925 ||| NNP
accumulation  ||| S:17925 E:17938 ||| NN
requires  ||| S:17938 E:17947 ||| VBZ
the  ||| S:17947 E:17951 ||| DT
whole  ||| S:17951 E:17957 ||| JJ
molecule ||| S:17957 E:17965 ||| NN
;  ||| S:17965 E:17976 ||| :
( ||| S:17976 E:17977 ||| -LRB-
iii ||| S:17977 E:17980 ||| LS
)  ||| S:17980 E:17982 ||| -RRB-
the  ||| S:17982 E:17986 ||| DT
increase  ||| S:17986 E:17995 ||| NN
in  ||| S:17995 E:17998 ||| IN
FN  ||| S:17998 E:18001 ||| NNP
protein  ||| S:18001 E:18009 ||| NN
is  ||| S:18009 E:18012 ||| VBZ
not  ||| S:18012 E:18024 ||| RB
a  ||| S:18024 E:18026 ||| DT
result  ||| S:18026 E:18033 ||| NN
of  ||| S:18033 E:18036 ||| IN
a  ||| S:18036 E:18038 ||| DT
corresponding  ||| S:18038 E:18052 ||| JJ
increase  ||| S:18052 E:18061 ||| NN
in  ||| S:18061 E:18064 ||| IN
mRNA ||| S:18064 E:18068 ||| NNP
,  ||| S:18068 E:18070 ||| ,
or  ||| S:18070 E:18073 ||| CC
increase  ||| S:18073 E:18090 ||| NN
in  ||| S:18090 E:18093 ||| IN
MMP  ||| S:18093 E:18097 ||| NNP
production  ||| S:18097 E:18108 ||| NN
or  ||| S:18108 E:18111 ||| CC
PA  ||| S:18111 E:18114 ||| NNP
activity  ||| S:18114 E:18123 ||| NN
but  ||| S:18123 E:18127 ||| CC
appears  ||| S:18127 E:18135 ||| VBZ
to  ||| S:18135 E:18138 ||| TO
be  ||| S:18138 E:18141 ||| VB
linked  ||| S:18141 E:18156 ||| VBN
TN  ||| S:18156 E:18159 ||| NNP
production ||| S:18159 E:18169 ||| NN
;  ||| S:18169 E:18180 ||| :
( ||| S:18180 E:18181 ||| -LRB-
iv ||| S:18181 E:18183 ||| LS
)  ||| S:18183 E:18185 ||| -RRB-
increase  ||| S:18185 E:18194 ||| NN
in  ||| S:18194 E:18197 ||| IN
Coll  ||| S:18197 E:18202 ||| NNP
I  ||| S:18202 E:18204 ||| PRP
correlates  ||| S:18204 E:18215 ||| VBD
with  ||| S:18215 E:18228 ||| IN
decreased  ||| S:18228 E:18238 ||| JJ
levels  ||| S:18238 E:18245 ||| NNS
of  ||| S:18245 E:18248 ||| IN
MMP-1 ||| S:18248 E:18253 ||| CD
;  ||| S:18253 E:18264 ||| :
( ||| S:18264 E:18265 ||| -LRB-
v ||| S:18265 E:18266 ||| LS
)  ||| S:18266 E:18268 ||| -RRB-
cCAF  ||| S:18268 E:18273 ||| JJ
chemoattracts  ||| S:18273 E:18287 ||| JJ
fibroblasts  ||| S:18287 E:18299 ||| NN
and  ||| S:18299 E:18311 ||| CC
accelerates  ||| S:18311 E:18323 ||| VBZ
their  ||| S:18323 E:18329 ||| PRP$
migration ||| S:18329 E:18338 ||| NN
;  ||| S:18338 E:18349 ||| :
( ||| S:18349 E:18350 ||| -LRB-
vi ||| S:18350 E:18352 ||| LS
)  ||| S:18352 E:18354 ||| -RRB-
treatment  ||| S:18354 E:18364 ||| NN
of  ||| S:18364 E:18367 ||| IN
excision  ||| S:18367 E:18376 ||| JJ
wounds  ||| S:18376 E:18383 ||| NNS
with  ||| S:18383 E:18396 ||| IN
cCAF  ||| S:18396 E:18401 ||| NNP
increased  ||| S:18401 E:18411 ||| VBD
the  ||| S:18411 E:18415 ||| DT
levels  ||| S:18415 E:18422 ||| NNS
of  ||| S:18422 E:18425 ||| IN
all  ||| S:18425 E:18429 ||| DT
three  ||| S:18429 E:18435 ||| CD
ECM  ||| S:18435 E:18439 ||| NN
molecules  ||| S:18439 E:18449 ||| NNS
in  ||| S:18449 E:18452 ||| IN
the  ||| S:18452 E:18464 ||| DT
granulation  ||| S:18464 E:18476 ||| JJ
tissue  ||| S:18476 E:18483 ||| NN
of  ||| S:18483 E:18486 ||| IN
wounds  ||| S:18486 E:18493 ||| NNS
albeit  ||| S:18493 E:18500 ||| IN
with  ||| S:18500 E:18505 ||| IN
different  ||| S:18505 E:18523 ||| JJ
dynamics ||| S:18523 E:18531 ||| NNS
.  ||| S:18531 E:18533 ||| .
This  ||| S:18533 E:18538 ||| DT
is  ||| S:18538 E:18541 ||| VBZ
the  ||| S:18541 E:18545 ||| DT
first  ||| S:18545 E:18551 ||| JJ
demonstration  ||| S:18551 E:18565 ||| NN
that  ||| S:18565 E:18570 ||| IN
treatment  ||| S:18570 E:18580 ||| NN
of  ||| S:18580 E:18591 ||| IN
wounds  ||| S:18591 E:18598 ||| NNS
with  ||| S:18598 E:18603 ||| IN
a  ||| S:18603 E:18605 ||| DT
pro-inflammatory  ||| S:18605 E:18622 ||| JJ
and  ||| S:18622 E:18626 ||| CC
angiogenic  ||| S:18626 E:18637 ||| JJ
chemokine  ||| S:18637 E:18655 ||| NN
accelerates  ||| S:18655 E:18667 ||| VBZ
development  ||| S:18667 E:18679 ||| NN
of  ||| S:18679 E:18682 ||| IN
the  ||| S:18682 E:18686 ||| DT
granulation  ||| S:18686 E:18698 ||| JJ
tissue  ||| S:18698 E:18705 ||| NN
during  ||| S:18705 E:18720 ||| IN
healing  ||| S:18720 E:18728 ||| NN
by  ||| S:18728 E:18731 ||| IN
stimulating  ||| S:18731 E:18743 ||| VBG
the  ||| S:18743 E:18747 ||| DT
precocious  ||| S:18747 E:18758 ||| JJ
deposition  ||| S:18758 E:18769 ||| NN
of  ||| S:18769 E:18772 ||| IN
ECM  ||| S:18772 E:18784 ||| NNP
molecules  ||| S:18784 E:18794 ||| NNS
that  ||| S:18794 E:18799 ||| WDT
are  ||| S:18799 E:18803 ||| VBP
critical  ||| S:18803 E:18812 ||| JJ
for  ||| S:18812 E:18816 ||| IN
proper  ||| S:18816 E:18823 ||| JJ
healing ||| S:18823 E:18830 ||| NN
.  ||| S:18830 E:18840 ||| .
We  ||| S:18840 E:18843 ||| PRP
showed  ||| S:18843 E:18850 ||| VBD
previously  ||| S:18850 E:18861 ||| RB
that  ||| S:18861 E:18866 ||| IN
cCAF  ||| S:18866 E:18871 ||| NNP
is  ||| S:18871 E:18874 ||| VBZ
highly  ||| S:18874 E:18881 ||| RB
expressed  ||| S:18881 E:18891 ||| VBN
in  ||| S:18891 E:18902 ||| IN
the  ||| S:18902 E:18906 ||| DT
granulation  ||| S:18906 E:18918 ||| JJ
tissue  ||| S:18918 E:18925 ||| NN
of  ||| S:18925 E:18928 ||| IN
wounds  ||| S:18928 E:18935 ||| NNS
[  ||| S:18935 E:18937 ||| -LRB-
6  ||| S:18937 E:18939 ||| CD
36  ||| S:18939 E:18942 ||| CD
]  ||| S:18942 E:18944 ||| -RRB-
,  ||| S:18944 E:18946 ||| ,
that  ||| S:18946 E:18951 ||| IN
this  ||| S:18951 E:18964 ||| DT
chemokine  ||| S:18964 E:18974 ||| NN
and  ||| S:18974 E:18978 ||| CC
several  ||| S:18978 E:18986 ||| JJ
of  ||| S:18986 E:18989 ||| IN
its  ||| S:18989 E:18993 ||| PRP$
human  ||| S:18993 E:18999 ||| JJ
homologues  ||| S:18999 E:19010 ||| JJ
stimulate  ||| S:19010 E:19028 ||| JJ
differentiation  ||| S:19028 E:19044 ||| NN
of  ||| S:19044 E:19047 ||| IN
fibroblasts  ||| S:19047 E:19059 ||| NN
into  ||| S:19059 E:19064 ||| IN
myofibroblasts  ||| S:19064 E:19079 ||| VBG
both  ||| S:19079 E:19084 ||| DT
in  ||| S:19084 E:19095 ||| IN
culture  ||| S:19095 E:19103 ||| NN
and  ||| S:19103 E:19116 ||| CC
in  ||| S:19116 E:19119 ||| IN
vivo ||| S:19119 E:19123 ||| NN
,  ||| S:19123 E:19125 ||| ,
and  ||| S:19125 E:19129 ||| CC
that  ||| S:19129 E:19134 ||| IN
the  ||| S:19134 E:19138 ||| DT
latter  ||| S:19138 E:19145 ||| JJ
effect  ||| S:19145 E:19160 ||| NN
can  ||| S:19160 E:19164 ||| MD
be  ||| S:19164 E:19167 ||| VB
achieved  ||| S:19167 E:19176 ||| VBN
very  ||| S:19176 E:19181 ||| RB
effectively  ||| S:19181 E:19193 ||| RB
by  ||| S:19193 E:19196 ||| IN
the  ||| S:19196 E:19200 ||| DT
N-terminal  ||| S:19200 E:19211 ||| JJ
15aas  ||| S:19211 E:19217 ||| NN
of  ||| S:19217 E:19228 ||| IN
the  ||| S:19228 E:19232 ||| DT
protein  ||| S:19232 E:19240 ||| NN
[  ||| S:19240 E:19242 ||| -LRB-
4  ||| S:19242 E:19244 ||| CD
37  ||| S:19244 E:19247 ||| CD
]  ||| S:19247 E:19249 ||| -RRB-
.  ||| S:19249 E:19251 ||| .
In  ||| S:19251 E:19254 ||| IN
addition  ||| S:19254 E:19263 ||| NN
to  ||| S:19263 E:19266 ||| TO
cCAF ||| S:19266 E:19270 ||| JJ
,  ||| S:19270 E:19272 ||| ,
other  ||| S:19272 E:19278 ||| JJ
CXC  ||| S:19278 E:19290 ||| NN
chemokines  ||| S:19290 E:19301 ||| NNS
have  ||| S:19301 E:19306 ||| VBP
been  ||| S:19306 E:19311 ||| VBN
associated  ||| S:19311 E:19322 ||| VBN
with  ||| S:19322 E:19327 ||| IN
wound  ||| S:19327 E:19333 ||| JJ
healing  ||| S:19333 E:19341 ||| NN
events ||| S:19341 E:19347 ||| NNS
.  ||| S:19347 E:19357 ||| .
In  ||| S:19357 E:19360 ||| IN
the  ||| S:19360 E:19364 ||| DT
granulation  ||| S:19364 E:19376 ||| JJ
tissue  ||| S:19376 E:19383 ||| NN
of  ||| S:19383 E:19386 ||| IN
burn  ||| S:19386 E:19391 ||| JJ
wounds ||| S:19391 E:19397 ||| NNS
,  ||| S:19397 E:19399 ||| ,
expression  ||| S:19399 E:19410 ||| NN
of  ||| S:19410 E:19421 ||| IN
groα  ||| S:19421 E:19426 ||| JJ
/ ||| S:19426 E:19427 ||| NNP
MGSA  ||| S:19427 E:19432 ||| NNP
and  ||| S:19432 E:19436 ||| CC
CXCR2  ||| S:19436 E:19442 ||| NNP
( ||| S:19442 E:19443 ||| -LRB-
the  ||| S:19443 E:19447 ||| DT
receptor  ||| S:19447 E:19456 ||| NN
for  ||| S:19456 E:19460 ||| IN
MGSA ||| S:19460 E:19464 ||| NNP
)  ||| S:19464 E:19466 ||| -RRB-
was  ||| S:19466 E:19470 ||| VBD
associated  ||| S:19470 E:19489 ||| VBN
with  ||| S:19489 E:19494 ||| IN
fibroblasts ||| S:19494 E:19505 ||| NN
,  ||| S:19505 E:19507 ||| ,
smooth  ||| S:19507 E:19514 ||| JJ
muscle  ||| S:19514 E:19521 ||| NN
cells ||| S:19521 E:19526 ||| NNS
/ ||| S:19526 E:19527 ||| VBP
myofibroblasts  ||| S:19527 E:19542 ||| VBN
and  ||| S:19542 E:19546 ||| CC
a  ||| S:19546 E:19556 ||| DT
subpopulation  ||| S:19556 E:19570 ||| NN
of  ||| S:19570 E:19573 ||| IN
macrophages  ||| S:19573 E:19585 ||| NNS
[  ||| S:19585 E:19587 ||| -LRB-
7  ||| S:19587 E:19589 ||| CD
]  ||| S:19589 E:19591 ||| -RRB-
.  ||| S:19591 E:19593 ||| .
Groα ||| S:19593 E:19597 ||| NNP
/ ||| S:19597 E:19598 ||| NNP
MGSA  ||| S:19598 E:19603 ||| NNP
and  ||| S:19603 E:19607 ||| CC
IL-8  ||| S:19607 E:19620 ||| NNP
have  ||| S:19620 E:19625 ||| VBP
also  ||| S:19625 E:19630 ||| RB
been  ||| S:19630 E:19635 ||| VBN
shown  ||| S:19635 E:19641 ||| VBN
to  ||| S:19641 E:19644 ||| TO
enhance  ||| S:19644 E:19652 ||| VB
re-epithelialization  ||| S:19652 E:19673 ||| JJ
of  ||| S:19673 E:19684 ||| IN
human  ||| S:19684 E:19690 ||| JJ
skin  ||| S:19690 E:19695 ||| NN
grafts  ||| S:19695 E:19702 ||| NN
in  ||| S:19702 E:19705 ||| IN
chimeric  ||| S:19705 E:19714 ||| JJ
mice  ||| S:19714 E:19719 ||| NNS
[  ||| S:19719 E:19721 ||| -LRB-
29  ||| S:19721 E:19724 ||| CD
38  ||| S:19724 E:19727 ||| CD
]  ||| S:19727 E:19729 ||| -RRB-
.  ||| S:19729 E:19731 ||| .
It  ||| S:19731 E:19734 ||| PRP
has  ||| S:19734 E:19738 ||| VBZ
also  ||| S:19738 E:19751 ||| RB
been  ||| S:19751 E:19756 ||| VBN
found  ||| S:19756 E:19762 ||| VBN
that  ||| S:19762 E:19767 ||| IN
several  ||| S:19767 E:19775 ||| JJ
CXC  ||| S:19775 E:19779 ||| NNP
chemokines  ||| S:19779 E:19790 ||| NN
can  ||| S:19790 E:19794 ||| MD
modulate  ||| S:19794 E:19811 ||| VB
angiogenesis  ||| S:19811 E:19824 ||| NNS
[  ||| S:19824 E:19826 ||| -LRB-
39  ||| S:19826 E:19829 ||| CD
]  ||| S:19829 E:19831 ||| -RRB-
,  ||| S:19831 E:19833 ||| ,
a  ||| S:19833 E:19835 ||| DT
process  ||| S:19835 E:19843 ||| NN
that  ||| S:19843 E:19848 ||| WDT
is  ||| S:19848 E:19851 ||| VBZ
critical  ||| S:19851 E:19860 ||| JJ
for  ||| S:19860 E:19864 ||| IN
proper  ||| S:19864 E:19879 ||| JJ
healing ||| S:19879 E:19886 ||| NN
.  ||| S:19886 E:19888 ||| .
Some  ||| S:19888 E:19893 ||| DT
CXC  ||| S:19893 E:19897 ||| NNP
chemokines ||| S:19897 E:19907 ||| NN
,  ||| S:19907 E:19909 ||| ,
such  ||| S:19909 E:19914 ||| JJ
as  ||| S:19914 E:19917 ||| IN
IL-8  ||| S:19917 E:19922 ||| NNP
and  ||| S:19922 E:19926 ||| CC
cCAF ||| S:19926 E:19930 ||| JJ
,  ||| S:19930 E:19932 ||| ,
are  ||| S:19932 E:19944 ||| VBP
angiogenic  ||| S:19944 E:19964 ||| VBN
in  ||| S:19964 E:19967 ||| IN
vivo  ||| S:19967 E:19972 ||| NNS
[  ||| S:19972 E:19974 ||| -LRB-
3  ||| S:19974 E:19976 ||| CD
39  ||| S:19976 E:19979 ||| CD
40  ||| S:19979 E:19982 ||| CD
41  ||| S:19982 E:19985 ||| CD
]  ||| S:19985 E:19987 ||| -RRB-
.  ||| S:19987 E:19989 ||| .
Others ||| S:19989 E:19995 ||| NNS
,  ||| S:19995 E:19997 ||| ,
such  ||| S:19997 E:20010 ||| JJ
as  ||| S:20010 E:20013 ||| IN
IP-10  ||| S:20013 E:20019 ||| NNP
( ||| S:20019 E:20020 ||| -LRB-
interferon-γ10 ||| S:20020 E:20034 ||| NNP
)  ||| S:20034 E:20036 ||| -RRB-
and  ||| S:20036 E:20040 ||| CC
PF-4  ||| S:20040 E:20045 ||| NNP
( ||| S:20045 E:20046 ||| -LRB-
platelet  ||| S:20046 E:20055 ||| FW
factor-4 ||| S:20055 E:20063 ||| FW
) ||| S:20063 E:20064 ||| -RRB-
,  ||| S:20064 E:20066 ||| ,
are  ||| S:20066 E:20078 ||| VBP
anti-angiogenic ||| S:20078 E:20093 ||| JJ
.  ||| S:20093 E:20095 ||| .
In  ||| S:20095 E:20098 ||| IN
the  ||| S:20098 E:20102 ||| DT
case  ||| S:20102 E:20107 ||| NN
of  ||| S:20107 E:20110 ||| IN
IP-10 ||| S:20110 E:20115 ||| NNP
,  ||| S:20115 E:20117 ||| ,
it  ||| S:20117 E:20120 ||| PRP
has  ||| S:20120 E:20124 ||| VBZ
been  ||| S:20124 E:20129 ||| VBN
shown  ||| S:20129 E:20143 ||| VBN
that  ||| S:20143 E:20148 ||| IN
in  ||| S:20148 E:20151 ||| IN
transgenic  ||| S:20151 E:20162 ||| JJ
mice  ||| S:20162 E:20167 ||| NNS
treated  ||| S:20167 E:20175 ||| VBN
with  ||| S:20175 E:20180 ||| IN
this  ||| S:20180 E:20185 ||| DT
chemokine ||| S:20185 E:20194 ||| NN
,  ||| S:20194 E:20196 ||| ,
wounds  ||| S:20196 E:20211 ||| NNS
heal  ||| S:20211 E:20216 ||| VBP
poorly  ||| S:20216 E:20223 ||| RB
and  ||| S:20223 E:20227 ||| CC
exhibit  ||| S:20227 E:20235 ||| NN
defects  ||| S:20235 E:20243 ||| NNS
in  ||| S:20243 E:20246 ||| IN
angiogenesis  ||| S:20246 E:20259 ||| NN
and  ||| S:20259 E:20271 ||| CC
development  ||| S:20271 E:20283 ||| NN
of  ||| S:20283 E:20286 ||| IN
the  ||| S:20286 E:20290 ||| DT
granulation  ||| S:20290 E:20302 ||| JJ
tissue  ||| S:20302 E:20309 ||| NN
[  ||| S:20309 E:20311 ||| -LRB-
8  ||| S:20311 E:20313 ||| CD
]  ||| S:20313 E:20315 ||| -RRB-
.  ||| S:20315 E:20325 ||| .
Work  ||| S:20325 E:20330 ||| NN
of  ||| S:20330 E:20333 ||| IN
others  ||| S:20333 E:20340 ||| NNS
has  ||| S:20340 E:20344 ||| VBZ
shown  ||| S:20344 E:20350 ||| VBN
that  ||| S:20350 E:20355 ||| IN
TN  ||| S:20355 E:20358 ||| NNP
is  ||| S:20358 E:20361 ||| VBZ
expressed  ||| S:20361 E:20371 ||| VBN
in  ||| S:20371 E:20382 ||| IN
association  ||| S:20382 E:20394 ||| NN
with  ||| S:20394 E:20399 ||| IN
differentiation  ||| S:20399 E:20415 ||| NN
of  ||| S:20415 E:20418 ||| IN
myofibroblasts  ||| S:20418 E:20433 ||| NN
and  ||| S:20433 E:20437 ||| CC
is  ||| S:20437 E:20448 ||| VBZ
important  ||| S:20448 E:20458 ||| JJ
in  ||| S:20458 E:20461 ||| IN
cell  ||| S:20461 E:20466 ||| NN
migration  ||| S:20466 E:20476 ||| NN
during  ||| S:20476 E:20483 ||| IN
healing  ||| S:20483 E:20491 ||| NN
[  ||| S:20491 E:20493 ||| -LRB-
25  ||| S:20493 E:20496 ||| CD
42  ||| S:20496 E:20499 ||| CD
43  ||| S:20499 E:20502 ||| CD
44  ||| S:20502 E:20505 ||| CD
]  ||| S:20505 E:20515 ||| -RRB-
.  ||| S:20515 E:20517 ||| .
Here  ||| S:20517 E:20522 ||| RB
we  ||| S:20522 E:20525 ||| PRP
show  ||| S:20525 E:20530 ||| VBP
that  ||| S:20530 E:20535 ||| IN
cCAF  ||| S:20535 E:20540 ||| JJ
and  ||| S:20540 E:20544 ||| CC
the  ||| S:20544 E:20548 ||| DT
N-peptide  ||| S:20548 E:20558 ||| JJ
stimulate  ||| S:20558 E:20576 ||| JJ
fibroblasts  ||| S:20576 E:20588 ||| NN
in  ||| S:20588 E:20591 ||| IN
culture  ||| S:20591 E:20599 ||| NN
to  ||| S:20599 E:20602 ||| TO
express  ||| S:20602 E:20610 ||| VB
TN  ||| S:20610 E:20613 ||| NNP
and  ||| S:20613 E:20617 ||| CC
that  ||| S:20617 E:20622 ||| IN
this  ||| S:20622 E:20627 ||| DT
increase  ||| S:20627 E:20644 ||| NN
in  ||| S:20644 E:20647 ||| IN
TN  ||| S:20647 E:20650 ||| NNP
is  ||| S:20650 E:20653 ||| VBZ
due  ||| S:20653 E:20657 ||| JJ
to  ||| S:20657 E:20660 ||| TO
an  ||| S:20660 E:20663 ||| DT
increase  ||| S:20663 E:20672 ||| NN
in  ||| S:20672 E:20675 ||| IN
mRNA  ||| S:20675 E:20680 ||| JJ
levels ||| S:20680 E:20686 ||| NNS
.  ||| S:20686 E:20688 ||| .
The  ||| S:20688 E:20692 ||| DT
increase  ||| S:20692 E:20701 ||| NN
is  ||| S:20701 E:20712 ||| VBZ
lower  ||| S:20712 E:20718 ||| JJR
for  ||| S:20718 E:20722 ||| IN
C-peptide  ||| S:20722 E:20732 ||| JJ
treated  ||| S:20732 E:20740 ||| JJ
cells ||| S:20740 E:20745 ||| NNS
;  ||| S:20745 E:20747 ||| :
after  ||| S:20747 E:20753 ||| IN
3  ||| S:20753 E:20755 ||| CD
days  ||| S:20755 E:20760 ||| NNS
in  ||| S:20760 E:20763 ||| IN
an  ||| S:20763 E:20774 ||| DT
environment  ||| S:20774 E:20786 ||| NN
mimicking  ||| S:20786 E:20796 ||| VBD
the  ||| S:20796 E:20800 ||| DT
wound ||| S:20800 E:20805 ||| NN
,  ||| S:20805 E:20807 ||| ,
these  ||| S:20807 E:20813 ||| DT
cells  ||| S:20813 E:20819 ||| NNS
had  ||| S:20819 E:20823 ||| VBD
lesser  ||| S:20823 E:20830 ||| JJR
but  ||| S:20830 E:20842 ||| CC
significant  ||| S:20842 E:20854 ||| JJ
tenascin  ||| S:20854 E:20863 ||| JJ
protein  ||| S:20863 E:20871 ||| NN
levels ||| S:20871 E:20877 ||| NNS
,  ||| S:20877 E:20879 ||| ,
most  ||| S:20879 E:20884 ||| RBS
likely  ||| S:20884 E:20891 ||| JJ
due  ||| S:20891 E:20895 ||| JJ
to  ||| S:20895 E:20898 ||| TO
the  ||| S:20898 E:20910 ||| DT
small  ||| S:20910 E:20916 ||| JJ
increase  ||| S:20916 E:20925 ||| NN
seen  ||| S:20925 E:20930 ||| VBN
in  ||| S:20930 E:20933 ||| IN
mRNA ||| S:20933 E:20937 ||| JJ
.  ||| S:20937 E:20939 ||| .
In  ||| S:20939 E:20942 ||| IN
addition ||| S:20942 E:20950 ||| NN
,  ||| S:20950 E:20952 ||| ,
in  ||| S:20952 E:20955 ||| IN
wounds  ||| S:20955 E:20962 ||| NNS
treated  ||| S:20962 E:20978 ||| VBN
with  ||| S:20978 E:20983 ||| IN
the  ||| S:20983 E:20987 ||| DT
chemokine ||| S:20987 E:20996 ||| NN
,  ||| S:20996 E:20998 ||| ,
TN  ||| S:20998 E:21001 ||| NNP
levels  ||| S:21001 E:21008 ||| NNS
are  ||| S:21008 E:21012 ||| VBP
much  ||| S:21012 E:21017 ||| RB
higher  ||| S:21017 E:21024 ||| JJR
at  ||| S:21024 E:21027 ||| IN
early  ||| S:21027 E:21041 ||| JJ
times  ||| S:21041 E:21047 ||| NNS
after  ||| S:21047 E:21053 ||| IN
wounding  ||| S:21053 E:21062 ||| NN
but  ||| S:21062 E:21066 ||| CC
drop  ||| S:21066 E:21071 ||| NN
by  ||| S:21071 E:21074 ||| IN
7  ||| S:21074 E:21076 ||| CD
days  ||| S:21076 E:21081 ||| NNS
after  ||| S:21081 E:21087 ||| IN
wounding ||| S:21087 E:21095 ||| NN
.  ||| S:21095 E:21097 ||| .
At  ||| S:21097 E:21108 ||| IN
this  ||| S:21108 E:21113 ||| DT
stage ||| S:21113 E:21118 ||| NN
,  ||| S:21118 E:21120 ||| ,
the  ||| S:21120 E:21124 ||| DT
wounds  ||| S:21124 E:21131 ||| NNS
are  ||| S:21131 E:21135 ||| VBP
closed  ||| S:21135 E:21142 ||| VBN
and  ||| S:21142 E:21146 ||| CC
are  ||| S:21146 E:21150 ||| VBP
beginning  ||| S:21150 E:21160 ||| VBG
to  ||| S:21160 E:21171 ||| TO
remodel  ||| S:21171 E:21179 ||| VB
in  ||| S:21179 E:21182 ||| IN
the  ||| S:21182 E:21186 ||| DT
cCAF-treated  ||| S:21186 E:21199 ||| JJ
wounds  ||| S:21199 E:21206 ||| NNS
while  ||| S:21206 E:21212 ||| IN
the  ||| S:21212 E:21216 ||| DT
granulation  ||| S:21216 E:21236 ||| JJ
tissue  ||| S:21236 E:21243 ||| NN
in  ||| S:21243 E:21246 ||| IN
the  ||| S:21246 E:21250 ||| DT
control  ||| S:21250 E:21258 ||| NN
wings  ||| S:21258 E:21264 ||| NNS
is  ||| S:21264 E:21267 ||| VBZ
still  ||| S:21267 E:21273 ||| RB
maturing ||| S:21273 E:21281 ||| VBG
.  ||| S:21281 E:21283 ||| .
These  ||| S:21283 E:21289 ||| DT
data  ||| S:21289 E:21302 ||| NNS
taken  ||| S:21302 E:21308 ||| VBN
together  ||| S:21308 E:21317 ||| RB
strongly  ||| S:21317 E:21326 ||| RB
suggest  ||| S:21326 E:21334 ||| VB
that  ||| S:21334 E:21339 ||| IN
as  ||| S:21339 E:21342 ||| RB
chemokines  ||| S:21342 E:21353 ||| RB
induce  ||| S:21353 E:21368 ||| VB
the  ||| S:21368 E:21372 ||| DT
differentiation  ||| S:21372 E:21388 ||| NN
of  ||| S:21388 E:21391 ||| IN
fibroblasts  ||| S:21391 E:21403 ||| NN
into  ||| S:21403 E:21408 ||| IN
myofibroblasts  ||| S:21408 E:21423 ||| VBG
they  ||| S:21423 E:21436 ||| PRP
contribute  ||| S:21436 E:21447 ||| VBP
to  ||| S:21447 E:21450 ||| TO
the  ||| S:21450 E:21454 ||| DT
production  ||| S:21454 E:21465 ||| NN
of  ||| S:21465 E:21468 ||| IN
TN  ||| S:21468 E:21471 ||| NNP
in  ||| S:21471 E:21474 ||| IN
the  ||| S:21474 E:21478 ||| DT
granulation  ||| S:21478 E:21498 ||| JJ
tissue ||| S:21498 E:21504 ||| NN
.  ||| S:21504 E:21506 ||| .
Our  ||| S:21506 E:21510 ||| PRP$
finding  ||| S:21510 E:21518 ||| NN
that  ||| S:21518 E:21523 ||| IN
the  ||| S:21523 E:21527 ||| DT
N-terminal  ||| S:21527 E:21538 ||| JJ
peptide  ||| S:21538 E:21546 ||| NN
is  ||| S:21546 E:21549 ||| VBZ
able  ||| S:21549 E:21554 ||| JJ
to  ||| S:21554 E:21565 ||| TO
stimulate  ||| S:21565 E:21575 ||| VB
expression  ||| S:21575 E:21586 ||| NN
of  ||| S:21586 E:21589 ||| IN
TN  ||| S:21589 E:21592 ||| NNP
much  ||| S:21592 E:21597 ||| RB
like  ||| S:21597 E:21602 ||| IN
the  ||| S:21602 E:21606 ||| DT
whole  ||| S:21606 E:21612 ||| JJ
protein  ||| S:21612 E:21620 ||| NN
is  ||| S:21620 E:21631 ||| VBZ
potentially  ||| S:21631 E:21643 ||| RB
important  ||| S:21643 E:21653 ||| JJ
because  ||| S:21653 E:21661 ||| IN
this  ||| S:21661 E:21666 ||| DT
small  ||| S:21666 E:21672 ||| JJ
peptide  ||| S:21672 E:21680 ||| NN
may  ||| S:21680 E:21684 ||| MD
be  ||| S:21684 E:21695 ||| VB
useful  ||| S:21695 E:21702 ||| JJ
to  ||| S:21702 E:21705 ||| TO
develop  ||| S:21705 E:21713 ||| VB
therapeutic  ||| S:21713 E:21725 ||| JJ
agonists  ||| S:21725 E:21734 ||| NN
or  ||| S:21734 E:21737 ||| CC
antagonists  ||| S:21737 E:21749 ||| NNS
for  ||| S:21749 E:21761 ||| IN
wound  ||| S:21761 E:21767 ||| JJ
healing ||| S:21767 E:21774 ||| NN
.  ||| S:21774 E:21784 ||| .
The  ||| S:21784 E:21788 ||| DT
effect  ||| S:21788 E:21795 ||| NN
of  ||| S:21795 E:21798 ||| IN
cCAF  ||| S:21798 E:21803 ||| JJ
treatment  ||| S:21803 E:21813 ||| NN
on  ||| S:21813 E:21816 ||| IN
Coll  ||| S:21816 E:21821 ||| NNP
I  ||| S:21821 E:21823 ||| NNP
accumulation  ||| S:21823 E:21836 ||| NN
in  ||| S:21836 E:21847 ||| IN
culture  ||| S:21847 E:21855 ||| NN
and  ||| S:21855 E:21859 ||| CC
in  ||| S:21859 E:21862 ||| IN
wounded  ||| S:21862 E:21870 ||| JJ
tissues  ||| S:21870 E:21878 ||| NNS
is  ||| S:21878 E:21881 ||| VBZ
small  ||| S:21881 E:21887 ||| JJ
but  ||| S:21887 E:21891 ||| CC
reproducible ||| S:21891 E:21903 ||| NN
.  ||| S:21903 E:21913 ||| .
Because  ||| S:21913 E:21921 ||| IN
MMP-1  ||| S:21921 E:21927 ||| CD
levels  ||| S:21927 E:21934 ||| NNS
were  ||| S:21934 E:21939 ||| VBD
also  ||| S:21939 E:21944 ||| RB
decreased  ||| S:21944 E:21954 ||| VBN
by  ||| S:21954 E:21957 ||| IN
cCAF  ||| S:21957 E:21962 ||| JJ
treatment ||| S:21962 E:21971 ||| NN
,  ||| S:21971 E:21981 ||| ,
it  ||| S:21981 E:21984 ||| PRP
is  ||| S:21984 E:21987 ||| VBZ
possible  ||| S:21987 E:21996 ||| JJ
that  ||| S:21996 E:22001 ||| IN
the  ||| S:22001 E:22005 ||| DT
small  ||| S:22005 E:22011 ||| JJ
rise  ||| S:22011 E:22016 ||| NN
in  ||| S:22016 E:22019 ||| IN
Coll  ||| S:22019 E:22024 ||| NNP
I  ||| S:22024 E:22026 ||| NNP
levels  ||| S:22026 E:22033 ||| NNS
is  ||| S:22033 E:22036 ||| VBZ
due  ||| S:22036 E:22048 ||| JJ
to  ||| S:22048 E:22051 ||| TO
decreased  ||| S:22051 E:22061 ||| VB
degradation  ||| S:22061 E:22073 ||| VBN
of  ||| S:22073 E:22076 ||| IN
this  ||| S:22076 E:22081 ||| DT
ECM  ||| S:22081 E:22085 ||| NNP
molecule  ||| S:22085 E:22094 ||| NN
by  ||| S:22094 E:22097 ||| IN
the  ||| S:22097 E:22109 ||| DT
collagenase ||| S:22109 E:22120 ||| NN
.  ||| S:22120 E:22122 ||| .
Another  ||| S:22122 E:22130 ||| DT
chemokine  ||| S:22130 E:22140 ||| NN
that  ||| S:22140 E:22145 ||| WDT
has  ||| S:22145 E:22149 ||| VBZ
been  ||| S:22149 E:22154 ||| VBN
associated  ||| S:22154 E:22173 ||| VBN
with  ||| S:22173 E:22178 ||| IN
Coll  ||| S:22178 E:22183 ||| NNP
I  ||| S:22183 E:22185 ||| NNP
production  ||| S:22185 E:22196 ||| NN
is  ||| S:22196 E:22199 ||| VBZ
monocyte  ||| S:22199 E:22208 ||| JJ
chemotactic  ||| S:22208 E:22220 ||| JJ
protein  ||| S:22220 E:22228 ||| NN
1  ||| S:22228 E:22238 ||| CD
( ||| S:22238 E:22239 ||| -LRB-
MCP-1 ||| S:22239 E:22244 ||| NNP
) ||| S:22244 E:22245 ||| -RRB-
.  ||| S:22245 E:22247 ||| .
This  ||| S:22247 E:22252 ||| DT
chemokine  ||| S:22252 E:22262 ||| NN
belongs  ||| S:22262 E:22270 ||| VBZ
to  ||| S:22270 E:22273 ||| TO
the  ||| S:22273 E:22277 ||| DT
CC  ||| S:22277 E:22280 ||| NNP
chemokine  ||| S:22280 E:22290 ||| JJ
family  ||| S:22290 E:22305 ||| NN
and  ||| S:22305 E:22309 ||| CC
stimulates  ||| S:22309 E:22320 ||| JJ
Coll  ||| S:22320 E:22325 ||| NNP
I  ||| S:22325 E:22327 ||| NNP
production  ||| S:22327 E:22338 ||| NN
both  ||| S:22338 E:22343 ||| CC
by  ||| S:22343 E:22346 ||| IN
lung  ||| S:22346 E:22351 ||| NN
fibroblasts  ||| S:22351 E:22371 ||| VBZ
taken  ||| S:22371 E:22377 ||| VBN
from  ||| S:22377 E:22382 ||| IN
areas  ||| S:22382 E:22388 ||| NNS
of  ||| S:22388 E:22391 ||| IN
inflammation  ||| S:22391 E:22404 ||| NNS
[  ||| S:22404 E:22406 ||| -LRB-
26  ||| S:22406 E:22409 ||| CD
]  ||| S:22409 E:22411 ||| -RRB-
and  ||| S:22411 E:22415 ||| CC
in  ||| S:22415 E:22418 ||| IN
kidneys  ||| S:22418 E:22426 ||| NNS
that  ||| S:22426 E:22439 ||| WDT
suffer  ||| S:22439 E:22446 ||| VBP
from  ||| S:22446 E:22451 ||| IN
crescentic  ||| S:22451 E:22462 ||| JJ
nephritis  ||| S:22462 E:22472 ||| NNS
[  ||| S:22472 E:22474 ||| -LRB-
45  ||| S:22474 E:22477 ||| CD
]  ||| S:22477 E:22479 ||| -RRB-
.  ||| S:22479 E:22481 ||| .
The  ||| S:22481 E:22485 ||| DT
former  ||| S:22485 E:22500 ||| JJ
investigators  ||| S:22500 E:22514 ||| NNS
reported  ||| S:22514 E:22523 ||| VBD
that  ||| S:22523 E:22528 ||| IN
MCP-1  ||| S:22528 E:22534 ||| CD
increases  ||| S:22534 E:22544 ||| NNS
collagen  ||| S:22544 E:22561 ||| JJ
accumulation  ||| S:22561 E:22574 ||| NN
not  ||| S:22574 E:22578 ||| RB
by  ||| S:22578 E:22581 ||| IN
decreasing  ||| S:22581 E:22592 ||| VBG
the  ||| S:22592 E:22596 ||| DT
levels  ||| S:22596 E:22603 ||| NNS
of  ||| S:22603 E:22606 ||| IN
the  ||| S:22606 E:22618 ||| DT
collagenase  ||| S:22618 E:22630 ||| JJ
MMP-1 ||| S:22630 E:22635 ||| NN
,  ||| S:22635 E:22637 ||| ,
but  ||| S:22637 E:22641 ||| CC
by  ||| S:22641 E:22644 ||| IN
stimulating  ||| S:22644 E:22656 ||| VBG
the  ||| S:22656 E:22660 ||| DT
production  ||| S:22660 E:22671 ||| NN
of  ||| S:22671 E:22682 ||| IN
TGFβ1 ||| S:22682 E:22687 ||| NNP
,  ||| S:22687 E:22689 ||| ,
a  ||| S:22689 E:22691 ||| DT
well-known  ||| S:22691 E:22702 ||| JJ
stimulator  ||| S:22702 E:22713 ||| NN
of  ||| S:22713 E:22716 ||| IN
collagen  ||| S:22716 E:22725 ||| JJ
expression  ||| S:22725 E:22736 ||| NN
and  ||| S:22736 E:22748 ||| CC
expression  ||| S:22748 E:22759 ||| NN
of  ||| S:22759 E:22762 ||| IN
TIMPs ||| S:22762 E:22767 ||| NNP
,  ||| S:22767 E:22769 ||| ,
the  ||| S:22769 E:22773 ||| DT
natural  ||| S:22773 E:22781 ||| JJ
inhibitors  ||| S:22781 E:22792 ||| NN
of  ||| S:22792 E:22795 ||| IN
MMPs ||| S:22795 E:22799 ||| JJ
.  ||| S:22799 E:22801 ||| .
In  ||| S:22801 E:22812 ||| IN
addition  ||| S:22812 E:22821 ||| NN
to  ||| S:22821 E:22824 ||| TO
MCP-1 ||| S:22824 E:22829 ||| CD
,  ||| S:22829 E:22831 ||| ,
IL-8  ||| S:22831 E:22836 ||| NNP
and  ||| S:22836 E:22840 ||| CC
MGSA  ||| S:22840 E:22845 ||| NNP
have  ||| S:22845 E:22850 ||| VBP
also  ||| S:22850 E:22855 ||| RB
been  ||| S:22855 E:22860 ||| VBN
evaluated  ||| S:22860 E:22878 ||| VBN
for  ||| S:22878 E:22882 ||| IN
production  ||| S:22882 E:22893 ||| NN
of  ||| S:22893 E:22896 ||| IN
collagen  ||| S:22896 E:22905 ||| NN
[  ||| S:22905 E:22907 ||| -LRB-
46  ||| S:22907 E:22910 ||| CD
]  ||| S:22910 E:22912 ||| -RRB-
.  ||| S:22912 E:22914 ||| .
These  ||| S:22914 E:22920 ||| DT
investigators  ||| S:22920 E:22942 ||| NNS
reported  ||| S:22942 E:22951 ||| VBD
that  ||| S:22951 E:22956 ||| DT
treatment  ||| S:22956 E:22966 ||| NN
of  ||| S:22966 E:22969 ||| IN
normal  ||| S:22969 E:22976 ||| JJ
fibroblasts  ||| S:22976 E:22988 ||| NN
with  ||| S:22988 E:22993 ||| IN
these  ||| S:22993 E:23007 ||| DT
chemokines  ||| S:23007 E:23018 ||| NN
did  ||| S:23018 E:23022 ||| VBD
not  ||| S:23022 E:23026 ||| RB
affect  ||| S:23026 E:23033 ||| VB
collagen  ||| S:23033 E:23042 ||| JJ
levels ||| S:23042 E:23048 ||| NNS
.  ||| S:23048 E:23050 ||| .
It  ||| S:23050 E:23053 ||| PRP
is  ||| S:23053 E:23056 ||| VBZ
not  ||| S:23056 E:23060 ||| RB
clear  ||| S:23060 E:23074 ||| JJ
from  ||| S:23074 E:23079 ||| IN
their  ||| S:23079 E:23085 ||| PRP$
results  ||| S:23085 E:23093 ||| NNS
whether  ||| S:23093 E:23101 ||| IN
the  ||| S:23101 E:23105 ||| DT
elevation  ||| S:23105 E:23115 ||| NN
in  ||| S:23115 E:23118 ||| IN
collagen  ||| S:23118 E:23135 ||| JJ
production  ||| S:23135 E:23146 ||| NN
in  ||| S:23146 E:23149 ||| IN
normal  ||| S:23149 E:23156 ||| JJ
fibroblasts  ||| S:23156 E:23168 ||| NN
may  ||| S:23168 E:23172 ||| MD
have  ||| S:23172 E:23177 ||| VB
been  ||| S:23177 E:23182 ||| VBN
small ||| S:23182 E:23187 ||| JJ
,  ||| S:23187 E:23189 ||| ,
like  ||| S:23189 E:23202 ||| IN
that  ||| S:23202 E:23207 ||| WDT
observed  ||| S:23207 E:23216 ||| VBD
with  ||| S:23216 E:23221 ||| IN
cCAF ||| S:23221 E:23225 ||| NNP
,  ||| S:23225 E:23227 ||| ,
and  ||| S:23227 E:23231 ||| CC
therefore  ||| S:23231 E:23241 ||| RB
gone  ||| S:23241 E:23246 ||| VBN
unnoticed ||| S:23246 E:23255 ||| NN
.  ||| S:23255 E:23265 ||| .
FN  ||| S:23265 E:23268 ||| NNP
accumulation  ||| S:23268 E:23281 ||| VBD
due  ||| S:23281 E:23285 ||| JJ
to  ||| S:23285 E:23288 ||| TO
cCAF  ||| S:23288 E:23293 ||| JJ
treatment  ||| S:23293 E:23303 ||| NN
also  ||| S:23303 E:23308 ||| RB
differs  ||| S:23308 E:23316 ||| VBZ
from  ||| S:23316 E:23329 ||| IN
that  ||| S:23329 E:23334 ||| DT
of  ||| S:23334 E:23337 ||| IN
TN ||| S:23337 E:23339 ||| NNP
.  ||| S:23339 E:23341 ||| .
The  ||| S:23341 E:23345 ||| DT
FN  ||| S:23345 E:23348 ||| NNP
mRNA  ||| S:23348 E:23353 ||| JJ
levels  ||| S:23353 E:23360 ||| NNS
are  ||| S:23360 E:23364 ||| VBP
not  ||| S:23364 E:23368 ||| RB
affected  ||| S:23368 E:23377 ||| VBN
by  ||| S:23377 E:23380 ||| IN
cCAF  ||| S:23380 E:23393 ||| JJ
treatment  ||| S:23393 E:23403 ||| NN
but  ||| S:23403 E:23407 ||| CC
the  ||| S:23407 E:23411 ||| DT
protein  ||| S:23411 E:23419 ||| NN
accumulates  ||| S:23419 E:23431 ||| NN
in  ||| S:23431 E:23434 ||| IN
culture  ||| S:23434 E:23442 ||| NN
and  ||| S:23442 E:23446 ||| CC
in  ||| S:23446 E:23449 ||| IN
the  ||| S:23449 E:23461 ||| DT
granulation  ||| S:23461 E:23473 ||| JJ
tissue  ||| S:23473 E:23480 ||| NN
of  ||| S:23480 E:23483 ||| IN
wounds  ||| S:23483 E:23490 ||| NNS
upon  ||| S:23490 E:23495 ||| IN
exposure  ||| S:23495 E:23504 ||| NN
to  ||| S:23504 E:23507 ||| TO
the  ||| S:23507 E:23519 ||| DT
chemokine ||| S:23519 E:23528 ||| NN
.  ||| S:23528 E:23530 ||| .
By  ||| S:23530 E:23533 ||| IN
analogy  ||| S:23533 E:23541 ||| NN
with  ||| S:23541 E:23546 ||| IN
the  ||| S:23546 E:23550 ||| DT
increase  ||| S:23550 E:23559 ||| NN
in  ||| S:23559 E:23562 ||| IN
Coll  ||| S:23562 E:23567 ||| NNP
I ||| S:23567 E:23568 ||| NNP
,  ||| S:23568 E:23570 ||| ,
we  ||| S:23570 E:23581 ||| PRP
hypothesized  ||| S:23581 E:23594 ||| VBD
that  ||| S:23594 E:23599 ||| DT
decrease  ||| S:23599 E:23608 ||| NN
in  ||| S:23608 E:23611 ||| IN
protease  ||| S:23611 E:23620 ||| JJ
levels ||| S:23620 E:23626 ||| NNS
/ ||| S:23626 E:23627 ||| JJ
activity  ||| S:23627 E:23636 ||| NN
is  ||| S:23636 E:23647 ||| VBZ
involved  ||| S:23647 E:23656 ||| VBN
in  ||| S:23656 E:23659 ||| IN
the  ||| S:23659 E:23663 ||| DT
accumulation  ||| S:23663 E:23676 ||| NN
of  ||| S:23676 E:23679 ||| IN
FN ||| S:23679 E:23681 ||| NNP
.  ||| S:23681 E:23683 ||| .
Plasmin  ||| S:23683 E:23691 ||| RB
resulting  ||| S:23691 E:23701 ||| VBG
from  ||| S:23701 E:23714 ||| IN
cleavage  ||| S:23714 E:23723 ||| NN
of  ||| S:23723 E:23726 ||| IN
plasminogen  ||| S:23726 E:23738 ||| NN
by  ||| S:23738 E:23741 ||| IN
plasminogen  ||| S:23741 E:23753 ||| JJ
activator  ||| S:23753 E:23763 ||| NNS
( ||| S:23763 E:23764 ||| -LRB-
PA ||| S:23764 E:23766 ||| NNP
)  ||| S:23766 E:23768 ||| -RRB-
is  ||| S:23768 E:23779 ||| VBZ
the  ||| S:23779 E:23783 ||| DT
major  ||| S:23783 E:23789 ||| JJ
enzyme  ||| S:23789 E:23796 ||| NNS
affecting  ||| S:23796 E:23806 ||| VBG
FN  ||| S:23806 E:23809 ||| NNP
degradation  ||| S:23809 E:23821 ||| NN
in  ||| S:23821 E:23824 ||| IN
chickens ||| S:23824 E:23832 ||| NNS
.  ||| S:23832 E:23842 ||| .
However ||| S:23842 E:23849 ||| RB
,  ||| S:23849 E:23851 ||| ,
testing  ||| S:23851 E:23859 ||| VBG
for  ||| S:23859 E:23863 ||| IN
decrease  ||| S:23863 E:23872 ||| NN
in  ||| S:23872 E:23875 ||| IN
PA  ||| S:23875 E:23878 ||| NNP
activity  ||| S:23878 E:23887 ||| NN
showed  ||| S:23887 E:23894 ||| VBD
that  ||| S:23894 E:23907 ||| IN
this  ||| S:23907 E:23912 ||| DT
enzyme  ||| S:23912 E:23919 ||| NN
is  ||| S:23919 E:23922 ||| VBZ
not  ||| S:23922 E:23926 ||| RB
activated  ||| S:23926 E:23936 ||| VBN
even  ||| S:23936 E:23941 ||| RB
in  ||| S:23941 E:23944 ||| IN
the  ||| S:23944 E:23948 ||| DT
controls ||| S:23948 E:23956 ||| NNS
,  ||| S:23956 E:23966 ||| ,
therefore ||| S:23966 E:23975 ||| RB
,  ||| S:23975 E:23977 ||| ,
it  ||| S:23977 E:23980 ||| PRP
is  ||| S:23980 E:23983 ||| VBZ
unlikely  ||| S:23983 E:23992 ||| JJ
that  ||| S:23992 E:23997 ||| IN
this  ||| S:23997 E:24002 ||| DT
would  ||| S:24002 E:24008 ||| MD
be  ||| S:24008 E:24011 ||| VB
a  ||| S:24011 E:24013 ||| DT
major  ||| S:24013 E:24027 ||| JJ
mechanism  ||| S:24027 E:24037 ||| NN
involved  ||| S:24037 E:24046 ||| VBN
in  ||| S:24046 E:24049 ||| IN
degrading  ||| S:24049 E:24059 ||| JJ
FN ||| S:24059 E:24061 ||| NNP
.  ||| S:24061 E:24063 ||| .
In  ||| S:24063 E:24066 ||| IN
humans ||| S:24066 E:24072 ||| NNS
,  ||| S:24072 E:24074 ||| ,
there  ||| S:24074 E:24080 ||| EX
are  ||| S:24080 E:24092 ||| VBP
several  ||| S:24092 E:24100 ||| JJ
MMPs  ||| S:24100 E:24105 ||| NN
that  ||| S:24105 E:24110 ||| WDT
are  ||| S:24110 E:24114 ||| VBP
known  ||| S:24114 E:24120 ||| VBN
to  ||| S:24120 E:24123 ||| TO
degrade  ||| S:24123 E:24131 ||| VB
FN ||| S:24131 E:24133 ||| NNP
.  ||| S:24133 E:24135 ||| .
We  ||| S:24135 E:24138 ||| PRP
found  ||| S:24138 E:24144 ||| VBD
that  ||| S:24144 E:24157 ||| IN
MMP-2  ||| S:24157 E:24163 ||| CD
levels  ||| S:24163 E:24170 ||| NNS
are  ||| S:24170 E:24174 ||| VBP
unaffected  ||| S:24174 E:24185 ||| VBN
by  ||| S:24185 E:24188 ||| IN
cCAF  ||| S:24188 E:24193 ||| JJ
treatment  ||| S:24193 E:24203 ||| NN
and  ||| S:24203 E:24207 ||| CC
that  ||| S:24207 E:24220 ||| IN
there  ||| S:24220 E:24226 ||| EX
is  ||| S:24226 E:24229 ||| VBZ
no  ||| S:24229 E:24232 ||| DT
detectable  ||| S:24232 E:24243 ||| JJ
MMP-3 ||| S:24243 E:24248 ||| NN
,  ||| S:24248 E:24250 ||| ,
-7  ||| S:24250 E:24253 ||| NNP
and  ||| S:24253 E:24257 ||| CC
-10  ||| S:24257 E:24261 ||| CD
activity  ||| S:24261 E:24270 ||| NN
as  ||| S:24270 E:24281 ||| IN
evaluated  ||| S:24281 E:24291 ||| NN
by  ||| S:24291 E:24294 ||| IN
casein  ||| S:24294 E:24301 ||| JJ
zymography  ||| S:24301 E:24312 ||| NNS
using  ||| S:24312 E:24318 ||| VBG
tCEFs  ||| S:24318 E:24324 ||| JJ
as  ||| S:24324 E:24327 ||| IN
control  ||| S:24327 E:24335 ||| NN
for  ||| S:24335 E:24347 ||| IN
production  ||| S:24347 E:24358 ||| NN
of  ||| S:24358 E:24361 ||| IN
these  ||| S:24361 E:24367 ||| DT
stromelysins ||| S:24367 E:24379 ||| NN
.  ||| S:24379 E:24381 ||| .
Another  ||| S:24381 E:24389 ||| DT
FN-degrading  ||| S:24389 E:24410 ||| JJ
metalloproteinase ||| S:24410 E:24427 ||| NN
,  ||| S:24427 E:24429 ||| ,
MT-MMP1 ||| S:24429 E:24436 ||| NNP
,  ||| S:24436 E:24438 ||| ,
is  ||| S:24438 E:24441 ||| VBZ
unlikely  ||| S:24441 E:24450 ||| JJ
to  ||| S:24450 E:24453 ||| TO
be  ||| S:24453 E:24456 ||| VB
involved  ||| S:24456 E:24473 ||| VBN
because  ||| S:24473 E:24481 ||| IN
it  ||| S:24481 E:24484 ||| PRP
also  ||| S:24484 E:24489 ||| RB
activates  ||| S:24489 E:24499 ||| JJ
MMP-2  ||| S:24499 E:24505 ||| NN
and  ||| S:24505 E:24509 ||| CC
this  ||| S:24509 E:24514 ||| DT
enzyme  ||| S:24514 E:24521 ||| NN
is  ||| S:24521 E:24524 ||| VBZ
not  ||| S:24524 E:24536 ||| RB
activated  ||| S:24536 E:24546 ||| VBN
by  ||| S:24546 E:24549 ||| IN
cCAF  ||| S:24549 E:24554 ||| JJ
treatment ||| S:24554 E:24563 ||| NN
.  ||| S:24563 E:24573 ||| .
Another  ||| S:24573 E:24581 ||| DT
possible  ||| S:24581 E:24590 ||| JJ
mechanism  ||| S:24590 E:24600 ||| NN
that  ||| S:24600 E:24605 ||| WDT
may  ||| S:24605 E:24609 ||| MD
explain  ||| S:24609 E:24617 ||| VB
FN  ||| S:24617 E:24628 ||| JJ
accumulation  ||| S:24628 E:24641 ||| NN
could  ||| S:24641 E:24647 ||| MD
be  ||| S:24647 E:24650 ||| VB
an  ||| S:24650 E:24653 ||| DT
increase  ||| S:24653 E:24662 ||| NN
in  ||| S:24662 E:24665 ||| IN
TN ||| S:24665 E:24667 ||| NNP
.  ||| S:24667 E:24669 ||| .
TN-C  ||| S:24669 E:24674 ||| JJ
knockout  ||| S:24674 E:24683 ||| NN
mice  ||| S:24683 E:24696 ||| NNS
show  ||| S:24696 E:24701 ||| VBP
decreased  ||| S:24701 E:24711 ||| VBN
accumulation  ||| S:24711 E:24724 ||| NN
of  ||| S:24724 E:24727 ||| IN
FN  ||| S:24727 E:24730 ||| NNP
in  ||| S:24730 E:24733 ||| IN
wounded  ||| S:24733 E:24741 ||| JJ
tissue  ||| S:24741 E:24748 ||| NN
and  ||| S:24748 E:24760 ||| CC
this  ||| S:24760 E:24765 ||| DT
decrease  ||| S:24765 E:24774 ||| NN
has  ||| S:24774 E:24778 ||| VBZ
been  ||| S:24778 E:24783 ||| VBN
hypothesized  ||| S:24783 E:24796 ||| VBN
to  ||| S:24796 E:24799 ||| TO
be  ||| S:24799 E:24802 ||| VB
due  ||| S:24802 E:24806 ||| JJ
to  ||| S:24806 E:24809 ||| TO
disrupted  ||| S:24809 E:24827 ||| VB
incorporation  ||| S:24827 E:24841 ||| VBN
on  ||| S:24841 E:24844 ||| IN
FN  ||| S:24844 E:24847 ||| NNP
into  ||| S:24847 E:24852 ||| IN
the  ||| S:24852 E:24856 ||| DT
matrix  ||| S:24856 E:24863 ||| NN
in  ||| S:24863 E:24866 ||| IN
the  ||| S:24866 E:24870 ||| DT
absence  ||| S:24870 E:24878 ||| NN
of  ||| S:24878 E:24881 ||| IN
TN-C  ||| S:24881 E:24894 ||| NNP
[  ||| S:24894 E:24896 ||| -LRB-
32  ||| S:24896 E:24899 ||| CD
33  ||| S:24899 E:24902 ||| CD
]  ||| S:24902 E:24904 ||| -RRB-
.  ||| S:24904 E:24906 ||| .
Therefore ||| S:24906 E:24915 ||| RB
,  ||| S:24915 E:24917 ||| ,
our  ||| S:24917 E:24921 ||| PRP$
observation  ||| S:24921 E:24933 ||| NN
that  ||| S:24933 E:24938 ||| IN
inhibition  ||| S:24938 E:24949 ||| NN
of  ||| S:24949 E:24960 ||| IN
cCAF-induced  ||| S:24960 E:24973 ||| NNP
TN  ||| S:24973 E:24976 ||| NNP
production  ||| S:24976 E:24987 ||| NN
decreases  ||| S:24987 E:24997 ||| VBZ
the  ||| S:24997 E:25001 ||| DT
accumulation  ||| S:25001 E:25014 ||| NN
of  ||| S:25014 E:25017 ||| IN
FN  ||| S:25017 E:25028 ||| NNP
supports  ||| S:25028 E:25037 ||| VBZ
the  ||| S:25037 E:25041 ||| DT
findings  ||| S:25041 E:25050 ||| NNS
in  ||| S:25050 E:25053 ||| IN
the  ||| S:25053 E:25057 ||| DT
knockout  ||| S:25057 E:25066 ||| JJ
mice ||| S:25066 E:25070 ||| NNS
.  ||| S:25070 E:25072 ||| .
However ||| S:25072 E:25079 ||| RB
,  ||| S:25079 E:25081 ||| ,
this  ||| S:25081 E:25094 ||| DT
does  ||| S:25094 E:25099 ||| VBZ
not  ||| S:25099 E:25103 ||| RB
explain  ||| S:25103 E:25111 ||| VB
the  ||| S:25111 E:25115 ||| DT
unchanged  ||| S:25115 E:25125 ||| JJ
FN  ||| S:25125 E:25128 ||| NN
levels  ||| S:25128 E:25135 ||| NNS
with  ||| S:25135 E:25140 ||| IN
the  ||| S:25140 E:25144 ||| DT
N-peptide  ||| S:25144 E:25162 ||| JJ
treatment ||| S:25162 E:25171 ||| NN
.  ||| S:25171 E:25173 ||| .
One  ||| S:25173 E:25177 ||| CD
possible  ||| S:25177 E:25186 ||| JJ
explanation  ||| S:25186 E:25198 ||| NN
for  ||| S:25198 E:25202 ||| IN
these  ||| S:25202 E:25208 ||| DT
findings  ||| S:25208 E:25225 ||| NNS
could  ||| S:25225 E:25231 ||| MD
relate  ||| S:25231 E:25238 ||| VB
to  ||| S:25238 E:25241 ||| TO
the  ||| S:25241 E:25245 ||| DT
fact  ||| S:25245 E:25250 ||| NN
that  ||| S:25250 E:25255 ||| IN
FN  ||| S:25255 E:25258 ||| NNP
does  ||| S:25258 E:25263 ||| VBZ
not  ||| S:25263 E:25267 ||| RB
self-assemble ||| S:25267 E:25280 ||| JJ
.  ||| S:25280 E:25290 ||| .
Therefore ||| S:25290 E:25299 ||| RB
,  ||| S:25299 E:25301 ||| ,
it  ||| S:25301 E:25304 ||| PRP
is  ||| S:25304 E:25307 ||| VBZ
possible  ||| S:25307 E:25316 ||| JJ
that  ||| S:25316 E:25321 ||| IN
alterations  ||| S:25321 E:25333 ||| NN
in  ||| S:25333 E:25336 ||| IN
the  ||| S:25336 E:25348 ||| DT
activities  ||| S:25348 E:25359 ||| NNS
of  ||| S:25359 E:25362 ||| IN
integrins  ||| S:25362 E:25372 ||| NN
or  ||| S:25372 E:25375 ||| CC
adhesive  ||| S:25375 E:25384 ||| JJ
sites  ||| S:25384 E:25390 ||| NNS
on  ||| S:25390 E:25393 ||| IN
other  ||| S:25393 E:25399 ||| JJ
ECM  ||| S:25399 E:25411 ||| NNP
molecules  ||| S:25411 E:25421 ||| VBD
induced  ||| S:25421 E:25429 ||| VBN
by  ||| S:25429 E:25432 ||| IN
the  ||| S:25432 E:25436 ||| DT
whole  ||| S:25436 E:25442 ||| JJ
cCAF  ||| S:25442 E:25447 ||| JJ
molecule ||| S:25447 E:25455 ||| NN
,  ||| S:25455 E:25457 ||| ,
and  ||| S:25457 E:25461 ||| CC
not  ||| S:25461 E:25465 ||| RB
by  ||| S:25465 E:25476 ||| IN
the  ||| S:25476 E:25480 ||| DT
N-peptide ||| S:25480 E:25489 ||| JJ
,  ||| S:25489 E:25491 ||| ,
could  ||| S:25491 E:25497 ||| MD
affect  ||| S:25497 E:25504 ||| VB
FN  ||| S:25504 E:25507 ||| JJ
accumulation  ||| S:25507 E:25520 ||| NN
[  ||| S:25520 E:25522 ||| -LRB-
47  ||| S:25522 E:25525 ||| CD
]  ||| S:25525 E:25527 ||| -RRB-
.  ||| S:25527 E:25529 ||| .
We  ||| S:25529 E:25532 ||| PRP
are  ||| S:25532 E:25544 ||| VBP
currently  ||| S:25544 E:25554 ||| RB
pursuing  ||| S:25554 E:25563 ||| VBG
studies  ||| S:25563 E:25571 ||| NNS
to  ||| S:25571 E:25574 ||| TO
determine  ||| S:25574 E:25584 ||| VB
whether  ||| S:25584 E:25592 ||| IN
adhesion  ||| S:25592 E:25609 ||| JJ
molecules  ||| S:25609 E:25619 ||| NNS
or  ||| S:25619 E:25622 ||| CC
other  ||| S:25622 E:25628 ||| JJ
ECM  ||| S:25628 E:25632 ||| NN
molecules  ||| S:25632 E:25642 ||| NNS
play  ||| S:25642 E:25647 ||| VBP
a  ||| S:25647 E:25649 ||| DT
role  ||| S:25649 E:25654 ||| NN
in  ||| S:25654 E:25657 ||| IN
FN  ||| S:25657 E:25668 ||| NNP
accumulation  ||| S:25668 E:25681 ||| VBD
due  ||| S:25681 E:25685 ||| JJ
to  ||| S:25685 E:25688 ||| TO
cCAF-induced  ||| S:25688 E:25701 ||| NNP
TN  ||| S:25701 E:25704 ||| NNP
production ||| S:25704 E:25714 ||| NN
.  ||| S:25714 E:25724 ||| .
Migration  ||| S:25724 E:25734 ||| NNP
of  ||| S:25734 E:25737 ||| IN
fibroblasts  ||| S:25737 E:25749 ||| NN
from  ||| S:25749 E:25754 ||| IN
the  ||| S:25754 E:25758 ||| DT
area  ||| S:25758 E:25763 ||| NN
surrounding  ||| S:25763 E:25775 ||| VBG
the  ||| S:25775 E:25787 ||| DT
wound  ||| S:25787 E:25793 ||| NN
into  ||| S:25793 E:25798 ||| IN
the  ||| S:25798 E:25802 ||| DT
wound  ||| S:25802 E:25808 ||| JJ
site  ||| S:25808 E:25813 ||| NN
is  ||| S:25813 E:25816 ||| VBZ
critical  ||| S:25816 E:25825 ||| JJ
in  ||| S:25825 E:25828 ||| IN
order  ||| S:25828 E:25834 ||| NN
for  ||| S:25834 E:25846 ||| IN
remodeling  ||| S:25846 E:25857 ||| VBG
of  ||| S:25857 E:25860 ||| IN
the  ||| S:25860 E:25864 ||| DT
extracellular  ||| S:25864 E:25878 ||| JJ
matrix  ||| S:25878 E:25885 ||| NN
and  ||| S:25885 E:25889 ||| CC
for  ||| S:25889 E:25893 ||| IN
wound  ||| S:25893 E:25907 ||| JJ
contraction  ||| S:25907 E:25919 ||| NN
to  ||| S:25919 E:25922 ||| TO
occur ||| S:25922 E:25927 ||| VB
.  ||| S:25927 E:25929 ||| .
TN  ||| S:25929 E:25932 ||| NNP
and  ||| S:25932 E:25936 ||| CC
FN ||| S:25936 E:25938 ||| NNP
,  ||| S:25938 E:25940 ||| ,
especially  ||| S:25940 E:25951 ||| RB
in  ||| S:25951 E:25954 ||| IN
combination ||| S:25954 E:25965 ||| NN
,  ||| S:25965 E:25975 ||| ,
promote  ||| S:25975 E:25983 ||| VB
migration ||| S:25983 E:25992 ||| NNS
,  ||| S:25992 E:25994 ||| ,
therefore  ||| S:25994 E:26004 ||| RB
cCAF  ||| S:26004 E:26009 ||| JJ
may  ||| S:26009 E:26013 ||| MD
facilitate  ||| S:26013 E:26024 ||| VB
fibroblast  ||| S:26024 E:26043 ||| JJ
migration  ||| S:26043 E:26053 ||| NN
by  ||| S:26053 E:26056 ||| IN
increasing  ||| S:26056 E:26067 ||| VBG
TN  ||| S:26067 E:26070 ||| NNP
and  ||| S:26070 E:26074 ||| CC
FN  ||| S:26074 E:26077 ||| NNP
levels ||| S:26077 E:26083 ||| NNS
.  ||| S:26083 E:26085 ||| .
However ||| S:26085 E:26092 ||| RB
,  ||| S:26092 E:26094 ||| ,
this  ||| S:26094 E:26107 ||| DT
chemokine  ||| S:26107 E:26117 ||| NN
is  ||| S:26117 E:26120 ||| VBZ
also  ||| S:26120 E:26125 ||| RB
able  ||| S:26125 E:26130 ||| JJ
to  ||| S:26130 E:26133 ||| TO
chemoattract  ||| S:26133 E:26146 ||| VB
fibroblasts  ||| S:26146 E:26158 ||| NNS
and  ||| S:26158 E:26170 ||| CC
accelerate  ||| S:26170 E:26181 ||| VB
their  ||| S:26181 E:26187 ||| PRP$
migration  ||| S:26187 E:26197 ||| NN
in  ||| S:26197 E:26200 ||| IN
the  ||| S:26200 E:26204 ||| DT
absence  ||| S:26204 E:26212 ||| NN
of  ||| S:26212 E:26215 ||| IN
these  ||| S:26215 E:26229 ||| DT
molecules ||| S:26229 E:26238 ||| NN
,  ||| S:26238 E:26240 ||| ,
strongly  ||| S:26240 E:26249 ||| RB
suggesting  ||| S:26249 E:26260 ||| VBG
that  ||| S:26260 E:26265 ||| IN
it  ||| S:26265 E:26268 ||| PRP
contributes  ||| S:26268 E:26280 ||| VBZ
to  ||| S:26280 E:26291 ||| TO
fibroblast  ||| S:26291 E:26302 ||| VB
movement  ||| S:26302 E:26311 ||| NN
independently  ||| S:26311 E:26325 ||| RB
of  ||| S:26325 E:26328 ||| IN
the  ||| S:26328 E:26332 ||| DT
deposition  ||| S:26332 E:26343 ||| NN
of  ||| S:26343 E:26354 ||| IN
these  ||| S:26354 E:26360 ||| DT
ECM  ||| S:26360 E:26364 ||| NNP
molecule ||| S:26364 E:26372 ||| NN
.  ||| S:26372 E:26374 ||| .
These  ||| S:26374 E:26380 ||| DT
findings  ||| S:26380 E:26389 ||| NNS
suggest  ||| S:26389 E:26397 ||| VBP
that  ||| S:26397 E:26402 ||| IN
during  ||| S:26402 E:26417 ||| IN
wound  ||| S:26417 E:26423 ||| JJ
healing ||| S:26423 E:26430 ||| NN
,  ||| S:26430 E:26432 ||| ,
cCAF  ||| S:26432 E:26437 ||| NNP
produced  ||| S:26437 E:26446 ||| VBD
by  ||| S:26446 E:26449 ||| IN
the  ||| S:26449 E:26453 ||| DT
resident  ||| S:26453 E:26462 ||| NN
fibroblasts  ||| S:26462 E:26482 ||| NNS
chemoattracts  ||| S:26482 E:26496 ||| VBP
additional  ||| S:26496 E:26507 ||| JJ
fibroblasts  ||| S:26507 E:26519 ||| NN
that  ||| S:26519 E:26524 ||| WDT
contribute  ||| S:26524 E:26535 ||| VBP
to  ||| S:26535 E:26538 ||| TO
the  ||| S:26538 E:26550 ||| DT
production  ||| S:26550 E:26561 ||| NN
of  ||| S:26561 E:26564 ||| IN
these  ||| S:26564 E:26570 ||| DT
ECM  ||| S:26570 E:26574 ||| NNP
molecules ||| S:26574 E:26583 ||| NNS
,  ||| S:26583 E:26585 ||| ,
which  ||| S:26585 E:26591 ||| WDT
then  ||| S:26591 E:26596 ||| RB
support  ||| S:26596 E:26612 ||| VB
migration  ||| S:26612 E:26622 ||| VBN
of  ||| S:26622 E:26625 ||| IN
both  ||| S:26625 E:26630 ||| DT
fibroblasts  ||| S:26630 E:26642 ||| NN
and  ||| S:26642 E:26646 ||| CC
other  ||| S:26646 E:26652 ||| JJ
cells  ||| S:26652 E:26658 ||| NNS
in  ||| S:26658 E:26661 ||| IN
the  ||| S:26661 E:26665 ||| DT
wound  ||| S:26665 E:26679 ||| JJ
tissue ||| S:26679 E:26685 ||| NN
.  ||| S:26685 E:26695 ||| .
TGFβ1  ||| S:26695 E:26701 ||| NNP
is  ||| S:26701 E:26704 ||| VBZ
another  ||| S:26704 E:26712 ||| DT
factor  ||| S:26712 E:26719 ||| NN
known  ||| S:26719 E:26725 ||| VBN
to  ||| S:26725 E:26728 ||| TO
stimulate  ||| S:26728 E:26738 ||| VB
myofibroblast  ||| S:26738 E:26760 ||| JJ
differentiation ||| S:26760 E:26775 ||| NN
,  ||| S:26775 E:26777 ||| ,
ECM  ||| S:26777 E:26781 ||| NNP
production  ||| S:26781 E:26792 ||| NN
and  ||| S:26792 E:26796 ||| CC
accelerate  ||| S:26796 E:26807 ||| VB
wound  ||| S:26807 E:26821 ||| JJ
closure  ||| S:26821 E:26829 ||| NN
and  ||| S:26829 E:26833 ||| CC
healing ||| S:26833 E:26840 ||| NN
.  ||| S:26840 E:26842 ||| .
However ||| S:26842 E:26849 ||| RB
,  ||| S:26849 E:26851 ||| ,
this  ||| S:26851 E:26856 ||| DT
growth  ||| S:26856 E:26863 ||| NN
factor  ||| S:26863 E:26870 ||| NN
has  ||| S:26870 E:26874 ||| VBZ
a  ||| S:26874 E:26884 ||| DT
strong  ||| S:26884 E:26891 ||| JJ
inflammatory  ||| S:26891 E:26904 ||| JJ
effect  ||| S:26904 E:26911 ||| NN
that  ||| S:26911 E:26916 ||| WDT
leads  ||| S:26916 E:26922 ||| VBZ
to  ||| S:26922 E:26925 ||| TO
excess  ||| S:26925 E:26932 ||| JJ
fibrosis  ||| S:26932 E:26949 ||| NN
and  ||| S:26949 E:26953 ||| CC
scarring ||| S:26953 E:26961 ||| NN
.  ||| S:26961 E:26963 ||| .
In  ||| S:26963 E:26966 ||| IN
addition  ||| S:26966 E:26975 ||| NN
to  ||| S:26975 E:26978 ||| TO
greatly  ||| S:26978 E:26986 ||| RB
increasing  ||| S:26986 E:27005 ||| VBG
accumulation  ||| S:27005 E:27018 ||| NN
of  ||| S:27018 E:27021 ||| IN
Colls  ||| S:27021 E:27027 ||| NNP
I  ||| S:27027 E:27029 ||| NNP
and  ||| S:27029 E:27033 ||| CC
III ||| S:27033 E:27036 ||| NNP
,  ||| S:27036 E:27038 ||| ,
TGFβ1  ||| S:27038 E:27044 ||| NNP
has  ||| S:27044 E:27048 ||| VBZ
been  ||| S:27048 E:27053 ||| VBN
shown  ||| S:27053 E:27059 ||| VBN
to  ||| S:27059 E:27070 ||| TO
also  ||| S:27070 E:27075 ||| RB
increase  ||| S:27075 E:27084 ||| VB
FN  ||| S:27084 E:27087 ||| NNP
and  ||| S:27087 E:27091 ||| CC
TN  ||| S:27091 E:27094 ||| NNP
production.  ||| S:27094 E:27106 ||| NNP
cCAF  ||| S:27106 E:27111 ||| NNP
( ||| S:27111 E:27112 ||| -LRB-
and  ||| S:27112 E:27116 ||| CC
maybe  ||| S:27116 E:27122 ||| RB
other  ||| S:27122 E:27136 ||| JJ
chemokines ||| S:27136 E:27146 ||| NN
) ||| S:27146 E:27147 ||| -RRB-
,  ||| S:27147 E:27149 ||| ,
on  ||| S:27149 E:27152 ||| IN
the  ||| S:27152 E:27156 ||| DT
other  ||| S:27156 E:27162 ||| JJ
hand ||| S:27162 E:27166 ||| NN
,  ||| S:27166 E:27168 ||| ,
may  ||| S:27168 E:27172 ||| MD
have  ||| S:27172 E:27177 ||| VB
a  ||| S:27177 E:27179 ||| DT
subtler ||| S:27179 E:27186 ||| NN
,  ||| S:27186 E:27188 ||| ,
more  ||| S:27188 E:27201 ||| RBR
controlled  ||| S:27201 E:27212 ||| JJ
effect ||| S:27212 E:27218 ||| NN
,  ||| S:27218 E:27220 ||| ,
promoting  ||| S:27220 E:27230 ||| VBG
the  ||| S:27230 E:27234 ||| DT
earlier  ||| S:27234 E:27242 ||| JJR
appearance  ||| S:27242 E:27253 ||| NN
of  ||| S:27253 E:27256 ||| IN
a  ||| S:27256 E:27266 ||| DT
normal  ||| S:27266 E:27273 ||| JJ
granulation  ||| S:27273 E:27285 ||| JJ
tissue  ||| S:27285 E:27292 ||| NN
without  ||| S:27292 E:27300 ||| IN
leading  ||| S:27300 E:27308 ||| VBG
to  ||| S:27308 E:27311 ||| TO
excess  ||| S:27311 E:27318 ||| JJ
matrix  ||| S:27318 E:27333 ||| JJ
accumulation  ||| S:27333 E:27346 ||| NN
and  ||| S:27346 E:27350 ||| CC
scarring ||| S:27350 E:27358 ||| NN
.  ||| S:27358 E:27382 ||| .
Conclusions  ||| S:27382 E:27402 ||| VBG
Our  ||| S:27402 E:27406 ||| PRP$
results  ||| S:27406 E:27414 ||| NNS
strongly  ||| S:27414 E:27423 ||| RB
suggest  ||| S:27423 E:27431 ||| VB
that  ||| S:27431 E:27436 ||| DT
cCAF  ||| S:27436 E:27441 ||| NN
plays  ||| S:27441 E:27447 ||| VBZ
an  ||| S:27447 E:27458 ||| DT
important  ||| S:27458 E:27468 ||| JJ
role  ||| S:27468 E:27473 ||| NN
in  ||| S:27473 E:27476 ||| IN
wound  ||| S:27476 E:27482 ||| JJ
repair  ||| S:27482 E:27489 ||| NN
by  ||| S:27489 E:27492 ||| IN
activating  ||| S:27492 E:27503 ||| JJ
fibroblasts  ||| S:27503 E:27515 ||| NN
to  ||| S:27515 E:27526 ||| TO
form  ||| S:27526 E:27531 ||| VB
early  ||| S:27531 E:27537 ||| JJ
granulation  ||| S:27537 E:27549 ||| JJ
tissue ||| S:27549 E:27555 ||| NN
,  ||| S:27555 E:27557 ||| ,
through  ||| S:27557 E:27565 ||| IN
cell  ||| S:27565 E:27570 ||| NN
migration ||| S:27570 E:27579 ||| NN
,  ||| S:27579 E:27589 ||| ,
myofibroblast  ||| S:27589 E:27603 ||| JJ
differentiation  ||| S:27603 E:27619 ||| NN
and  ||| S:27619 E:27623 ||| CC
production ||| S:27623 E:27633 ||| NN
/ ||| S:27633 E:27634 ||| CD
accumulation  ||| S:27634 E:27655 ||| NN
of  ||| S:27655 E:27658 ||| IN
ECM  ||| S:27658 E:27662 ||| NNP
molecules  ||| S:27662 E:27672 ||| NNS
that  ||| S:27672 E:27677 ||| WDT
are  ||| S:27677 E:27681 ||| VBP
critical  ||| S:27681 E:27690 ||| JJ
for  ||| S:27690 E:27694 ||| IN
proper  ||| S:27694 E:27701 ||| JJ
development  ||| S:27701 E:27721 ||| NN
of  ||| S:27721 E:27724 ||| IN
the  ||| S:27724 E:27728 ||| DT
healing  ||| S:27728 E:27736 ||| NN
tissue  ||| S:27736 E:27743 ||| NN
of  ||| S:27743 E:27746 ||| IN
wounds ||| S:27746 E:27752 ||| NNS
.  ||| S:27752 E:27754 ||| .
This  ||| S:27754 E:27759 ||| DT
is  ||| S:27759 E:27762 ||| VBZ
a  ||| S:27762 E:27764 ||| DT
previously  ||| S:27764 E:27783 ||| RB
unknown  ||| S:27783 E:27791 ||| JJ
role  ||| S:27791 E:27796 ||| NN
for  ||| S:27796 E:27800 ||| IN
chemokines  ||| S:27800 E:27811 ||| NN
and ||| S:27811 E:27814 ||| CC
,  ||| S:27814 E:27816 ||| ,
unlike  ||| S:27816 E:27823 ||| IN
other  ||| S:27823 E:27829 ||| JJ
inflammatory  ||| S:27829 E:27850 ||| JJ
factors  ||| S:27850 E:27858 ||| NNS
that  ||| S:27858 E:27863 ||| WDT
promote  ||| S:27863 E:27871 ||| VBP
granulation  ||| S:27871 E:27883 ||| JJ
tissue  ||| S:27883 E:27890 ||| NN
formation ||| S:27890 E:27899 ||| NN
,  ||| S:27899 E:27901 ||| ,
cCAF  ||| S:27901 E:27914 ||| NNP
does  ||| S:27914 E:27919 ||| VBZ
not  ||| S:27919 E:27923 ||| RB
appear  ||| S:27923 E:27930 ||| VB
to  ||| S:27930 E:27933 ||| TO
stimulate  ||| S:27933 E:27943 ||| VB
increased  ||| S:27943 E:27953 ||| VBN
fibrosis ||| S:27953 E:27961 ||| NN
.  ||| S:27961 E:27963 ||| .
If  ||| S:27963 E:27966 ||| IN
similar  ||| S:27966 E:27982 ||| JJ
behavior  ||| S:27982 E:27991 ||| NN
is  ||| S:27991 E:27994 ||| VBZ
seen  ||| S:27994 E:27999 ||| VBN
in  ||| S:27999 E:28002 ||| IN
human  ||| S:28002 E:28008 ||| JJ
chemokines ||| S:28008 E:28018 ||| NN
,  ||| S:28018 E:28020 ||| ,
it  ||| S:28020 E:28023 ||| PRP
could  ||| S:28023 E:28029 ||| MD
be  ||| S:28029 E:28032 ||| VB
a  ||| S:28032 E:28042 ||| DT
promising  ||| S:28042 E:28052 ||| JJ
target  ||| S:28052 E:28059 ||| NN
in  ||| S:28059 E:28062 ||| IN
designing  ||| S:28062 E:28072 ||| VBG
drugs  ||| S:28072 E:28078 ||| NNS
that  ||| S:28078 E:28083 ||| IN
promote  ||| S:28083 E:28091 ||| JJ
formation  ||| S:28091 E:28109 ||| NN
of  ||| S:28109 E:28112 ||| IN
granulation  ||| S:28112 E:28124 ||| JJ
tissue  ||| S:28124 E:28131 ||| NN
in  ||| S:28131 E:28134 ||| IN
poorly  ||| S:28134 E:28141 ||| RB
healing  ||| S:28141 E:28149 ||| JJ
wounds  ||| S:28149 E:28156 ||| NNS
without  ||| S:28156 E:28172 ||| IN
causing  ||| S:28172 E:28180 ||| VBG
excess  ||| S:28180 E:28187 ||| JJ
scarring ||| S:28187 E:28195 ||| NN
.  ||| S:28195 E:28219 ||| .
Materials  ||| S:28219 E:28229 ||| NNS
and  ||| S:28229 E:28233 ||| CC
methods  ||| S:28233 E:28260 ||| NNS
Reagents  ||| S:28260 E:28279 ||| VBG
All  ||| S:28279 E:28283 ||| DT
tissue  ||| S:28283 E:28290 ||| NN
culture  ||| S:28290 E:28298 ||| NN
supplies  ||| S:28298 E:28307 ||| NNS
and  ||| S:28307 E:28311 ||| CC
the  ||| S:28311 E:28315 ||| DT
TRIzol  ||| S:28315 E:28322 ||| JJ
reagent  ||| S:28322 E:28340 ||| NN
were  ||| S:28340 E:28345 ||| VBD
purchased  ||| S:28345 E:28355 ||| VBN
from  ||| S:28355 E:28360 ||| IN
Gibco-BRL.  ||| S:28360 E:28371 ||| NNP
cCAF  ||| S:28371 E:28376 ||| NNP
and  ||| S:28376 E:28380 ||| CC
the  ||| S:28380 E:28384 ||| DT
N-terminal  ||| S:28384 E:28405 ||| JJ
peptide  ||| S:28405 E:28413 ||| NNS
( ||| S:28413 E:28414 ||| -LRB-
15a.a. ||| S:28414 E:28420 ||| NNP
)  ||| S:28420 E:28422 ||| -RRB-
were  ||| S:28422 E:28427 ||| VBD
synthesized  ||| S:28427 E:28439 ||| VBN
by  ||| S:28439 E:28442 ||| IN
Gryphon  ||| S:28442 E:28450 ||| NNP
Sciences  ||| S:28450 E:28469 ||| NNPS
( ||| S:28469 E:28470 ||| -LRB-
San  ||| S:28470 E:28474 ||| NNP
Francisco ||| S:28474 E:28483 ||| NNP
,  ||| S:28483 E:28485 ||| ,
CA ||| S:28485 E:28487 ||| NNP
)  ||| S:28487 E:28489 ||| -RRB-
and  ||| S:28489 E:28493 ||| CC
C-terminus  ||| S:28493 E:28504 ||| JJ
peptide  ||| S:28504 E:28512 ||| NNS
( ||| S:28512 E:28513 ||| -LRB-
28a.a ||| S:28513 E:28518 ||| NNP
)  ||| S:28518 E:28520 ||| -RRB-
was  ||| S:28520 E:28534 ||| VBD
made  ||| S:28534 E:28539 ||| VBN
by  ||| S:28539 E:28542 ||| IN
Milligen  ||| S:28542 E:28551 ||| NNP
Biosearch  ||| S:28551 E:28561 ||| NNP
( ||| S:28561 E:28562 ||| -LRB-
San  ||| S:28562 E:28566 ||| NNP
Rafael ||| S:28566 E:28572 ||| NNP
,  ||| S:28572 E:28574 ||| ,
CA ||| S:28574 E:28576 ||| NNP
) ||| S:28576 E:28577 ||| -RRB-
.  ||| S:28577 E:28579 ||| .
Secondary  ||| S:28579 E:28599 ||| JJ
antibodies  ||| S:28599 E:28610 ||| NNS
used ||| S:28610 E:28614 ||| VBN
:  ||| S:28614 E:28616 ||| :
anti-mouse  ||| S:28616 E:28627 ||| JJ
and  ||| S:28627 E:28631 ||| CC
anti-rabbit  ||| S:28631 E:28643 ||| JJ
horseradish  ||| S:28643 E:28665 ||| JJ
peroxidase ||| S:28665 E:28675 ||| NN
,  ||| S:28675 E:28677 ||| ,
anti-mouse  ||| S:28677 E:28688 ||| NNP
Texas  ||| S:28688 E:28694 ||| NNP
Red  ||| S:28694 E:28698 ||| NNP
( ||| S:28698 E:28699 ||| -LRB-
Amersham ||| S:28699 E:28707 ||| NNP
:  ||| S:28707 E:28709 ||| :
Piscataway ||| S:28709 E:28719 ||| NNP
,  ||| S:28719 E:28731 ||| ,
NJ ||| S:28731 E:28733 ||| NNP
)  ||| S:28733 E:28735 ||| -RRB-
and  ||| S:28735 E:28739 ||| CC
anti-mouse  ||| S:28739 E:28750 ||| NNP
FITC  ||| S:28750 E:28755 ||| NNP
( ||| S:28755 E:28756 ||| -LRB-
DAKO ||| S:28756 E:28760 ||| NNP
:  ||| S:28760 E:28762 ||| :
Carpinteria ||| S:28762 E:28773 ||| NNP
,  ||| S:28773 E:28775 ||| ,
CA ||| S:28775 E:28777 ||| NNP
) ||| S:28777 E:28778 ||| -RRB-
.  ||| S:28778 E:28780 ||| .
Primary  ||| S:28780 E:28798 ||| JJ
antibodies  ||| S:28798 E:28809 ||| NNS
used ||| S:28809 E:28813 ||| VBN
:  ||| S:28813 E:28815 ||| :
mouse  ||| S:28815 E:28821 ||| JJ
anti-chicken  ||| S:28821 E:28834 ||| JJ
Coll  ||| S:28834 E:28839 ||| NNP
I ||| S:28839 E:28840 ||| NNP
,  ||| S:28840 E:28842 ||| ,
Coll  ||| S:28842 E:28847 ||| NNP
III ||| S:28847 E:28850 ||| NNP
,  ||| S:28850 E:28852 ||| ,
FN ||| S:28852 E:28854 ||| NNP
,  ||| S:28854 E:28866 ||| ,
and  ||| S:28866 E:28870 ||| CC
TN  ||| S:28870 E:28873 ||| NNP
( ||| S:28873 E:28874 ||| -LRB-
Hybridoma  ||| S:28874 E:28884 ||| NNP
Bank ||| S:28884 E:28888 ||| NNP
,  ||| S:28888 E:28890 ||| ,
Iowa ||| S:28890 E:28894 ||| NNP
) ||| S:28894 E:28895 ||| -RRB-
,  ||| S:28895 E:28897 ||| ,
rabbit  ||| S:28897 E:28904 ||| JJ
anti-chicken  ||| S:28904 E:28917 ||| JJ
TN  ||| S:28917 E:28930 ||| NNP
( ||| S:28930 E:28931 ||| -LRB-
Chemicon ||| S:28931 E:28939 ||| NNP
,  ||| S:28939 E:28941 ||| ,
Temecula  ||| S:28941 E:28950 ||| NNP
CA ||| S:28950 E:28952 ||| NNP
) ||| S:28952 E:28953 ||| -RRB-
.  ||| S:28953 E:28955 ||| .
Rabbit  ||| S:28955 E:28962 ||| NNP
anti-human  ||| S:28962 E:28973 ||| NNP
MMP-1  ||| S:28973 E:28979 ||| NNP
and  ||| S:28979 E:28993 ||| CC
TIMP-2  ||| S:28993 E:29000 ||| NNP
and  ||| S:29000 E:29004 ||| CC
mouse  ||| S:29004 E:29010 ||| JJ
anti-human  ||| S:29010 E:29021 ||| JJ
TIMP-1  ||| S:29021 E:29028 ||| NN
were  ||| S:29028 E:29033 ||| VBD
the  ||| S:29033 E:29037 ||| DT
kind  ||| S:29037 E:29042 ||| NN
gift  ||| S:29042 E:29047 ||| NN
of  ||| S:29047 E:29060 ||| IN
Dr.  ||| S:29060 E:29064 ||| NNP
Tai-Lan  ||| S:29064 E:29072 ||| NNP
Tuan ||| S:29072 E:29076 ||| NNP
.  ||| S:29076 E:29078 ||| .
The  ||| S:29078 E:29082 ||| DT
ECL  ||| S:29082 E:29086 ||| NNP
reagents  ||| S:29086 E:29095 ||| NN
were  ||| S:29095 E:29100 ||| VBD
purchased  ||| S:29100 E:29110 ||| VBN
from  ||| S:29110 E:29125 ||| IN
Amersham ||| S:29125 E:29133 ||| NNP
;  ||| S:29133 E:29135 ||| :
Vectashield  ||| S:29135 E:29147 ||| NNP
mounting  ||| S:29147 E:29156 ||| VBG
medium  ||| S:29156 E:29163 ||| NN
from  ||| S:29163 E:29168 ||| IN
Vector  ||| S:29168 E:29185 ||| NNP
Laboratories  ||| S:29185 E:29198 ||| NNPS
( ||| S:29198 E:29199 ||| -LRB-
Burlingame ||| S:29199 E:29209 ||| NNP
,  ||| S:29209 E:29211 ||| ,
CA ||| S:29211 E:29213 ||| NNP
) ||| S:29213 E:29214 ||| -RRB-
;  ||| S:29214 E:29216 ||| :
DC  ||| S:29216 E:29219 ||| NNP
protein  ||| S:29219 E:29227 ||| NN
assay  ||| S:29227 E:29233 ||| NN
kit  ||| S:29233 E:29237 ||| NN
from  ||| S:29237 E:29252 ||| IN
Bio-Rad  ||| S:29252 E:29260 ||| NNP
( ||| S:29260 E:29261 ||| -LRB-
Hercules ||| S:29261 E:29269 ||| NNP
,  ||| S:29269 E:29271 ||| ,
CA ||| S:29271 E:29273 ||| NNP
) ||| S:29273 E:29274 ||| -RRB-
;  ||| S:29274 E:29276 ||| :
Biocoat  ||| S:29276 E:29284 ||| NNP
and  ||| S:29284 E:29288 ||| CC
Transwells  ||| S:29288 E:29299 ||| NNP
from  ||| S:29299 E:29314 ||| IN
Fisher  ||| S:29314 E:29321 ||| NNP
and  ||| S:29321 E:29325 ||| CC
Biocclusive  ||| S:29325 E:29337 ||| NNP
bandage  ||| S:29337 E:29345 ||| NN
from  ||| S:29345 E:29350 ||| IN
Johnson ||| S:29350 E:29357 ||| NNP
& ||| S:29357 E:29358 ||| CC
Johnson  ||| S:29358 E:29376 ||| NNP
Medical  ||| S:29376 E:29384 ||| NNP
( ||| S:29384 E:29385 ||| -LRB-
Arlington ||| S:29385 E:29394 ||| NNP
,  ||| S:29394 E:29396 ||| ,
TX ||| S:29396 E:29398 ||| NNP
) ||| S:29398 E:29399 ||| -RRB-
.  ||| S:29399 E:29429 ||| .
Cell  ||| S:29429 E:29434 ||| NN
culture  ||| S:29434 E:29452 ||| NN
Primary  ||| S:29452 E:29460 ||| JJ
chicken  ||| S:29460 E:29468 ||| NN
embryonic  ||| S:29468 E:29478 ||| NN
fibroblasts  ||| S:29478 E:29490 ||| NNS
were  ||| S:29490 E:29495 ||| VBD
cultured  ||| S:29495 E:29504 ||| VBN
as  ||| S:29504 E:29517 ||| IN
previously  ||| S:29517 E:29528 ||| RB
described  ||| S:29528 E:29538 ||| VBN
[  ||| S:29538 E:29540 ||| -LRB-
3  ||| S:29540 E:29542 ||| CD
4  ||| S:29542 E:29544 ||| CD
]  ||| S:29544 E:29546 ||| -RRB-
.  ||| S:29546 E:29548 ||| .
Briefly ||| S:29548 E:29555 ||| RB
,  ||| S:29555 E:29557 ||| ,
primary  ||| S:29557 E:29575 ||| JJ
fibroblasts  ||| S:29575 E:29587 ||| NN
were  ||| S:29587 E:29592 ||| VBD
isolated  ||| S:29592 E:29601 ||| VBN
from  ||| S:29601 E:29606 ||| IN
10-day-old  ||| S:29606 E:29617 ||| CD
chicken  ||| S:29617 E:29625 ||| NN
embryos  ||| S:29625 E:29643 ||| NNS
and  ||| S:29643 E:29647 ||| CC
cultured  ||| S:29647 E:29656 ||| NN
for  ||| S:29656 E:29660 ||| IN
4  ||| S:29660 E:29662 ||| CD
days ||| S:29662 E:29666 ||| NNS
.  ||| S:29666 E:29668 ||| .
These  ||| S:29668 E:29674 ||| DT
cultures  ||| S:29674 E:29683 ||| NNS
were  ||| S:29683 E:29688 ||| VBD
passaged  ||| S:29688 E:29707 ||| VBN
once  ||| S:29707 E:29712 ||| RB
and  ||| S:29712 E:29716 ||| CC
used  ||| S:29716 E:29721 ||| VBN
as  ||| S:29721 E:29724 ||| IN
secondary  ||| S:29724 E:29734 ||| JJ
cultures  ||| S:29734 E:29743 ||| NNS
at  ||| S:29743 E:29746 ||| IN
a  ||| S:29746 E:29748 ||| DT
density  ||| S:29748 E:29756 ||| NN
of  ||| S:29756 E:29759 ||| IN
0.3  ||| S:29759 E:29763 ||| CD
×  ||| S:29763 E:29775 ||| CD
106  ||| S:29775 E:29779 ||| CD
cells ||| S:29779 E:29784 ||| CD
/ ||| S:29784 E:29785 ||| CD
35  ||| S:29785 E:29788 ||| CD
mm  ||| S:29788 E:29791 ||| JJ
plate ||| S:29791 E:29796 ||| NN
.  ||| S:29796 E:29798 ||| .
Due  ||| S:29798 E:29802 ||| JJ
to  ||| S:29802 E:29805 ||| TO
the  ||| S:29805 E:29809 ||| DT
use  ||| S:29809 E:29813 ||| NN
of  ||| S:29813 E:29816 ||| IN
primary  ||| S:29816 E:29824 ||| JJ
cells  ||| S:29824 E:29840 ||| NNS
rather  ||| S:29840 E:29847 ||| RB
than  ||| S:29847 E:29852 ||| IN
cell  ||| S:29852 E:29857 ||| NN
lines ||| S:29857 E:29862 ||| NNS
,  ||| S:29862 E:29864 ||| ,
there  ||| S:29864 E:29870 ||| EX
are  ||| S:29870 E:29874 ||| VBP
variations  ||| S:29874 E:29885 ||| NNS
in  ||| S:29885 E:29888 ||| IN
cellular  ||| S:29888 E:29907 ||| JJ
responses  ||| S:29907 E:29917 ||| NNS
between  ||| S:29917 E:29925 ||| IN
sets  ||| S:29925 E:29930 ||| NNS
of  ||| S:29930 E:29933 ||| IN
cells ||| S:29933 E:29938 ||| NNS
.  ||| S:29938 E:29940 ||| .
Therefore ||| S:29940 E:29949 ||| RB
,  ||| S:29949 E:29951 ||| ,
internal  ||| S:29951 E:29970 ||| JJ
controls  ||| S:29970 E:29979 ||| NNS
were  ||| S:29979 E:29984 ||| VBD
always  ||| S:29984 E:29991 ||| RB
included  ||| S:29991 E:30000 ||| VBN
and  ||| S:30000 E:30004 ||| CC
results  ||| S:30004 E:30012 ||| NNS
from  ||| S:30012 E:30017 ||| IN
different  ||| S:30017 E:30037 ||| JJ
batches  ||| S:30037 E:30045 ||| NNS
of  ||| S:30045 E:30048 ||| IN
cells  ||| S:30048 E:30054 ||| NNS
were  ||| S:30054 E:30059 ||| VBD
not  ||| S:30059 E:30063 ||| RB
averaged ||| S:30063 E:30071 ||| VBD
.  ||| S:30071 E:30073 ||| .
Secondary  ||| S:30073 E:30083 ||| JJ
cultures  ||| S:30083 E:30102 ||| NNS
were  ||| S:30102 E:30107 ||| VBD
treated  ||| S:30107 E:30115 ||| VBN
with  ||| S:30115 E:30120 ||| IN
750  ||| S:30120 E:30124 ||| CD
ng ||| S:30124 E:30126 ||| FW
/ ||| S:30126 E:30127 ||| FW
ml  ||| S:30127 E:30130 ||| FW
cCAF  ||| S:30130 E:30135 ||| FW
[ ||| S:30135 E:30136 ||| -LRB-
68  ||| S:30136 E:30139 ||| CD
nM ||| S:30139 E:30141 ||| NN
]  ||| S:30141 E:30143 ||| -RRB-
or  ||| S:30143 E:30146 ||| CC
its  ||| S:30146 E:30150 ||| PRP$
terminal  ||| S:30150 E:30169 ||| NN
peptides  ||| S:30169 E:30178 ||| NN
in  ||| S:30178 E:30181 ||| IN
199 ||| S:30181 E:30184 ||| CD
/ ||| S:30184 E:30185 ||| CD
tryptose  ||| S:30185 E:30194 ||| CD
phosphate  ||| S:30194 E:30204 ||| CD
broth  ||| S:30204 E:30210 ||| NNS
and  ||| S:30210 E:30214 ||| CC
2 ||| S:30214 E:30215 ||| CD
%  ||| S:30215 E:30217 ||| NN
donor  ||| S:30217 E:30233 ||| NN
calf  ||| S:30233 E:30238 ||| NN
serum ||| S:30238 E:30243 ||| NN
.  ||| S:30243 E:30245 ||| .
This  ||| S:30245 E:30250 ||| DT
dose  ||| S:30250 E:30255 ||| NN
of  ||| S:30255 E:30258 ||| IN
cCAF  ||| S:30258 E:30263 ||| NNP
was  ||| S:30263 E:30267 ||| VBD
chosen  ||| S:30267 E:30274 ||| VBN
because  ||| S:30274 E:30282 ||| IN
it  ||| S:30282 E:30285 ||| PRP
was  ||| S:30285 E:30299 ||| VBD
the  ||| S:30299 E:30303 ||| DT
optimal  ||| S:30303 E:30311 ||| JJ
dose  ||| S:30311 E:30316 ||| NN
for  ||| S:30316 E:30320 ||| IN
inducing  ||| S:30320 E:30329 ||| JJ
differentiation  ||| S:30329 E:30345 ||| NN
of  ||| S:30345 E:30358 ||| IN
myofibroblasts ||| S:30358 E:30372 ||| NN
,  ||| S:30372 E:30374 ||| ,
cells  ||| S:30374 E:30380 ||| NNS
known  ||| S:30380 E:30386 ||| VBN
to  ||| S:30386 E:30389 ||| TO
produce  ||| S:30389 E:30397 ||| VB
large  ||| S:30397 E:30403 ||| JJ
amounts  ||| S:30403 E:30411 ||| NNS
of  ||| S:30411 E:30424 ||| IN
ECM  ||| S:30424 E:30428 ||| NNP
[  ||| S:30428 E:30430 ||| -LRB-
4  ||| S:30430 E:30432 ||| LS
]  ||| S:30432 E:30434 ||| -RRB-
.  ||| S:30434 E:30436 ||| .
Media  ||| S:30436 E:30442 ||| NNS
was  ||| S:30442 E:30446 ||| VBD
changed  ||| S:30446 E:30454 ||| VBN
and  ||| S:30454 E:30458 ||| CC
new  ||| S:30458 E:30462 ||| JJ
cCAF  ||| S:30462 E:30467 ||| JJ
or  ||| S:30467 E:30470 ||| CC
peptides  ||| S:30470 E:30489 ||| NNS
added  ||| S:30489 E:30495 ||| VBD
every  ||| S:30495 E:30501 ||| DT
day  ||| S:30501 E:30505 ||| NN
for  ||| S:30505 E:30509 ||| IN
4  ||| S:30509 E:30511 ||| CD
days ||| S:30511 E:30515 ||| NNS
.  ||| S:30515 E:30545 ||| .
Immunoblotting  ||| S:30545 E:30570 ||| NNP
Proteins  ||| S:30570 E:30579 ||| NNPS
were  ||| S:30579 E:30584 ||| VBD
extracted  ||| S:30584 E:30594 ||| VBN
from  ||| S:30594 E:30599 ||| IN
the  ||| S:30599 E:30603 ||| DT
cells  ||| S:30603 E:30609 ||| NNS
after  ||| S:30609 E:30615 ||| IN
4  ||| S:30615 E:30617 ||| CD
days  ||| S:30617 E:30622 ||| NNS
of  ||| S:30622 E:30635 ||| IN
treatment ||| S:30635 E:30644 ||| NN
,  ||| S:30644 E:30646 ||| ,
using  ||| S:30646 E:30652 ||| VBG
150  ||| S:30652 E:30656 ||| CD
mM  ||| S:30656 E:30659 ||| JJ
RIPA  ||| S:30659 E:30664 ||| FW
buffer  ||| S:30664 E:30671 ||| FW
containing  ||| S:30671 E:30682 ||| FW
protease  ||| S:30682 E:30701 ||| FW
inhibitors ||| S:30701 E:30711 ||| FW
.  ||| S:30711 E:30713 ||| .
Protein  ||| S:30713 E:30721 ||| NN
concentrations  ||| S:30721 E:30736 ||| NNS
were  ||| S:30736 E:30741 ||| VBD
determined  ||| S:30741 E:30752 ||| VBN
using  ||| S:30752 E:30768 ||| VBG
the  ||| S:30768 E:30772 ||| DT
DC  ||| S:30772 E:30775 ||| FW
protein  ||| S:30775 E:30783 ||| FW
assay  ||| S:30783 E:30789 ||| FW
kit  ||| S:30789 E:30793 ||| FW
( ||| S:30793 E:30794 ||| -LRB-
Bio-Rad ||| S:30794 E:30801 ||| NNP
)  ||| S:30801 E:30803 ||| -RRB-
and  ||| S:30803 E:30807 ||| CC
samples  ||| S:30807 E:30815 ||| NNS
were  ||| S:30815 E:30830 ||| VBD
adjusted  ||| S:30830 E:30839 ||| VBN
to  ||| S:30839 E:30842 ||| TO
contain  ||| S:30842 E:30850 ||| VB
equal  ||| S:30850 E:30856 ||| JJ
amounts  ||| S:30856 E:30864 ||| NNS
of  ||| S:30864 E:30867 ||| IN
protein ||| S:30867 E:30874 ||| NN
.  ||| S:30874 E:30876 ||| .
Proteins  ||| S:30876 E:30895 ||| NNS
were  ||| S:30895 E:30900 ||| VBD
separated  ||| S:30900 E:30910 ||| VBN
on  ||| S:30910 E:30913 ||| IN
7.5 ||| S:30913 E:30916 ||| CD
%  ||| S:30916 E:30918 ||| NN
Doucet  ||| S:30918 E:30925 ||| FW
gels  ||| S:30925 E:30930 ||| FW
[  ||| S:30930 E:30932 ||| -LRB-
48  ||| S:30932 E:30935 ||| CD
]  ||| S:30935 E:30937 ||| -RRB-
and  ||| S:30937 E:30941 ||| CC
transferred  ||| S:30941 E:30963 ||| VBN
to  ||| S:30963 E:30966 ||| TO
nitrocellulose  ||| S:30966 E:30981 ||| NNS
was  ||| S:30981 E:30985 ||| VBD
performed  ||| S:30985 E:30995 ||| VBN
using  ||| S:30995 E:31001 ||| VBG
a  ||| S:31001 E:31003 ||| DT
wet-transfer  ||| S:31003 E:31026 ||| JJ
apparatus  ||| S:31026 E:31036 ||| NN
( ||| S:31036 E:31037 ||| -LRB-
Bio-Rad ||| S:31037 E:31044 ||| NNP
)  ||| S:31044 E:31046 ||| -RRB-
at  ||| S:31046 E:31049 ||| IN
100  ||| S:31049 E:31053 ||| CD
V  ||| S:31053 E:31055 ||| NNP
for  ||| S:31055 E:31059 ||| IN
45  ||| S:31059 E:31062 ||| CD
min ||| S:31062 E:31065 ||| NNS
.  ||| S:31065 E:31067 ||| .
The  ||| S:31067 E:31071 ||| DT
membranes  ||| S:31071 E:31091 ||| NN
were  ||| S:31091 E:31096 ||| VBD
blocked  ||| S:31096 E:31104 ||| VBN
for  ||| S:31104 E:31108 ||| IN
1  ||| S:31108 E:31110 ||| CD
h  ||| S:31110 E:31112 ||| NN
in  ||| S:31112 E:31115 ||| IN
5 ||| S:31115 E:31116 ||| CD
%  ||| S:31116 E:31118 ||| NN
milk  ||| S:31118 E:31123 ||| NN
in  ||| S:31123 E:31126 ||| IN
TTBS  ||| S:31126 E:31131 ||| NNP
and  ||| S:31131 E:31135 ||| CC
then  ||| S:31135 E:31150 ||| RB
incubated  ||| S:31150 E:31160 ||| JJ
overnight  ||| S:31160 E:31170 ||| JJ
at  ||| S:31170 E:31173 ||| IN
4°C  ||| S:31173 E:31177 ||| CD
in  ||| S:31177 E:31180 ||| IN
primary  ||| S:31180 E:31188 ||| JJ
antibody  ||| S:31188 E:31197 ||| NN
( ||| S:31197 E:31198 ||| -LRB-
1 ||| S:31198 E:31199 ||| LS
: ||| S:31199 E:31200 ||| :
50  ||| S:31200 E:31213 ||| CD
anti-Coll  ||| S:31213 E:31223 ||| JJ
I ||| S:31223 E:31224 ||| NN
,  ||| S:31224 E:31226 ||| ,
anti-Coll  ||| S:31226 E:31236 ||| NNP
III  ||| S:31236 E:31240 ||| NNP
and  ||| S:31240 E:31244 ||| CC
anti-FN ||| S:31244 E:31251 ||| JJ
,  ||| S:31251 E:31253 ||| ,
1 ||| S:31253 E:31254 ||| CD
: ||| S:31254 E:31255 ||| :
100  ||| S:31255 E:31259 ||| CD
TIMP-1 ||| S:31259 E:31265 ||| CD
,  ||| S:31265 E:31277 ||| ,
1 ||| S:31277 E:31278 ||| CD
: ||| S:31278 E:31279 ||| :
500  ||| S:31279 E:31283 ||| CD
anti-MMP-1  ||| S:31283 E:31294 ||| CD
and  ||| S:31294 E:31298 ||| CC
anti-TIMP-2 ||| S:31298 E:31309 ||| NNP
,  ||| S:31309 E:31311 ||| ,
1 ||| S:31311 E:31312 ||| CD
: ||| S:31312 E:31313 ||| :
1000  ||| S:31313 E:31318 ||| CD
anti-TN ||| S:31318 E:31325 ||| NN
) ||| S:31325 E:31326 ||| -RRB-
,  ||| S:31326 E:31328 ||| ,
in  ||| S:31328 E:31331 ||| IN
1 ||| S:31331 E:31332 ||| CD
%  ||| S:31332 E:31344 ||| NN
milk  ||| S:31344 E:31349 ||| NN
in  ||| S:31349 E:31352 ||| IN
TTBS ||| S:31352 E:31356 ||| NNP
.  ||| S:31356 E:31358 ||| .
The  ||| S:31358 E:31362 ||| DT
membranes  ||| S:31362 E:31372 ||| NN
were  ||| S:31372 E:31377 ||| VBD
washed  ||| S:31377 E:31384 ||| VBN
3  ||| S:31384 E:31386 ||| CD
times  ||| S:31386 E:31392 ||| NNS
for  ||| S:31392 E:31396 ||| IN
10  ||| S:31396 E:31409 ||| CD
min  ||| S:31409 E:31413 ||| CD
each  ||| S:31413 E:31418 ||| DT
with  ||| S:31418 E:31423 ||| IN
TTBS ||| S:31423 E:31427 ||| NNP
,  ||| S:31427 E:31429 ||| ,
incubated  ||| S:31429 E:31439 ||| VBG
in  ||| S:31439 E:31442 ||| IN
anti-mouse  ||| S:31442 E:31453 ||| JJ
or  ||| S:31453 E:31466 ||| CC
anti-rabbit  ||| S:31466 E:31478 ||| NNP
HRP  ||| S:31478 E:31482 ||| NNP
( ||| S:31482 E:31483 ||| -LRB-
1 ||| S:31483 E:31484 ||| LS
: ||| S:31484 E:31485 ||| :
10,000 ||| S:31485 E:31491 ||| CD
)  ||| S:31491 E:31493 ||| -RRB-
in  ||| S:31493 E:31496 ||| IN
1 ||| S:31496 E:31497 ||| CD
%  ||| S:31497 E:31499 ||| NN
milk  ||| S:31499 E:31504 ||| NN
for  ||| S:31504 E:31508 ||| IN
1  ||| S:31508 E:31510 ||| CD
hr  ||| S:31510 E:31513 ||| NNS
and  ||| S:31513 E:31517 ||| CC
washed  ||| S:31517 E:31534 ||| VBN
as  ||| S:31534 E:31537 ||| IN
above ||| S:31537 E:31542 ||| JJ
,  ||| S:31542 E:31544 ||| ,
the  ||| S:31544 E:31548 ||| DT
bands  ||| S:31548 E:31554 ||| NNS
visualized  ||| S:31554 E:31565 ||| VBP
using  ||| S:31565 E:31571 ||| VBG
the  ||| S:31571 E:31575 ||| DT
ECL  ||| S:31575 E:31579 ||| NNP
( ||| S:31579 E:31580 ||| -LRB-
Amersham ||| S:31580 E:31588 ||| NNP
) ||| S:31588 E:31589 ||| -RRB-
.  ||| S:31589 E:31601 ||| .
Densitometry  ||| S:31601 E:31614 ||| NNP
was  ||| S:31614 E:31618 ||| VBD
performed  ||| S:31618 E:31628 ||| VBN
using  ||| S:31628 E:31634 ||| VBG
BandScan  ||| S:31634 E:31643 ||| JJ
software  ||| S:31643 E:31662 ||| NN
( ||| S:31662 E:31663 ||| -LRB-
Glyko ||| S:31663 E:31668 ||| NNP
) ||| S:31668 E:31669 ||| -RRB-
.  ||| S:31669 E:31699 ||| .
Immunostaining  ||| S:31699 E:31724 ||| NNP
At  ||| S:31724 E:31727 ||| IN
the  ||| S:31727 E:31731 ||| DT
end  ||| S:31731 E:31735 ||| NN
of  ||| S:31735 E:31738 ||| IN
treatment ||| S:31738 E:31747 ||| NN
,  ||| S:31747 E:31749 ||| ,
the  ||| S:31749 E:31753 ||| DT
cells  ||| S:31753 E:31759 ||| NNS
were  ||| S:31759 E:31764 ||| VBD
rinsed  ||| S:31764 E:31771 ||| VBN
with  ||| S:31771 E:31786 ||| IN
PBS ||| S:31786 E:31789 ||| NNP
,  ||| S:31789 E:31791 ||| ,
fixed  ||| S:31791 E:31797 ||| VBN
and  ||| S:31797 E:31801 ||| CC
permeabilized  ||| S:31801 E:31815 ||| NN
in  ||| S:31815 E:31818 ||| IN
4 ||| S:31818 E:31819 ||| CD
%  ||| S:31819 E:31821 ||| NN
paraformaldehyde  ||| S:31821 E:31838 ||| NN
with  ||| S:31838 E:31853 ||| IN
0.15 ||| S:31853 E:31857 ||| CD
%  ||| S:31857 E:31859 ||| NN
Triton  ||| S:31859 E:31866 ||| NNP
X-100 ||| S:31866 E:31871 ||| NNP
.  ||| S:31871 E:31873 ||| .
After  ||| S:31873 E:31879 ||| IN
fixation ||| S:31879 E:31887 ||| NN
,  ||| S:31887 E:31889 ||| ,
the  ||| S:31889 E:31893 ||| DT
cells  ||| S:31893 E:31899 ||| NNS
were  ||| S:31899 E:31904 ||| VBD
washed  ||| S:31904 E:31921 ||| VBN
and  ||| S:31921 E:31925 ||| CC
then  ||| S:31925 E:31930 ||| RB
incubated  ||| S:31930 E:31940 ||| VBN
with  ||| S:31940 E:31945 ||| IN
PBS  ||| S:31945 E:31949 ||| NNP
containing  ||| S:31949 E:31960 ||| VBG
0.1  ||| S:31960 E:31964 ||| CD
M  ||| S:31964 E:31966 ||| NNP
glycine  ||| S:31966 E:31974 ||| NN
for  ||| S:31974 E:31988 ||| IN
10  ||| S:31988 E:31991 ||| CD
min ||| S:31991 E:31994 ||| NNS
.  ||| S:31994 E:31996 ||| .
Cells  ||| S:31996 E:32002 ||| NNS
were  ||| S:32002 E:32007 ||| VBD
blocked  ||| S:32007 E:32015 ||| VBN
for  ||| S:32015 E:32019 ||| IN
30  ||| S:32019 E:32022 ||| CD
min  ||| S:32022 E:32026 ||| NN
with  ||| S:32026 E:32031 ||| IN
10 ||| S:32031 E:32033 ||| CD
%  ||| S:32033 E:32035 ||| NN
goat  ||| S:32035 E:32040 ||| NN
serum  ||| S:32040 E:32056 ||| NN
in  ||| S:32056 E:32059 ||| IN
PBS ||| S:32059 E:32062 ||| NNP
,  ||| S:32062 E:32064 ||| ,
incubated  ||| S:32064 E:32074 ||| VBG
with  ||| S:32074 E:32079 ||| IN
primary  ||| S:32079 E:32087 ||| JJ
antibody  ||| S:32087 E:32096 ||| NN
( ||| S:32096 E:32097 ||| -LRB-
1 ||| S:32097 E:32098 ||| LS
: ||| S:32098 E:32099 ||| :
100 ||| S:32099 E:32102 ||| CD
)  ||| S:32102 E:32104 ||| -RRB-
in  ||| S:32104 E:32117 ||| IN
1 ||| S:32117 E:32118 ||| CD
% ||| S:32118 E:32119 ||| NN
BSA ||| S:32119 E:32122 ||| NNP
/ ||| S:32122 E:32123 ||| NNP
PBS  ||| S:32123 E:32127 ||| NNP
for  ||| S:32127 E:32131 ||| IN
1  ||| S:32131 E:32133 ||| CD
hr  ||| S:32133 E:32136 ||| NN
at  ||| S:32136 E:32139 ||| IN
room  ||| S:32139 E:32144 ||| NN
temperature  ||| S:32144 E:32156 ||| NN
( ||| S:32156 E:32157 ||| -LRB-
RT ||| S:32157 E:32159 ||| NNP
) ||| S:32159 E:32160 ||| -RRB-
,  ||| S:32160 E:32162 ||| ,
and  ||| S:32162 E:32166 ||| CC
washed  ||| S:32166 E:32183 ||| VBD
three  ||| S:32183 E:32189 ||| CD
times  ||| S:32189 E:32195 ||| NNS
with  ||| S:32195 E:32200 ||| IN
0.1 ||| S:32200 E:32203 ||| CD
%  ||| S:32203 E:32205 ||| NN
BSA ||| S:32205 E:32208 ||| NNP
/ ||| S:32208 E:32209 ||| NNP
PBS  ||| S:32209 E:32213 ||| NNP
for  ||| S:32213 E:32217 ||| IN
10  ||| S:32217 E:32220 ||| CD
min  ||| S:32220 E:32224 ||| CD
each ||| S:32224 E:32228 ||| DT
.  ||| S:32228 E:32230 ||| .
The  ||| S:32230 E:32234 ||| DT
cells  ||| S:32234 E:32250 ||| NNS
were  ||| S:32250 E:32255 ||| VBD
then  ||| S:32255 E:32260 ||| RB
incubated  ||| S:32260 E:32270 ||| VBN
in  ||| S:32270 E:32273 ||| IN
secondary  ||| S:32273 E:32283 ||| JJ
antibody  ||| S:32283 E:32292 ||| NN
in  ||| S:32292 E:32295 ||| IN
1 ||| S:32295 E:32296 ||| CD
%  ||| S:32296 E:32298 ||| NN
BSA ||| S:32298 E:32301 ||| NNP
/ ||| S:32301 E:32302 ||| NNP
PBS  ||| S:32302 E:32316 ||| NNP
for  ||| S:32316 E:32320 ||| IN
1  ||| S:32320 E:32322 ||| CD
hr  ||| S:32322 E:32325 ||| NN
at  ||| S:32325 E:32328 ||| IN
RT ||| S:32328 E:32330 ||| NNP
,  ||| S:32330 E:32332 ||| ,
washed  ||| S:32332 E:32339 ||| VBD
three  ||| S:32339 E:32345 ||| CD
times  ||| S:32345 E:32351 ||| NNS
for  ||| S:32351 E:32355 ||| IN
10  ||| S:32355 E:32358 ||| CD
min  ||| S:32358 E:32362 ||| NN
with  ||| S:32362 E:32367 ||| IN
0.1 ||| S:32367 E:32370 ||| CD
%  ||| S:32370 E:32382 ||| NN
BSA  ||| S:32382 E:32386 ||| NN
in  ||| S:32386 E:32389 ||| IN
PBS  ||| S:32389 E:32393 ||| NNP
and  ||| S:32393 E:32397 ||| CC
mounted  ||| S:32397 E:32405 ||| VBN
with  ||| S:32405 E:32410 ||| IN
Vectashield ||| S:32410 E:32421 ||| NNP
.  ||| S:32421 E:32451 ||| .
Zymography  ||| S:32451 E:32472 ||| NNP
Zymography  ||| S:32472 E:32483 ||| NNP
was  ||| S:32483 E:32487 ||| VBD
performed  ||| S:32487 E:32497 ||| VBN
using  ||| S:32497 E:32503 ||| VBG
denaturing  ||| S:32503 E:32524 ||| JJ
polyacrylamide  ||| S:32524 E:32539 ||| NNS
gels  ||| S:32539 E:32544 ||| VBP
according  ||| S:32544 E:32554 ||| VBG
to  ||| S:32554 E:32557 ||| TO
the  ||| S:32557 E:32561 ||| DT
protocol  ||| S:32561 E:32570 ||| NN
of  ||| S:32570 E:32573 ||| IN
ref.  ||| S:32573 E:32578 ||| NNP
[  ||| S:32578 E:32590 ||| -LRB-
49  ||| S:32590 E:32593 ||| CD
]  ||| S:32593 E:32595 ||| -RRB-
.  ||| S:32595 E:32597 ||| .
Gels  ||| S:32597 E:32602 ||| JJ
to  ||| S:32602 E:32605 ||| TO
test  ||| S:32605 E:32610 ||| VB
for  ||| S:32610 E:32614 ||| IN
gelatinolytic  ||| S:32614 E:32628 ||| JJ
activity  ||| S:32628 E:32637 ||| NN
contained  ||| S:32637 E:32657 ||| VBD
1 ||| S:32657 E:32658 ||| CD
%  ||| S:32658 E:32660 ||| NN
gelatin  ||| S:32660 E:32668 ||| NNS
( ||| S:32668 E:32669 ||| -LRB-
Sigma ||| S:32669 E:32674 ||| NNP
)  ||| S:32674 E:32676 ||| -RRB-
and  ||| S:32676 E:32680 ||| CC
those  ||| S:32680 E:32686 ||| DT
that  ||| S:32686 E:32691 ||| WDT
tested  ||| S:32691 E:32698 ||| VBD
for  ||| S:32698 E:32702 ||| IN
caseinolytic  ||| S:32702 E:32725 ||| JJ
activity  ||| S:32725 E:32734 ||| NN
had  ||| S:32734 E:32738 ||| VBD
1 ||| S:32738 E:32739 ||| CD
%  ||| S:32739 E:32741 ||| NN
casein  ||| S:32741 E:32748 ||| NNS
( ||| S:32748 E:32749 ||| -LRB-
Sigma ||| S:32749 E:32754 ||| NNP
) ||| S:32754 E:32755 ||| -RRB-
.  ||| S:32755 E:32757 ||| .
5  ||| S:32757 E:32759 ||| CD
μl  ||| S:32759 E:32762 ||| NN
of  ||| S:32762 E:32765 ||| IN
0.25 ||| S:32765 E:32769 ||| CD
%  ||| S:32769 E:32781 ||| NN
trypsin-EDTA  ||| S:32781 E:32794 ||| NNS
( ||| S:32794 E:32795 ||| -LRB-
Gibco-BRL ||| S:32795 E:32804 ||| NNP
)  ||| S:32804 E:32806 ||| -RRB-
was  ||| S:32806 E:32810 ||| VBD
used  ||| S:32810 E:32815 ||| VBN
as  ||| S:32815 E:32818 ||| IN
a  ||| S:32818 E:32820 ||| DT
positive  ||| S:32820 E:32829 ||| JJ
control  ||| S:32829 E:32847 ||| NN
for  ||| S:32847 E:32851 ||| IN
the  ||| S:32851 E:32855 ||| DT
casein  ||| S:32855 E:32862 ||| JJ
zymogram ||| S:32862 E:32870 ||| NN
.  ||| S:32870 E:32900 ||| .
Plasminogen  ||| S:32900 E:32912 ||| JJ
activity  ||| S:32912 E:32921 ||| NN
assay  ||| S:32921 E:32937 ||| VBD
A  ||| S:32937 E:32939 ||| DT
chromogenic  ||| S:32939 E:32951 ||| FW
plasminogen  ||| S:32951 E:32963 ||| FW
activator  ||| S:32963 E:32973 ||| FW
substrate  ||| S:32973 E:32993 ||| FW
( ||| S:32993 E:32994 ||| -LRB-
Boc-Val-Gly-Arg-βNA.AcOH ||| S:32994 E:33018 ||| NNP
)  ||| S:33018 E:33020 ||| -RRB-
was  ||| S:33020 E:33024 ||| VBD
purchased  ||| S:33024 E:33034 ||| VBN
from  ||| S:33034 E:33039 ||| IN
Calbiochem.  ||| S:33039 E:33061 ||| CD
50  ||| S:33061 E:33064 ||| CD
μl  ||| S:33064 E:33067 ||| NN
of  ||| S:33067 E:33070 ||| IN
a  ||| S:33070 E:33072 ||| DT
10  ||| S:33072 E:33075 ||| CD
mM  ||| S:33075 E:33078 ||| JJ
stock  ||| S:33078 E:33084 ||| NN
solution  ||| S:33084 E:33093 ||| NN
of  ||| S:33093 E:33096 ||| IN
substrate  ||| S:33096 E:33106 ||| NN
in  ||| S:33106 E:33109 ||| IN
water  ||| S:33109 E:33115 ||| NN
was  ||| S:33115 E:33129 ||| VBD
added  ||| S:33129 E:33135 ||| VBN
to  ||| S:33135 E:33138 ||| TO
200  ||| S:33138 E:33142 ||| CD
μl  ||| S:33142 E:33145 ||| CD
0.1  ||| S:33145 E:33149 ||| CD
mM  ||| S:33149 E:33152 ||| JJ
HEPES  ||| S:33152 E:33158 ||| FW
buffer  ||| S:33158 E:33165 ||| FW
pH  ||| S:33165 E:33168 ||| FW
8.0  ||| S:33168 E:33172 ||| FW
and  ||| S:33172 E:33176 ||| CC
heated  ||| S:33176 E:33183 ||| VBN
to  ||| S:33183 E:33196 ||| TO
25°C.  ||| S:33196 E:33202 ||| CD
25  ||| S:33202 E:33205 ||| CD
μl  ||| S:33205 E:33208 ||| CD
fibroblast  ||| S:33208 E:33219 ||| CD
substrate  ||| S:33219 E:33229 ||| NNS
was  ||| S:33229 E:33233 ||| VBD
added  ||| S:33233 E:33239 ||| VBN
to  ||| S:33239 E:33242 ||| TO
the  ||| S:33242 E:33256 ||| DT
substrate  ||| S:33256 E:33266 ||| NN
and  ||| S:33266 E:33270 ||| CC
incubated  ||| S:33270 E:33280 ||| NN
for  ||| S:33280 E:33284 ||| IN
30  ||| S:33284 E:33287 ||| CD
min ||| S:33287 E:33290 ||| NNS
.  ||| S:33290 E:33292 ||| .
Absorbance  ||| S:33292 E:33303 ||| NNP
was  ||| S:33303 E:33307 ||| VBD
then  ||| S:33307 E:33322 ||| RB
read  ||| S:33322 E:33327 ||| VBN
at  ||| S:33327 E:33330 ||| IN
405  ||| S:33330 E:33334 ||| CD
nm ||| S:33334 E:33336 ||| NNS
.  ||| S:33336 E:33338 ||| .
Positive  ||| S:33338 E:33347 ||| JJ
control ||| S:33347 E:33354 ||| NN
:  ||| S:33354 E:33356 ||| :
Supernatant  ||| S:33356 E:33368 ||| NNP
from  ||| S:33368 E:33373 ||| IN
Rous  ||| S:33373 E:33388 ||| NNP
sarcoma  ||| S:33388 E:33396 ||| FW
virus-transformed  ||| S:33396 E:33414 ||| FW
CEFs  ||| S:33414 E:33419 ||| FW
( ||| S:33419 E:33420 ||| -LRB-
tCEFs ||| S:33420 E:33425 ||| NNP
) ||| S:33425 E:33426 ||| -RRB-
,  ||| S:33426 E:33428 ||| ,
which  ||| S:33428 E:33434 ||| WDT
are  ||| S:33434 E:33438 ||| VBP
known  ||| S:33438 E:33454 ||| VBN
to  ||| S:33454 E:33457 ||| TO
produce  ||| S:33457 E:33465 ||| VB
high  ||| S:33465 E:33470 ||| JJ
levels  ||| S:33470 E:33477 ||| NNS
of  ||| S:33477 E:33480 ||| IN
PA ||| S:33480 E:33482 ||| NNP
.  ||| S:33482 E:33512 ||| .
Inhibition  ||| S:33512 E:33523 ||| NNP
of  ||| S:33523 E:33526 ||| IN
TN  ||| S:33526 E:33529 ||| NNP
expression  ||| S:33529 E:33550 ||| NN
For  ||| S:33550 E:33554 ||| IN
these  ||| S:33554 E:33560 ||| DT
experiments  ||| S:33560 E:33572 ||| NNS
we  ||| S:33572 E:33575 ||| PRP
used  ||| S:33575 E:33580 ||| VBD
phosphothioated  ||| S:33580 E:33606 ||| FW
antisense  ||| S:33606 E:33616 ||| FW
oligodeoxynucleotide  ||| S:33616 E:33637 ||| FW
( ||| S:33637 E:33638 ||| -LRB-
ODN ||| S:33638 E:33641 ||| NNP
) ||| S:33641 E:33642 ||| -RRB-
,  ||| S:33642 E:33644 ||| ,
synthesized  ||| S:33644 E:33656 ||| NN
and  ||| S:33656 E:33670 ||| CC
HPLC  ||| S:33670 E:33675 ||| NNP
purified  ||| S:33675 E:33684 ||| NN
by  ||| S:33684 E:33687 ||| IN
Sigma  ||| S:33687 E:33693 ||| NNP
Genosys ||| S:33693 E:33700 ||| NNP
,  ||| S:33700 E:33702 ||| ,
to  ||| S:33702 E:33705 ||| TO
block  ||| S:33705 E:33711 ||| VB
the  ||| S:33711 E:33715 ||| DT
TN  ||| S:33715 E:33728 ||| NNP
production ||| S:33728 E:33738 ||| NN
.  ||| S:33738 E:33740 ||| .
The  ||| S:33740 E:33744 ||| DT
sequences  ||| S:33744 E:33754 ||| NN
for  ||| S:33754 E:33758 ||| IN
the  ||| S:33758 E:33762 ||| DT
oligonucleotides  ||| S:33762 E:33779 ||| NN
were  ||| S:33779 E:33794 ||| VBD
the  ||| S:33794 E:33798 ||| DT
same  ||| S:33798 E:33803 ||| JJ
as  ||| S:33803 E:33806 ||| IN
previously  ||| S:33806 E:33817 ||| RB
described  ||| S:33817 E:33827 ||| VBN
[  ||| S:33827 E:33829 ||| -LRB-
50  ||| S:33829 E:33832 ||| CD
]  ||| S:33832 E:33834 ||| -RRB-
except  ||| S:33834 E:33841 ||| IN
that  ||| S:33841 E:33846 ||| WDT
we  ||| S:33846 E:33859 ||| PRP
used  ||| S:33859 E:33864 ||| VBD
phosphothioated  ||| S:33864 E:33880 ||| JJ
oligos  ||| S:33880 E:33887 ||| NNS
rather  ||| S:33887 E:33894 ||| RB
than  ||| S:33894 E:33899 ||| IN
morpholino  ||| S:33899 E:33920 ||| JJ
oligos ||| S:33920 E:33926 ||| NN
.  ||| S:33926 E:33928 ||| .
The  ||| S:33928 E:33932 ||| DT
antisense  ||| S:33932 E:33942 ||| JJ
sequence  ||| S:33942 E:33951 ||| NN
of  ||| S:33951 E:33954 ||| IN
the  ||| S:33954 E:33958 ||| DT
ODN  ||| S:33958 E:33962 ||| NNP
was  ||| S:33962 E:33976 ||| VBD
5 ||| S:33976 E:33977 ||| CD
' ||| S:33977 E:33978 ||| POS
-GGAGTCCCATTGTAGTGCTCAGTTC-3 ||| S:33978 E:34006 ||| NNP
' ||| S:34006 E:34007 ||| POS
.  ||| S:34007 E:34009 ||| .
The  ||| S:34009 E:34013 ||| DT
sense  ||| S:34013 E:34019 ||| NN
strand  ||| S:34019 E:34026 ||| NN
of  ||| S:34026 E:34029 ||| IN
this  ||| S:34029 E:34044 ||| DT
ODN  ||| S:34044 E:34048 ||| NNP
was  ||| S:34048 E:34052 ||| VBD
used  ||| S:34052 E:34057 ||| VBN
as  ||| S:34057 E:34060 ||| IN
control  ||| S:34060 E:34078 ||| NN
( ||| S:34078 E:34079 ||| -LRB-
5 ||| S:34079 E:34080 ||| CD
' ||| S:34080 E:34081 ||| POS
-GAACTGAGCACTACAATGGGACTCC-3 ||| S:34081 E:34109 ||| NNP
' ||| S:34109 E:34110 ||| POS
) ||| S:34110 E:34111 ||| -RRB-
.  ||| S:34111 E:34113 ||| .
When  ||| S:34113 E:34118 ||| WRB
preparing  ||| S:34118 E:34128 ||| VBG
the  ||| S:34128 E:34142 ||| DT
cell  ||| S:34142 E:34147 ||| NN
cultures ||| S:34147 E:34155 ||| NNS
,  ||| S:34155 E:34157 ||| ,
1  ||| S:34157 E:34159 ||| CD
μM  ||| S:34159 E:34162 ||| JJ
and  ||| S:34162 E:34166 ||| CC
2  ||| S:34166 E:34168 ||| CD
μM  ||| S:34168 E:34171 ||| NN
of  ||| S:34171 E:34174 ||| IN
antisense  ||| S:34174 E:34184 ||| NN
or  ||| S:34184 E:34187 ||| CC
sense  ||| S:34187 E:34193 ||| NN
ODN  ||| S:34193 E:34207 ||| NNP
were  ||| S:34207 E:34212 ||| VBD
added  ||| S:34212 E:34218 ||| VBN
to  ||| S:34218 E:34221 ||| TO
the  ||| S:34221 E:34225 ||| DT
cells  ||| S:34225 E:34231 ||| NNS
at  ||| S:34231 E:34234 ||| IN
plating ||| S:34234 E:34241 ||| NN
.  ||| S:34241 E:34243 ||| .
The  ||| S:34243 E:34247 ||| DT
cells  ||| S:34247 E:34253 ||| NNS
where  ||| S:34253 E:34269 ||| WRB
treated  ||| S:34269 E:34277 ||| VBN
with  ||| S:34277 E:34282 ||| IN
antisense  ||| S:34282 E:34292 ||| NN
or  ||| S:34292 E:34295 ||| CC
sense  ||| S:34295 E:34301 ||| NN
ODN  ||| S:34301 E:34305 ||| NNP
and  ||| S:34305 E:34309 ||| CC
cCAF  ||| S:34309 E:34314 ||| JJ
every  ||| S:34314 E:34320 ||| DT
24  ||| S:34320 E:34323 ||| CD
hrs  ||| S:34323 E:34337 ||| NN
for  ||| S:34337 E:34341 ||| IN
3  ||| S:34341 E:34343 ||| CD
days  ||| S:34343 E:34348 ||| NNS
to  ||| S:34348 E:34351 ||| TO
allow  ||| S:34351 E:34357 ||| VB
accumulation  ||| S:34357 E:34370 ||| NN
of  ||| S:34370 E:34373 ||| IN
the  ||| S:34373 E:34377 ||| DT
ECM  ||| S:34377 E:34391 ||| NNP
molecules ||| S:34391 E:34400 ||| NNS
.  ||| S:34400 E:34430 ||| .
Northerns  ||| S:34430 E:34450 ||| NNP
Total  ||| S:34450 E:34456 ||| NNP
RNA  ||| S:34456 E:34460 ||| NNP
was  ||| S:34460 E:34464 ||| VBD
extracted  ||| S:34464 E:34474 ||| VBN
using  ||| S:34474 E:34480 ||| VBG
TRIzol  ||| S:34480 E:34487 ||| JJ
reagent  ||| S:34487 E:34495 ||| NN
from  ||| S:34495 E:34510 ||| IN
untreated  ||| S:34510 E:34520 ||| JJ
fibroblasts  ||| S:34520 E:34532 ||| NN
and  ||| S:34532 E:34536 ||| CC
fibroblasts  ||| S:34536 E:34548 ||| VB
treated  ||| S:34548 E:34556 ||| VBN
with  ||| S:34556 E:34561 ||| IN
750  ||| S:34561 E:34575 ||| CD
ng ||| S:34575 E:34577 ||| CD
/ ||| S:34577 E:34578 ||| CD
ml  ||| S:34578 E:34581 ||| JJ
cCAF  ||| S:34581 E:34586 ||| NN
for  ||| S:34586 E:34590 ||| IN
4-48  ||| S:34590 E:34595 ||| CD
hrs ||| S:34595 E:34598 ||| NNS
.  ||| S:34598 E:34600 ||| .
Transfer  ||| S:34600 E:34609 ||| NN
of  ||| S:34609 E:34612 ||| IN
RNA  ||| S:34612 E:34616 ||| NNP
to  ||| S:34616 E:34619 ||| TO
membrane  ||| S:34619 E:34628 ||| NNS
was  ||| S:34628 E:34642 ||| VBD
performed  ||| S:34642 E:34652 ||| VBN
as  ||| S:34652 E:34655 ||| IN
previously  ||| S:34655 E:34666 ||| RB
described  ||| S:34666 E:34676 ||| VBN
[  ||| S:34676 E:34678 ||| -LRB-
51  ||| S:34678 E:34681 ||| CD
]  ||| S:34681 E:34683 ||| -RRB-
.  ||| S:34683 E:34685 ||| .
RNA  ||| S:34685 E:34689 ||| NNP
probes  ||| S:34689 E:34706 ||| NNS
were  ||| S:34706 E:34711 ||| VBD
made  ||| S:34711 E:34716 ||| VBN
using  ||| S:34716 E:34722 ||| VBG
the  ||| S:34722 E:34726 ||| DT
Strip-EZ  ||| S:34726 E:34735 ||| JJ
kit  ||| S:34735 E:34739 ||| NN
from  ||| S:34739 E:34744 ||| IN
Ambion  ||| S:34744 E:34751 ||| NNP
( ||| S:34751 E:34752 ||| -LRB-
Arlington ||| S:34752 E:34761 ||| NNP
,  ||| S:34761 E:34773 ||| ,
TX ||| S:34773 E:34775 ||| NNP
) ||| S:34775 E:34776 ||| -RRB-
.  ||| S:34776 E:34778 ||| .
Membranes  ||| S:34778 E:34788 ||| NNP
were  ||| S:34788 E:34793 ||| VBD
prehybridized  ||| S:34793 E:34807 ||| VBN
for  ||| S:34807 E:34811 ||| IN
2  ||| S:34811 E:34813 ||| CD
hrs  ||| S:34813 E:34817 ||| NN
in  ||| S:34817 E:34820 ||| IN
Ambion  ||| S:34820 E:34837 ||| NNP
Hybridization  ||| S:34837 E:34851 ||| NNP
buffer  ||| S:34851 E:34858 ||| NN
at  ||| S:34858 E:34861 ||| IN
62°C ||| S:34861 E:34865 ||| NNP
,  ||| S:34865 E:34867 ||| ,
and  ||| S:34867 E:34871 ||| CC
hybridized  ||| S:34871 E:34882 ||| JJ
O ||| S:34882 E:34883 ||| NNP
/ ||| S:34883 E:34884 ||| NNP
N  ||| S:34884 E:34886 ||| NNP
at  ||| S:34886 E:34889 ||| IN
62°C ||| S:34889 E:34893 ||| CD
.  ||| S:34893 E:34905 ||| .
Membranes  ||| S:34905 E:34915 ||| NNP
were  ||| S:34915 E:34920 ||| VBD
washed  ||| S:34920 E:34927 ||| VBN
with  ||| S:34927 E:34932 ||| IN
2  ||| S:34932 E:34934 ||| CD
×  ||| S:34934 E:34936 ||| CD
SSC ||| S:34936 E:34939 ||| CD
/ ||| S:34939 E:34940 ||| CD
0.1 ||| S:34940 E:34943 ||| CD
%  ||| S:34943 E:34945 ||| NN
SDS  ||| S:34945 E:34949 ||| NN
at  ||| S:34949 E:34952 ||| IN
62°C  ||| S:34952 E:34957 ||| NNP
and  ||| S:34957 E:34971 ||| CC
exposed  ||| S:34971 E:34979 ||| VBN
to  ||| S:34979 E:34982 ||| TO
film  ||| S:34982 E:34987 ||| NN
for  ||| S:34987 E:34991 ||| IN
6-48  ||| S:34991 E:34996 ||| CD
hrs ||| S:34996 E:34999 ||| NNS
.  ||| S:34999 E:35029 ||| .
RT-PCR  ||| S:35029 E:35046 ||| NNP
Total  ||| S:35046 E:35052 ||| NNP
RNA  ||| S:35052 E:35056 ||| NNP
was  ||| S:35056 E:35060 ||| VBD
extracted  ||| S:35060 E:35070 ||| VBN
as  ||| S:35070 E:35073 ||| IN
above ||| S:35073 E:35078 ||| JJ
.  ||| S:35078 E:35080 ||| .
RT-PCR  ||| S:35080 E:35087 ||| NNP
was  ||| S:35087 E:35091 ||| VBD
performed  ||| S:35091 E:35111 ||| VBN
using  ||| S:35111 E:35117 ||| VBG
the  ||| S:35117 E:35121 ||| DT
Promega  ||| S:35121 E:35129 ||| NNP
Access  ||| S:35129 E:35136 ||| NNP
RT-PCR  ||| S:35136 E:35143 ||| NNP
System ||| S:35143 E:35149 ||| NNP
,  ||| S:35149 E:35151 ||| ,
following  ||| S:35151 E:35171 ||| VBG
Promega ||| S:35171 E:35178 ||| NNP
's  ||| S:35178 E:35181 ||| POS
instructions ||| S:35181 E:35193 ||| NNS
.  ||| S:35193 E:35195 ||| .
The  ||| S:35195 E:35199 ||| DT
first  ||| S:35199 E:35205 ||| JJ
strand  ||| S:35205 E:35212 ||| NN
was  ||| S:35212 E:35216 ||| VBD
synthesized  ||| S:35216 E:35238 ||| VBN
at  ||| S:35238 E:35241 ||| IN
48°C  ||| S:35241 E:35246 ||| NNP
and  ||| S:35246 E:35250 ||| CC
DNA  ||| S:35250 E:35254 ||| NNP
was  ||| S:35254 E:35258 ||| VBD
amplified  ||| S:35258 E:35268 ||| VBN
at  ||| S:35268 E:35271 ||| IN
95°C  ||| S:35271 E:35276 ||| CD
45  ||| S:35276 E:35279 ||| CD
sec ||| S:35279 E:35282 ||| NN
,  ||| S:35282 E:35284 ||| ,
55°C  ||| S:35284 E:35289 ||| CD
1  ||| S:35289 E:35291 ||| CD
min ||| S:35291 E:35294 ||| NN
,  ||| S:35294 E:35306 ||| ,
68°C  ||| S:35306 E:35311 ||| CD
1.5  ||| S:35311 E:35315 ||| CD
min  ||| S:35315 E:35319 ||| NN
for  ||| S:35319 E:35323 ||| IN
40  ||| S:35323 E:35326 ||| CD
cycles.  ||| S:35326 E:35334 ||| CD
3  ||| S:35334 E:35336 ||| CD
μl  ||| S:35336 E:35339 ||| JJ
Quantum  ||| S:35339 E:35347 ||| NNP
mRNA  ||| S:35347 E:35352 ||| JJ
classic  ||| S:35352 E:35360 ||| JJ
18S  ||| S:35360 E:35374 ||| CD
primers  ||| S:35374 E:35382 ||| NN
from  ||| S:35382 E:35387 ||| IN
Ambion  ||| S:35387 E:35394 ||| NNP
were  ||| S:35394 E:35399 ||| VBD
used  ||| S:35399 E:35404 ||| VBN
to  ||| S:35404 E:35407 ||| TO
quantify  ||| S:35407 E:35416 ||| VB
total  ||| S:35416 E:35422 ||| JJ
RNA  ||| S:35422 E:35436 ||| NNP
levels ||| S:35436 E:35442 ||| NNS
.  ||| S:35442 E:35444 ||| .
Primers  ||| S:35444 E:35452 ||| RB
used  ||| S:35452 E:35457 ||| VBN
for  ||| S:35457 E:35461 ||| IN
TN  ||| S:35461 E:35464 ||| NNP
amplification ||| S:35464 E:35477 ||| NN
:  ||| S:35477 E:35479 ||| :
sense  ||| S:35479 E:35495 ||| NN
5 ||| S:35495 E:35496 ||| CD
' ||| S:35496 E:35497 ||| POS
AAATGCATCTGCGAGGGC ||| S:35497 E:35515 ||| NNP
,  ||| S:35515 E:35517 ||| ,
antisense  ||| S:35517 E:35537 ||| CD
5 ||| S:35537 E:35538 ||| CD
"GGAAGCTTGTTATTGCAGTCCTTCGG  ||| S:35538 E:35566 ||| CD
[  ||| S:35566 E:35568 ||| -LRB-
41  ||| S:35568 E:35571 ||| CD
]  ||| S:35571 E:35573 ||| -RRB-
.  ||| S:35573 E:35603 ||| .
Wounding  ||| S:35603 E:35612 ||| JJ
experiment  ||| S:35612 E:35633 ||| NN
Full-thickness  ||| S:35633 E:35648 ||| JJ
excision  ||| S:35648 E:35657 ||| NN
wounds  ||| S:35657 E:35664 ||| NNS
( ||| S:35664 E:35665 ||| -LRB-
approximately  ||| S:35665 E:35679 ||| RB
0.5  ||| S:35679 E:35683 ||| CD
×  ||| S:35683 E:35695 ||| CD
0.5  ||| S:35695 E:35699 ||| CD
cm ||| S:35699 E:35701 ||| CD
)  ||| S:35701 E:35703 ||| -RRB-
were  ||| S:35703 E:35708 ||| VBD
made  ||| S:35708 E:35713 ||| VBN
on  ||| S:35713 E:35716 ||| IN
the  ||| S:35716 E:35720 ||| DT
underside  ||| S:35720 E:35730 ||| NN
of  ||| S:35730 E:35733 ||| IN
the  ||| S:35733 E:35737 ||| DT
wings  ||| S:35737 E:35743 ||| NNS
of  ||| S:35743 E:35746 ||| IN
2  ||| S:35746 E:35758 ||| CD
week-old  ||| S:35758 E:35767 ||| JJ
chicks ||| S:35767 E:35773 ||| NN
,  ||| S:35773 E:35775 ||| ,
using  ||| S:35775 E:35781 ||| VBG
a  ||| S:35781 E:35783 ||| DT
scalpel  ||| S:35783 E:35791 ||| JJ
blade ||| S:35791 E:35796 ||| NN
.  ||| S:35796 E:35798 ||| .
The  ||| S:35798 E:35802 ||| DT
left  ||| S:35802 E:35807 ||| JJ
wing  ||| S:35807 E:35812 ||| NN
was  ||| S:35812 E:35826 ||| VBD
treated  ||| S:35826 E:35834 ||| VBN
with  ||| S:35834 E:35839 ||| IN
vehicle  ||| S:35839 E:35847 ||| NN
alone ||| S:35847 E:35852 ||| RB
,  ||| S:35852 E:35854 ||| ,
and  ||| S:35854 E:35858 ||| CC
the  ||| S:35858 E:35862 ||| DT
right  ||| S:35862 E:35868 ||| JJ
wing  ||| S:35868 E:35873 ||| NN
with  ||| S:35873 E:35878 ||| IN
1  ||| S:35878 E:35880 ||| CD
μg  ||| S:35880 E:35893 ||| JJ
cCAF ||| S:35893 E:35897 ||| NN
.  ||| S:35897 E:35899 ||| .
The  ||| S:35899 E:35903 ||| DT
wounds  ||| S:35903 E:35910 ||| NNS
were  ||| S:35910 E:35915 ||| VBD
photographed  ||| S:35915 E:35928 ||| VBN
immediately  ||| S:35928 E:35940 ||| RB
after  ||| S:35940 E:35956 ||| IN
wounding  ||| S:35956 E:35965 ||| NN
and  ||| S:35965 E:35969 ||| CC
then  ||| S:35969 E:35974 ||| RB
covered  ||| S:35974 E:35982 ||| VBN
with  ||| S:35982 E:35987 ||| IN
Biocclusive  ||| S:35987 E:35999 ||| NNP
bandage.  ||| S:35999 E:36008 ||| CD
50  ||| S:36008 E:36011 ||| CD
μl  ||| S:36011 E:36024 ||| JJ
vehicle  ||| S:36024 E:36032 ||| NN
or  ||| S:36032 E:36035 ||| CC
cCAF  ||| S:36035 E:36040 ||| NNP
were  ||| S:36040 E:36045 ||| VBD
deposited  ||| S:36045 E:36055 ||| VBN
through  ||| S:36055 E:36063 ||| IN
the  ||| S:36063 E:36067 ||| DT
bandage  ||| S:36067 E:36075 ||| NN
onto  ||| S:36075 E:36090 ||| IN
the  ||| S:36090 E:36094 ||| DT
wound  ||| S:36094 E:36100 ||| NN
using  ||| S:36100 E:36106 ||| VBG
a  ||| S:36106 E:36108 ||| DT
30-gauge  ||| S:36108 E:36117 ||| JJ
needle ||| S:36117 E:36123 ||| NN
.  ||| S:36123 E:36125 ||| .
This  ||| S:36125 E:36130 ||| DT
procedure  ||| S:36130 E:36140 ||| NN
was  ||| S:36140 E:36154 ||| VBD
repeated  ||| S:36154 E:36163 ||| VBN
the  ||| S:36163 E:36167 ||| DT
next  ||| S:36167 E:36172 ||| JJ
day  ||| S:36172 E:36176 ||| NN
and  ||| S:36176 E:36180 ||| CC
every  ||| S:36180 E:36186 ||| DT
other  ||| S:36186 E:36192 ||| JJ
day  ||| S:36192 E:36196 ||| NN
thereafter  ||| S:36196 E:36207 ||| RB
on  ||| S:36207 E:36220 ||| IN
days  ||| S:36220 E:36225 ||| NNS
3 ||| S:36225 E:36226 ||| CD
,  ||| S:36226 E:36228 ||| ,
5  ||| S:36228 E:36230 ||| CD
and  ||| S:36230 E:36234 ||| CC
7 ||| S:36234 E:36235 ||| CD
.  ||| S:36235 E:36237 ||| .
Samples  ||| S:36237 E:36245 ||| NNS
were  ||| S:36245 E:36250 ||| VBD
collected  ||| S:36250 E:36260 ||| VBN
at  ||| S:36260 E:36263 ||| IN
days  ||| S:36263 E:36268 ||| NNS
3  ||| S:36268 E:36270 ||| CD
and  ||| S:36270 E:36274 ||| CC
7  ||| S:36274 E:36286 ||| CD
post-wounding  ||| S:36286 E:36300 ||| NN
for  ||| S:36300 E:36304 ||| IN
ECM  ||| S:36304 E:36308 ||| NNP
analysis ||| S:36308 E:36316 ||| NN
.  ||| S:36316 E:36318 ||| .
All  ||| S:36318 E:36322 ||| DT
experimental  ||| S:36322 E:36335 ||| JJ
work  ||| S:36335 E:36350 ||| NN
with  ||| S:36350 E:36355 ||| IN
animals  ||| S:36355 E:36363 ||| NNS
reported  ||| S:36363 E:36372 ||| VBD
here  ||| S:36372 E:36377 ||| RB
was  ||| S:36377 E:36381 ||| VBD
done  ||| S:36381 E:36386 ||| VBN
under  ||| S:36386 E:36392 ||| IN
full  ||| S:36392 E:36397 ||| JJ
compliance  ||| S:36397 E:36418 ||| NN
with  ||| S:36418 E:36423 ||| IN
our  ||| S:36423 E:36427 ||| PRP$
animal  ||| S:36427 E:36434 ||| JJ
protocol  ||| S:36434 E:36443 ||| NN
approved  ||| S:36443 E:36452 ||| VBN
by  ||| S:36452 E:36455 ||| IN
appropriate  ||| S:36455 E:36467 ||| JJ
campus  ||| S:36467 E:36484 ||| NN
authorities ||| S:36484 E:36495 ||| NNS
.  ||| S:36495 E:36525 ||| .
Preparation  ||| S:36525 E:36537 ||| NN
and  ||| S:36537 E:36541 ||| CC
staining  ||| S:36541 E:36550 ||| NN
of  ||| S:36550 E:36553 ||| IN
wing  ||| S:36553 E:36558 ||| JJ
sections  ||| S:36558 E:36577 ||| NNS
At  ||| S:36577 E:36580 ||| IN
the  ||| S:36580 E:36584 ||| DT
specified  ||| S:36584 E:36594 ||| JJ
time  ||| S:36594 E:36599 ||| NN
points ||| S:36599 E:36605 ||| NNS
,  ||| S:36605 E:36607 ||| ,
chickens  ||| S:36607 E:36616 ||| NNS
were  ||| S:36616 E:36621 ||| VBD
euthanized  ||| S:36621 E:36642 ||| VBN
with  ||| S:36642 E:36647 ||| IN
sodium  ||| S:36647 E:36654 ||| JJ
pentobarbitol ||| S:36654 E:36667 ||| NN
.  ||| S:36667 E:36669 ||| .
The  ||| S:36669 E:36673 ||| DT
wounded  ||| S:36673 E:36681 ||| JJ
wings  ||| S:36681 E:36687 ||| NNS
were  ||| S:36687 E:36702 ||| VBD
collected  ||| S:36702 E:36712 ||| VBN
and  ||| S:36712 E:36716 ||| CC
fixed  ||| S:36716 E:36722 ||| VBN
for  ||| S:36722 E:36726 ||| IN
18  ||| S:36726 E:36729 ||| CD
hrs  ||| S:36729 E:36733 ||| NN
in  ||| S:36733 E:36736 ||| IN
4 ||| S:36736 E:36737 ||| CD
%  ||| S:36737 E:36739 ||| NN
paraformaldehyde  ||| S:36739 E:36756 ||| NNS
and  ||| S:36756 E:36770 ||| CC
decalcified  ||| S:36770 E:36782 ||| NN
for  ||| S:36782 E:36786 ||| IN
3  ||| S:36786 E:36788 ||| CD
days  ||| S:36788 E:36793 ||| NNS
in  ||| S:36793 E:36796 ||| IN
5 ||| S:36796 E:36797 ||| CD
%  ||| S:36797 E:36799 ||| NN
formic  ||| S:36799 E:36806 ||| NN
acid ||| S:36806 E:36810 ||| NN
,  ||| S:36810 E:36812 ||| ,
2.5 ||| S:36812 E:36815 ||| CD
%  ||| S:36815 E:36827 ||| NN
formaldehyde  ||| S:36827 E:36840 ||| NN
at  ||| S:36840 E:36843 ||| IN
4°C ||| S:36843 E:36846 ||| CD
.  ||| S:36846 E:36848 ||| .
The  ||| S:36848 E:36852 ||| DT
tissue  ||| S:36852 E:36859 ||| NN
was  ||| S:36859 E:36863 ||| VBD
embedded  ||| S:36863 E:36872 ||| VBN
in  ||| S:36872 E:36875 ||| IN
paraffin  ||| S:36875 E:36894 ||| NN
and  ||| S:36894 E:36898 ||| CC
sectioned ||| S:36898 E:36907 ||| NN
.  ||| S:36907 E:36909 ||| .
Sections  ||| S:36909 E:36918 ||| NNS
were  ||| S:36918 E:36923 ||| VBD
stained  ||| S:36923 E:36931 ||| VBN
with  ||| S:36931 E:36936 ||| IN
Masson  ||| S:36936 E:36953 ||| NNP
Trichrome  ||| S:36953 E:36963 ||| NNP
to  ||| S:36963 E:36966 ||| TO
visualize  ||| S:36966 E:36976 ||| VB
interstitial  ||| S:36976 E:36989 ||| JJ
collagen ||| S:36989 E:36997 ||| NN
.  ||| S:36997 E:36999 ||| .
Other  ||| S:36999 E:37015 ||| JJ
sections  ||| S:37015 E:37024 ||| NNS
were  ||| S:37024 E:37029 ||| VBD
immunolabeled  ||| S:37029 E:37043 ||| VBN
for  ||| S:37043 E:37047 ||| IN
FN  ||| S:37047 E:37050 ||| NNP
or  ||| S:37050 E:37053 ||| CC
TN ||| S:37053 E:37055 ||| NNP
.  ||| S:37055 E:37057 ||| .
Sections  ||| S:37057 E:37066 ||| NNS
were  ||| S:37066 E:37081 ||| VBD
deparaffinized  ||| S:37081 E:37096 ||| VBN
in  ||| S:37096 E:37099 ||| IN
3  ||| S:37099 E:37101 ||| CD
changes  ||| S:37101 E:37109 ||| NNS
of  ||| S:37109 E:37112 ||| IN
Hemo-De  ||| S:37112 E:37120 ||| JJ
for  ||| S:37120 E:37124 ||| IN
15  ||| S:37124 E:37127 ||| CD
min  ||| S:37127 E:37131 ||| CD
each  ||| S:37131 E:37146 ||| DT
and  ||| S:37146 E:37150 ||| CC
rehydrated  ||| S:37150 E:37161 ||| NN
in  ||| S:37161 E:37164 ||| IN
a  ||| S:37164 E:37166 ||| DT
descending  ||| S:37166 E:37177 ||| JJ
ethanol  ||| S:37177 E:37185 ||| JJ
series  ||| S:37185 E:37192 ||| NN
( ||| S:37192 E:37193 ||| -LRB-
5  ||| S:37193 E:37195 ||| CD
min  ||| S:37195 E:37209 ||| CD
each ||| S:37209 E:37213 ||| DT
:  ||| S:37213 E:37215 ||| :
100 ||| S:37215 E:37218 ||| CD
% ||| S:37218 E:37219 ||| NN
,  ||| S:37219 E:37221 ||| ,
95 ||| S:37221 E:37223 ||| CD
% ||| S:37223 E:37224 ||| NN
,  ||| S:37224 E:37226 ||| ,
70 ||| S:37226 E:37228 ||| CD
% ||| S:37228 E:37229 ||| NN
,  ||| S:37229 E:37231 ||| ,
50 ||| S:37231 E:37233 ||| CD
% ||| S:37233 E:37234 ||| NN
,  ||| S:37234 E:37236 ||| ,
30 ||| S:37236 E:37238 ||| CD
%  ||| S:37238 E:37240 ||| NN
ethanol ||| S:37240 E:37247 ||| NN
) ||| S:37247 E:37248 ||| -RRB-
.  ||| S:37248 E:37250 ||| .
After  ||| S:37250 E:37256 ||| IN
rinsing  ||| S:37256 E:37274 ||| NN
with  ||| S:37274 E:37279 ||| IN
PBS ||| S:37279 E:37282 ||| NNP
,  ||| S:37282 E:37284 ||| ,
sections  ||| S:37284 E:37293 ||| NNS
were  ||| S:37293 E:37298 ||| VBD
fixed  ||| S:37298 E:37304 ||| VBN
in  ||| S:37304 E:37307 ||| IN
2 ||| S:37307 E:37308 ||| CD
%  ||| S:37308 E:37310 ||| NN
paraformaldehyde  ||| S:37310 E:37327 ||| NN
for  ||| S:37327 E:37341 ||| IN
1  ||| S:37341 E:37343 ||| CD
hr ||| S:37343 E:37345 ||| NNS
.  ||| S:37345 E:37347 ||| .
Autofluorescence  ||| S:37347 E:37364 ||| NNP
and  ||| S:37364 E:37368 ||| CC
non-specific  ||| S:37368 E:37381 ||| JJ
staining  ||| S:37381 E:37390 ||| NN
were  ||| S:37390 E:37405 ||| VBD
blocked  ||| S:37405 E:37413 ||| VBN
for  ||| S:37413 E:37417 ||| IN
30  ||| S:37417 E:37420 ||| CD
min  ||| S:37420 E:37424 ||| NN
in  ||| S:37424 E:37427 ||| IN
0.1  ||| S:37427 E:37431 ||| CD
M  ||| S:37431 E:37433 ||| NNP
glycine  ||| S:37433 E:37441 ||| NN
in  ||| S:37441 E:37444 ||| IN
PBS ||| S:37444 E:37447 ||| NNP
,  ||| S:37447 E:37449 ||| ,
followed  ||| S:37449 E:37458 ||| VBN
by  ||| S:37458 E:37471 ||| IN
30  ||| S:37471 E:37474 ||| CD
min  ||| S:37474 E:37478 ||| NN
in  ||| S:37478 E:37481 ||| IN
1 ||| S:37481 E:37482 ||| CD
%  ||| S:37482 E:37484 ||| NN
Evans  ||| S:37484 E:37490 ||| NNP
Blue  ||| S:37490 E:37495 ||| NNP
in  ||| S:37495 E:37498 ||| IN
PBS  ||| S:37498 E:37502 ||| NNP
to  ||| S:37502 E:37505 ||| TO
quench  ||| S:37505 E:37512 ||| VB
red  ||| S:37512 E:37516 ||| JJ
blood  ||| S:37516 E:37522 ||| NN
cell  ||| S:37522 E:37537 ||| NN
autofluorescence ||| S:37537 E:37553 ||| NN
.  ||| S:37553 E:37555 ||| .
Sections  ||| S:37555 E:37564 ||| NNS
were  ||| S:37564 E:37569 ||| VBD
incubated  ||| S:37569 E:37579 ||| VBN
with  ||| S:37579 E:37584 ||| IN
anti-FN  ||| S:37584 E:37592 ||| JJ
or  ||| S:37592 E:37605 ||| CC
anti-TN  ||| S:37605 E:37613 ||| JJ
antibodies  ||| S:37613 E:37624 ||| NNS
( ||| S:37624 E:37625 ||| -LRB-
1 ||| S:37625 E:37626 ||| LS
: ||| S:37626 E:37627 ||| :
50 ||| S:37627 E:37629 ||| CD
)  ||| S:37629 E:37631 ||| -RRB-
in  ||| S:37631 E:37634 ||| IN
1 ||| S:37634 E:37635 ||| CD
%  ||| S:37635 E:37637 ||| NN
BSA  ||| S:37637 E:37641 ||| NN
in  ||| S:37641 E:37644 ||| IN
PBS  ||| S:37644 E:37648 ||| NNP
for  ||| S:37648 E:37652 ||| IN
2  ||| S:37652 E:37654 ||| CD
hr  ||| S:37654 E:37657 ||| NN
at  ||| S:37657 E:37670 ||| IN
room  ||| S:37670 E:37675 ||| NN
temperature ||| S:37675 E:37686 ||| NN
.  ||| S:37686 E:37688 ||| .
After  ||| S:37688 E:37694 ||| IN
3  ||| S:37694 E:37696 ||| CD
×  ||| S:37696 E:37698 ||| CD
10  ||| S:37698 E:37701 ||| CD
min  ||| S:37701 E:37705 ||| JJ
washes  ||| S:37705 E:37712 ||| NN
in  ||| S:37712 E:37715 ||| IN
0.1 ||| S:37715 E:37718 ||| CD
%  ||| S:37718 E:37720 ||| NN
BSA  ||| S:37720 E:37724 ||| NN
in  ||| S:37724 E:37737 ||| IN
PBS ||| S:37737 E:37740 ||| NNP
,  ||| S:37740 E:37742 ||| ,
the  ||| S:37742 E:37746 ||| DT
sections  ||| S:37746 E:37755 ||| NNS
were  ||| S:37755 E:37760 ||| VBD
incubated  ||| S:37760 E:37770 ||| VBN
for  ||| S:37770 E:37774 ||| IN
40  ||| S:37774 E:37777 ||| CD
min  ||| S:37777 E:37781 ||| NN
with  ||| S:37781 E:37796 ||| IN
anti-mouse  ||| S:37796 E:37807 ||| NNP
Alexa  ||| S:37807 E:37813 ||| NNP
antibody  ||| S:37813 E:37822 ||| NN
( ||| S:37822 E:37823 ||| -LRB-
1 ||| S:37823 E:37824 ||| LS
: ||| S:37824 E:37825 ||| :
200 ||| S:37825 E:37828 ||| CD
)  ||| S:37828 E:37830 ||| -RRB-
in  ||| S:37830 E:37833 ||| IN
1 ||| S:37833 E:37834 ||| CD
%  ||| S:37834 E:37836 ||| NN
BSA  ||| S:37836 E:37840 ||| NN
in  ||| S:37840 E:37843 ||| IN
PBS ||| S:37843 E:37846 ||| NNP
.  ||| S:37846 E:37848 ||| .
They  ||| S:37848 E:37863 ||| PRP
were  ||| S:37863 E:37868 ||| VBD
then  ||| S:37868 E:37873 ||| RB
washed  ||| S:37873 E:37880 ||| VBN
and  ||| S:37880 E:37884 ||| CC
mounted  ||| S:37884 E:37892 ||| VBN
with  ||| S:37892 E:37897 ||| IN
Vectashield ||| S:37897 E:37908 ||| NNP
.  ||| S:37908 E:37938 ||| .
Protein  ||| S:37938 E:37946 ||| NN
extracts  ||| S:37946 E:37955 ||| NN
of  ||| S:37955 E:37958 ||| IN
wounds  ||| S:37958 E:37975 ||| JJ
Wound  ||| S:37975 E:37981 ||| JJ
tissues  ||| S:37981 E:37989 ||| NNS
were  ||| S:37989 E:37994 ||| VBD
immediately  ||| S:37994 E:38006 ||| RB
frozen  ||| S:38006 E:38013 ||| VBN
on  ||| S:38013 E:38016 ||| IN
dry  ||| S:38016 E:38020 ||| JJ
ice  ||| S:38020 E:38024 ||| NN
and  ||| S:38024 E:38038 ||| CC
stored  ||| S:38038 E:38045 ||| VBD
at  ||| S:38045 E:38048 ||| IN
-70°C ||| S:38048 E:38053 ||| CD
.  ||| S:38053 E:38055 ||| .
To  ||| S:38055 E:38058 ||| TO
extract  ||| S:38058 E:38066 ||| VB
protein ||| S:38066 E:38073 ||| NN
,  ||| S:38073 E:38075 ||| ,
the  ||| S:38075 E:38079 ||| DT
tissue  ||| S:38079 E:38086 ||| NN
was  ||| S:38086 E:38100 ||| VBD
ground  ||| S:38100 E:38107 ||| NN
with  ||| S:38107 E:38112 ||| IN
glass  ||| S:38112 E:38118 ||| NN
beads  ||| S:38118 E:38124 ||| NN
in  ||| S:38124 E:38127 ||| IN
a  ||| S:38127 E:38129 ||| DT
mortar  ||| S:38129 E:38136 ||| NN
and  ||| S:38136 E:38140 ||| CC
pestle  ||| S:38140 E:38147 ||| NN
on  ||| S:38147 E:38150 ||| IN
dry  ||| S:38150 E:38164 ||| JJ
ice ||| S:38164 E:38167 ||| NN
.  ||| S:38167 E:38169 ||| .
The  ||| S:38169 E:38173 ||| DT
powdered  ||| S:38173 E:38182 ||| JJ
tissue  ||| S:38182 E:38189 ||| NN
was  ||| S:38189 E:38193 ||| VBD
dissolved  ||| S:38193 E:38203 ||| VBN
in  ||| S:38203 E:38206 ||| IN
RIPA  ||| S:38206 E:38211 ||| NNP
containing  ||| S:38211 E:38232 ||| VBG
300  ||| S:38232 E:38236 ||| CD
mM  ||| S:38236 E:38239 ||| JJ
salt  ||| S:38239 E:38244 ||| NN
and  ||| S:38244 E:38248 ||| CC
a  ||| S:38248 E:38250 ||| DT
cocktail  ||| S:38250 E:38259 ||| NN
of  ||| S:38259 E:38262 ||| IN
protease  ||| S:38262 E:38271 ||| JJ
inhibitors ||| S:38271 E:38281 ||| NN
,  ||| S:38281 E:38283 ||| ,
and  ||| S:38283 E:38297 ||| CC
vortexed  ||| S:38297 E:38306 ||| JJ
vigorously ||| S:38306 E:38316 ||| NN
.  ||| S:38316 E:38318 ||| .
After  ||| S:38318 E:38324 ||| IN
centrifugation ||| S:38324 E:38338 ||| NN
,  ||| S:38338 E:38340 ||| ,
the  ||| S:38340 E:38354 ||| DT
supernatant  ||| S:38354 E:38366 ||| NN
was  ||| S:38366 E:38370 ||| VBD
used  ||| S:38370 E:38375 ||| VBN
in  ||| S:38375 E:38378 ||| IN
immunoblots ||| S:38378 E:38389 ||| NN
.  ||| S:38389 E:38419 ||| .
Transwell  ||| S:38419 E:38429 ||| JJ
assay  ||| S:38429 E:38435 ||| NN
for  ||| S:38435 E:38439 ||| IN
migration  ||| S:38439 E:38459 ||| CD
1  ||| S:38459 E:38461 ||| CD
×  ||| S:38461 E:38463 ||| CD
10  ||| S:38463 E:38466 ||| CD
6cells  ||| S:38466 E:38473 ||| CD
in  ||| S:38473 E:38476 ||| IN
100  ||| S:38476 E:38480 ||| CD
μl  ||| S:38480 E:38483 ||| CD
199  ||| S:38483 E:38487 ||| CD
medium  ||| S:38487 E:38494 ||| NN
containing  ||| S:38494 E:38505 ||| VBG
2 ||| S:38505 E:38506 ||| CD
%  ||| S:38506 E:38508 ||| NN
serum  ||| S:38508 E:38524 ||| NNS
were  ||| S:38524 E:38529 ||| VBD
plated  ||| S:38529 E:38536 ||| VBN
on  ||| S:38536 E:38539 ||| IN
the  ||| S:38539 E:38543 ||| DT
underside  ||| S:38543 E:38553 ||| NN
of  ||| S:38553 E:38556 ||| IN
transwell  ||| S:38556 E:38566 ||| JJ
membranes  ||| S:38566 E:38576 ||| NN
by  ||| S:38576 E:38589 ||| IN
inverting  ||| S:38589 E:38599 ||| VBG
the  ||| S:38599 E:38603 ||| DT
insert ||| S:38603 E:38609 ||| NN
.  ||| S:38609 E:38611 ||| .
They  ||| S:38611 E:38616 ||| PRP
were  ||| S:38616 E:38621 ||| VBD
allowed  ||| S:38621 E:38629 ||| VBN
to  ||| S:38629 E:38632 ||| TO
adhere  ||| S:38632 E:38639 ||| VB
for  ||| S:38639 E:38643 ||| IN
30  ||| S:38643 E:38656 ||| CD
minutes ||| S:38656 E:38663 ||| NNS
,  ||| S:38663 E:38665 ||| ,
then  ||| S:38665 E:38670 ||| RB
the  ||| S:38670 E:38674 ||| DT
well  ||| S:38674 E:38679 ||| RB
was  ||| S:38679 E:38683 ||| VBD
turned  ||| S:38683 E:38690 ||| VBN
right  ||| S:38690 E:38696 ||| JJ
side  ||| S:38696 E:38701 ||| NN
up  ||| S:38701 E:38704 ||| RB
and  ||| S:38704 E:38708 ||| CC
both  ||| S:38708 E:38723 ||| DT
sides  ||| S:38723 E:38729 ||| NNS
of  ||| S:38729 E:38732 ||| IN
the  ||| S:38732 E:38736 ||| DT
well  ||| S:38736 E:38741 ||| RB
were  ||| S:38741 E:38746 ||| VBD
filled  ||| S:38746 E:38753 ||| VBN
with  ||| S:38753 E:38758 ||| IN
serum-containing  ||| S:38758 E:38785 ||| JJ
medium ||| S:38785 E:38791 ||| NN
.  ||| S:38791 E:38793 ||| .
The  ||| S:38793 E:38797 ||| DT
cells  ||| S:38797 E:38803 ||| NNS
were  ||| S:38803 E:38808 ||| VBD
allowed  ||| S:38808 E:38816 ||| VBN
to  ||| S:38816 E:38819 ||| TO
recover  ||| S:38819 E:38827 ||| VB
for  ||| S:38827 E:38831 ||| IN
24  ||| S:38831 E:38834 ||| CD
hrs ||| S:38834 E:38837 ||| NN
,  ||| S:38837 E:38839 ||| ,
and  ||| S:38839 E:38853 ||| CC
express  ||| S:38853 E:38861 ||| VB
the  ||| S:38861 E:38865 ||| DT
cCAF  ||| S:38865 E:38870 ||| JJ
receptors ||| S:38870 E:38879 ||| NNS
.  ||| S:38879 E:38881 ||| .
Then  ||| S:38881 E:38886 ||| RB
the  ||| S:38886 E:38890 ||| DT
medium  ||| S:38890 E:38897 ||| NN
in  ||| S:38897 E:38900 ||| IN
the  ||| S:38900 E:38904 ||| DT
top  ||| S:38904 E:38918 ||| NN
well  ||| S:38918 E:38923 ||| RB
was  ||| S:38923 E:38927 ||| VBD
changed  ||| S:38927 E:38935 ||| VBN
to  ||| S:38935 E:38938 ||| TO
serum-free  ||| S:38938 E:38949 ||| FW
medium  ||| S:38949 E:38956 ||| FW
containing  ||| S:38956 E:38967 ||| FW
50-1000  ||| S:38967 E:38985 ||| FW
ng ||| S:38985 E:38987 ||| FW
/ ||| S:38987 E:38988 ||| FW
ml  ||| S:38988 E:38991 ||| FW
cCAF  ||| S:38991 E:38996 ||| FW
or  ||| S:38996 E:38999 ||| CC
2  ||| S:38999 E:39001 ||| CD
%  ||| S:39001 E:39003 ||| NN
serum  ||| S:39003 E:39009 ||| NNS
( ||| S:39009 E:39010 ||| -LRB-
positive  ||| S:39010 E:39019 ||| JJ
control ||| S:39019 E:39026 ||| NN
) ||| S:39026 E:39027 ||| -RRB-
;  ||| S:39027 E:39029 ||| :
serum  ||| S:39029 E:39035 ||| JJ
free  ||| S:39035 E:39050 ||| JJ
medium  ||| S:39050 E:39057 ||| NN
alone  ||| S:39057 E:39063 ||| RB
was  ||| S:39063 E:39067 ||| VBD
placed  ||| S:39067 E:39074 ||| VBN
in  ||| S:39074 E:39077 ||| IN
the  ||| S:39077 E:39081 ||| DT
bottom  ||| S:39081 E:39088 ||| NN
well ||| S:39088 E:39092 ||| RB
.  ||| S:39092 E:39094 ||| .
The  ||| S:39094 E:39098 ||| DT
cells  ||| S:39098 E:39114 ||| NNS
were  ||| S:39114 E:39119 ||| VBD
allowed  ||| S:39119 E:39127 ||| VBN
to  ||| S:39127 E:39130 ||| TO
migrate  ||| S:39130 E:39138 ||| VB
towards  ||| S:39138 E:39146 ||| IN
the  ||| S:39146 E:39150 ||| DT
chemoattractant  ||| S:39150 E:39166 ||| NN
for  ||| S:39166 E:39180 ||| IN
24  ||| S:39180 E:39183 ||| CD
hrs ||| S:39183 E:39186 ||| NNS
.  ||| S:39186 E:39188 ||| .
The  ||| S:39188 E:39192 ||| DT
cells  ||| S:39192 E:39198 ||| NNS
on  ||| S:39198 E:39201 ||| IN
the  ||| S:39201 E:39205 ||| DT
underside  ||| S:39205 E:39215 ||| NN
of  ||| S:39215 E:39218 ||| IN
the  ||| S:39218 E:39222 ||| DT
membrane  ||| S:39222 E:39231 ||| NN
were  ||| S:39231 E:39246 ||| VBD
removed  ||| S:39246 E:39254 ||| VBN
with  ||| S:39254 E:39259 ||| IN
a  ||| S:39259 E:39261 ||| DT
cotton  ||| S:39261 E:39268 ||| NN
swab ||| S:39268 E:39272 ||| NN
.  ||| S:39272 E:39274 ||| .
The  ||| S:39274 E:39278 ||| DT
membranes  ||| S:39278 E:39288 ||| NN
were  ||| S:39288 E:39293 ||| VBD
then  ||| S:39293 E:39298 ||| RB
fixed  ||| S:39298 E:39314 ||| VBN
and  ||| S:39314 E:39318 ||| CC
stained  ||| S:39318 E:39326 ||| NN
with  ||| S:39326 E:39331 ||| IN
2 ||| S:39331 E:39332 ||| CD
%  ||| S:39332 E:39334 ||| NN
toludine  ||| S:39334 E:39343 ||| NN
blue  ||| S:39343 E:39348 ||| NN
in  ||| S:39348 E:39351 ||| IN
formaldehyde ||| S:39351 E:39363 ||| NN
.  ||| S:39363 E:39365 ||| .
To  ||| S:39365 E:39378 ||| TO
determine  ||| S:39378 E:39388 ||| VB
the  ||| S:39388 E:39392 ||| DT
number  ||| S:39392 E:39399 ||| NN
of  ||| S:39399 E:39402 ||| IN
migrated  ||| S:39402 E:39411 ||| JJ
cells ||| S:39411 E:39416 ||| NNS
,  ||| S:39416 E:39418 ||| ,
all  ||| S:39418 E:39422 ||| DT
cells  ||| S:39422 E:39428 ||| NNS
on  ||| S:39428 E:39431 ||| IN
the  ||| S:39431 E:39445 ||| DT
upper  ||| S:39445 E:39451 ||| JJ
side  ||| S:39451 E:39456 ||| NN
of  ||| S:39456 E:39459 ||| IN
the  ||| S:39459 E:39463 ||| DT
membrane  ||| S:39463 E:39472 ||| NN
were  ||| S:39472 E:39477 ||| VBD
counted ||| S:39477 E:39484 ||| VBN
.  ||| S:39484 E:39486 ||| .
Control  ||| S:39486 E:39494 ||| NN
for  ||| S:39494 E:39508 ||| IN
chemotaxis  ||| S:39508 E:39519 ||| NN
was  ||| S:39519 E:39523 ||| VBD
performed  ||| S:39523 E:39533 ||| VBN
by  ||| S:39533 E:39536 ||| IN
adding  ||| S:39536 E:39543 ||| VBG
1000  ||| S:39543 E:39548 ||| CD
ng ||| S:39548 E:39550 ||| CD
/ ||| S:39550 E:39551 ||| CD
ml  ||| S:39551 E:39554 ||| CD
cCAF  ||| S:39554 E:39559 ||| JJ
to  ||| S:39559 E:39572 ||| TO
both  ||| S:39572 E:39577 ||| DT
wells  ||| S:39577 E:39583 ||| NNS
of  ||| S:39583 E:39586 ||| IN
the  ||| S:39586 E:39590 ||| DT
Transwell  ||| S:39590 E:39600 ||| JJ
unit ||| S:39600 E:39604 ||| NN
.  ||| S:39604 E:39634 ||| .
Cloning  ||| S:39634 E:39642 ||| NNS
ring  ||| S:39642 E:39647 ||| VBP
assay  ||| S:39647 E:39653 ||| VBN
for  ||| S:39653 E:39657 ||| IN
migration  ||| S:39657 E:39677 ||| CD
1  ||| S:39677 E:39679 ||| CD
×  ||| S:39679 E:39681 ||| CD
10  ||| S:39681 E:39684 ||| CD
6cells  ||| S:39684 E:39691 ||| CD
in  ||| S:39691 E:39694 ||| IN
100  ||| S:39694 E:39698 ||| CD
μl  ||| S:39698 E:39701 ||| CD
199  ||| S:39701 E:39705 ||| CD
medium  ||| S:39705 E:39712 ||| NN
containing  ||| S:39712 E:39723 ||| VBG
2 ||| S:39723 E:39724 ||| CD
%  ||| S:39724 E:39726 ||| NN
serum  ||| S:39726 E:39742 ||| NNS
were  ||| S:39742 E:39747 ||| VBD
plated  ||| S:39747 E:39754 ||| VBN
in  ||| S:39754 E:39757 ||| IN
a  ||| S:39757 E:39759 ||| DT
cloning  ||| S:39759 E:39767 ||| JJ
ring  ||| S:39767 E:39772 ||| NN
in  ||| S:39772 E:39775 ||| IN
a  ||| S:39775 E:39777 ||| DT
35  ||| S:39777 E:39780 ||| CD
mm  ||| S:39780 E:39783 ||| JJ
plate ||| S:39783 E:39788 ||| NN
.  ||| S:39788 E:39790 ||| .
They  ||| S:39790 E:39795 ||| PRP
were  ||| S:39795 E:39810 ||| VBD
allowed  ||| S:39810 E:39818 ||| VBN
to  ||| S:39818 E:39821 ||| TO
adhere  ||| S:39821 E:39828 ||| VB
for  ||| S:39828 E:39832 ||| IN
1  ||| S:39832 E:39834 ||| CD
hour ||| S:39834 E:39838 ||| NN
,  ||| S:39838 E:39840 ||| ,
then  ||| S:39840 E:39845 ||| RB
the  ||| S:39845 E:39849 ||| DT
ring  ||| S:39849 E:39854 ||| NN
was  ||| S:39854 E:39858 ||| VBD
removed ||| S:39858 E:39865 ||| VBN
,  ||| S:39865 E:39877 ||| ,
the  ||| S:39877 E:39881 ||| DT
culture  ||| S:39881 E:39889 ||| NN
medium  ||| S:39889 E:39896 ||| NN
added  ||| S:39896 E:39902 ||| VBD
to  ||| S:39902 E:39905 ||| TO
the  ||| S:39905 E:39909 ||| DT
plate  ||| S:39909 E:39915 ||| NN
and  ||| S:39915 E:39919 ||| CC
the  ||| S:39919 E:39923 ||| DT
cells  ||| S:39923 E:39939 ||| NNS
photographed  ||| S:39939 E:39952 ||| VBN
on  ||| S:39952 E:39955 ||| IN
a  ||| S:39955 E:39957 ||| DT
phase-contrast  ||| S:39957 E:39972 ||| JJ
microscope  ||| S:39972 E:39983 ||| NN
to  ||| S:39983 E:39986 ||| TO
record  ||| S:39986 E:39993 ||| VB
the  ||| S:39993 E:40007 ||| DT
area  ||| S:40007 E:40012 ||| NN
of  ||| S:40012 E:40015 ||| IN
the  ||| S:40015 E:40019 ||| DT
cells  ||| S:40019 E:40025 ||| NNS
and  ||| S:40025 E:40029 ||| CC
the  ||| S:40029 E:40033 ||| DT
edge  ||| S:40033 E:40038 ||| NN
of  ||| S:40038 E:40041 ||| IN
the  ||| S:40041 E:40045 ||| DT
ring.  ||| S:40045 E:40051 ||| NNP
cCAF  ||| S:40051 E:40056 ||| NNP
was  ||| S:40056 E:40060 ||| VBD
then  ||| S:40060 E:40075 ||| RB
added  ||| S:40075 E:40081 ||| VBN
at  ||| S:40081 E:40084 ||| IN
various  ||| S:40084 E:40092 ||| JJ
doses  ||| S:40092 E:40098 ||| NNS
( ||| S:40098 E:40099 ||| -LRB-
0-1000  ||| S:40099 E:40106 ||| FW
ng ||| S:40106 E:40108 ||| FW
/ ||| S:40108 E:40109 ||| FW
ml ||| S:40109 E:40111 ||| FW
) ||| S:40111 E:40112 ||| -RRB-
.  ||| S:40112 E:40114 ||| .
The  ||| S:40114 E:40118 ||| DT
following  ||| S:40118 E:40128 ||| JJ
day  ||| S:40128 E:40142 ||| NN
the  ||| S:40142 E:40146 ||| DT
medium  ||| S:40146 E:40153 ||| NN
was  ||| S:40153 E:40157 ||| VBD
changed  ||| S:40157 E:40165 ||| VBN
and  ||| S:40165 E:40169 ||| CC
the  ||| S:40169 E:40173 ||| DT
cells  ||| S:40173 E:40179 ||| NNS
were  ||| S:40179 E:40184 ||| VBD
treated  ||| S:40184 E:40192 ||| VBN
again ||| S:40192 E:40197 ||| RB
.  ||| S:40197 E:40209 ||| .
On  ||| S:40209 E:40212 ||| IN
the  ||| S:40212 E:40216 ||| DT
third  ||| S:40216 E:40222 ||| JJ
day  ||| S:40222 E:40226 ||| NN
after  ||| S:40226 E:40232 ||| IN
plating ||| S:40232 E:40239 ||| NN
,  ||| S:40239 E:40241 ||| ,
the  ||| S:40241 E:40245 ||| DT
cells  ||| S:40245 E:40251 ||| NNS
were  ||| S:40251 E:40266 ||| VBD
photographed  ||| S:40266 E:40279 ||| VBN
once  ||| S:40279 E:40284 ||| RB
more  ||| S:40284 E:40289 ||| JJR
before  ||| S:40289 E:40296 ||| IN
the  ||| S:40296 E:40300 ||| DT
experiment  ||| S:40300 E:40311 ||| NN
was  ||| S:40311 E:40325 ||| VBD
terminated ||| S:40325 E:40335 ||| VBN
.  ||| S:40335 E:40337 ||| .
To  ||| S:40337 E:40340 ||| TO
determine  ||| S:40340 E:40350 ||| VB
the  ||| S:40350 E:40354 ||| DT
extent  ||| S:40354 E:40361 ||| NN
of  ||| S:40361 E:40364 ||| IN
cell  ||| S:40364 E:40369 ||| NN
migration ||| S:40369 E:40378 ||| NN
,  ||| S:40378 E:40380 ||| ,
we  ||| S:40380 E:40393 ||| PRP
measured  ||| S:40393 E:40402 ||| VBD
the  ||| S:40402 E:40406 ||| DT
distance  ||| S:40406 E:40415 ||| NN
between  ||| S:40415 E:40423 ||| IN
the  ||| S:40423 E:40427 ||| DT
edge  ||| S:40427 E:40432 ||| NN
where  ||| S:40432 E:40438 ||| WRB
the  ||| S:40438 E:40442 ||| DT
cloning  ||| S:40442 E:40460 ||| JJ
ring  ||| S:40460 E:40465 ||| NN
was  ||| S:40465 E:40469 ||| VBD
at  ||| S:40469 E:40472 ||| IN
day  ||| S:40472 E:40476 ||| NN
zero  ||| S:40476 E:40481 ||| NN
and  ||| S:40481 E:40485 ||| CC
the  ||| S:40485 E:40489 ||| DT
edge  ||| S:40489 E:40494 ||| NN
of  ||| S:40494 E:40497 ||| IN
the  ||| S:40497 E:40501 ||| DT
culture  ||| S:40501 E:40519 ||| NN
delineated  ||| S:40519 E:40530 ||| NN
by  ||| S:40530 E:40533 ||| IN
the  ||| S:40533 E:40537 ||| DT
migrating  ||| S:40537 E:40547 ||| JJ
front  ||| S:40547 E:40553 ||| NN
of  ||| S:40553 E:40556 ||| IN
the  ||| S:40556 E:40560 ||| DT
cells  ||| S:40560 E:40566 ||| NNS
on  ||| S:40566 E:40569 ||| IN
the  ||| S:40569 E:40573 ||| DT
3  ||| S:40573 E:40585 ||| CD
rdday ||| S:40585 E:40590 ||| NNS
.  ||| S:40590 E:40620 ||| .
In  ||| S:40620 E:40623 ||| IN
situhybridization  ||| S:40623 E:40651 ||| JJ
Fibroblast  ||| S:40651 E:40662 ||| JJ
cultures  ||| S:40662 E:40671 ||| NNS
and  ||| S:40671 E:40675 ||| CC
probes  ||| S:40675 E:40682 ||| NNS
were  ||| S:40682 E:40687 ||| VBD
prepared  ||| S:40687 E:40696 ||| VBN
as  ||| S:40696 E:40709 ||| RB
described  ||| S:40709 E:40719 ||| VBN
previously  ||| S:40719 E:40730 ||| RB
( ||| S:40730 E:40731 ||| -LRB-
Martins-Green  ||| S:40731 E:40745 ||| NNP
and  ||| S:40745 E:40749 ||| CC
Bissell ||| S:40749 E:40756 ||| NNP
,  ||| S:40756 E:40758 ||| ,
1990 ||| S:40758 E:40762 ||| CD
) ||| S:40762 E:40763 ||| -RRB-
.  ||| S:40763 E:40775 ||| .
Briefly ||| S:40775 E:40782 ||| RB
,  ||| S:40782 E:40784 ||| ,
probes  ||| S:40784 E:40791 ||| NNS
were  ||| S:40791 E:40796 ||| VBD
prepared  ||| S:40796 E:40805 ||| VBN
as  ||| S:40805 E:40808 ||| RB
follows ||| S:40808 E:40815 ||| VBZ
:  ||| S:40815 E:40817 ||| :
1  ||| S:40817 E:40819 ||| CD
μg  ||| S:40819 E:40822 ||| NN
of  ||| S:40822 E:40835 ||| IN
pGEM1 ||| S:40835 E:40840 ||| NNP
/ ||| S:40840 E:40841 ||| NNP
cCAF  ||| S:40841 E:40846 ||| NNP
cDNA  ||| S:40846 E:40851 ||| NNP
was  ||| S:40851 E:40855 ||| VBD
transcribed  ||| S:40855 E:40867 ||| VBN
for  ||| S:40867 E:40871 ||| IN
1  ||| S:40871 E:40873 ||| CD
1 ||| S:40873 E:40874 ||| CD
/ ||| S:40874 E:40875 ||| CD
2  ||| S:40875 E:40877 ||| CD
h  ||| S:40877 E:40879 ||| NN
at  ||| S:40879 E:40882 ||| IN
37°C  ||| S:40882 E:40887 ||| CD
in  ||| S:40887 E:40890 ||| IN
a  ||| S:40890 E:40902 ||| DT
cocktail  ||| S:40902 E:40911 ||| NN
containing  ||| S:40911 E:40922 ||| VBG
100  ||| S:40922 E:40926 ||| CD
μM  ||| S:40926 E:40929 ||| JJ
each  ||| S:40929 E:40934 ||| NN
of  ||| S:40934 E:40937 ||| IN
3H-ATP  ||| S:40937 E:40944 ||| NNP
and  ||| S:40944 E:40948 ||| CC
3H-UTP  ||| S:40948 E:40965 ||| NNP
( ||| S:40965 E:40966 ||| -LRB-
Amersham  ||| S:40966 E:40975 ||| NNP
Corp. ||| S:40975 E:40980 ||| NNP
) ||| S:40980 E:40981 ||| -RRB-
,  ||| S:40981 E:40983 ||| ,
1  ||| S:40983 E:40985 ||| CD
mM  ||| S:40985 E:40988 ||| JJ
each  ||| S:40988 E:40993 ||| DT
GTP  ||| S:40993 E:40997 ||| NNP
and  ||| S:40997 E:41001 ||| CC
CTP ||| S:41001 E:41004 ||| NNP
,  ||| S:41004 E:41006 ||| ,
120  ||| S:41006 E:41010 ||| CD
mM  ||| S:41010 E:41023 ||| JJ
dithiothreitol ||| S:41023 E:41037 ||| NN
,  ||| S:41037 E:41039 ||| ,
and  ||| S:41039 E:41043 ||| CC
100  ||| S:41043 E:41047 ||| CD
U  ||| S:41047 E:41049 ||| NNP
of  ||| S:41049 E:41052 ||| IN
T7  ||| S:41052 E:41055 ||| CD
polymerase  ||| S:41055 E:41066 ||| NNS
( ||| S:41066 E:41067 ||| -LRB-
Amersham  ||| S:41067 E:41086 ||| NNP
Corop. ||| S:41086 E:41092 ||| NNP
) ||| S:41092 E:41093 ||| -RRB-
.  ||| S:41093 E:41095 ||| .
The  ||| S:41095 E:41099 ||| DT
probe  ||| S:41099 E:41105 ||| NN
was  ||| S:41105 E:41109 ||| VBD
separated  ||| S:41109 E:41119 ||| VBN
from  ||| S:41119 E:41124 ||| IN
the  ||| S:41124 E:41128 ||| DT
free  ||| S:41128 E:41143 ||| JJ
nucleotides  ||| S:41143 E:41155 ||| NN
in  ||| S:41155 E:41158 ||| IN
a  ||| S:41158 E:41160 ||| DT
Sephadex  ||| S:41160 E:41169 ||| NNP
G-50  ||| S:41169 E:41174 ||| NNP
column  ||| S:41174 E:41181 ||| NN
equilibrated  ||| S:41181 E:41194 ||| NN
with  ||| S:41194 E:41209 ||| IN
50  ||| S:41209 E:41212 ||| CD
mM  ||| S:41212 E:41215 ||| JJ
tris ||| S:41215 E:41219 ||| NNS
( ||| S:41219 E:41220 ||| -LRB-
hydroxymethyl ||| S:41220 E:41233 ||| LS
)  ||| S:41233 E:41235 ||| -RRB-
aminomethane  ||| S:41235 E:41248 ||| FW
pH  ||| S:41248 E:41251 ||| FW
8.0 ||| S:41251 E:41254 ||| FW
,  ||| S:41254 E:41256 ||| ,
15  ||| S:41256 E:41259 ||| CD
mM  ||| S:41259 E:41272 ||| JJ
NaCl ||| S:41272 E:41276 ||| NN
,  ||| S:41276 E:41278 ||| ,
and  ||| S:41278 E:41282 ||| CC
1  ||| S:41282 E:41284 ||| CD
mM  ||| S:41284 E:41287 ||| JJ
EDTA ||| S:41287 E:41291 ||| NNP
.  ||| S:41291 E:41293 ||| .
For  ||| S:41293 E:41308 ||| IN
in  ||| S:41308 E:41311 ||| IN
situ  ||| S:41311 E:41316 ||| JJ
hybridization ||| S:41316 E:41329 ||| NN
,  ||| S:41329 E:41331 ||| ,
cells  ||| S:41331 E:41337 ||| NNS
were  ||| S:41337 E:41352 ||| VBD
fixed  ||| S:41352 E:41358 ||| VBN
in  ||| S:41358 E:41361 ||| IN
4 ||| S:41361 E:41362 ||| CD
%  ||| S:41362 E:41364 ||| NN
paraformaldehyde  ||| S:41364 E:41381 ||| VBZ
containing  ||| S:41381 E:41392 ||| VBG
5  ||| S:41392 E:41394 ||| CD
mM  ||| S:41394 E:41397 ||| JJ
MgCl  ||| S:41397 E:41413 ||| JJ
2  ||| S:41413 E:41415 ||| CD
,  ||| S:41415 E:41417 ||| ,
incubated  ||| S:41417 E:41427 ||| VBG
in  ||| S:41427 E:41430 ||| IN
0.1  ||| S:41430 E:41434 ||| CD
M  ||| S:41434 E:41436 ||| NNP
glycine  ||| S:41436 E:41444 ||| NN
for  ||| S:41444 E:41448 ||| IN
10  ||| S:41448 E:41461 ||| CD
min ||| S:41461 E:41464 ||| NN
,  ||| S:41464 E:41466 ||| ,
dehydrated  ||| S:41466 E:41477 ||| CD
3  ||| S:41477 E:41479 ||| CD
min  ||| S:41479 E:41483 ||| CD
each  ||| S:41483 E:41488 ||| DT
in  ||| S:41488 E:41491 ||| IN
30 ||| S:41491 E:41493 ||| CD
,  ||| S:41493 E:41495 ||| ,
70 ||| S:41495 E:41497 ||| CD
,  ||| S:41497 E:41499 ||| ,
and  ||| S:41499 E:41503 ||| CC
100 ||| S:41503 E:41506 ||| CD
%  ||| S:41506 E:41508 ||| NN
ethanol ||| S:41508 E:41515 ||| NN
,  ||| S:41515 E:41527 ||| ,
and  ||| S:41527 E:41531 ||| CC
allowed  ||| S:41531 E:41539 ||| VBN
to  ||| S:41539 E:41542 ||| TO
dry ||| S:41542 E:41545 ||| VB
.  ||| S:41545 E:41547 ||| .
Prehybridization  ||| S:41547 E:41564 ||| NNP
was  ||| S:41564 E:41568 ||| VBD
performed  ||| S:41568 E:41578 ||| VBN
in  ||| S:41578 E:41581 ||| IN
a  ||| S:41581 E:41593 ||| DT
solution  ||| S:41593 E:41602 ||| NN
containing  ||| S:41602 E:41613 ||| VBG
60 ||| S:41613 E:41615 ||| CD
%  ||| S:41615 E:41617 ||| NN
formamide ||| S:41617 E:41626 ||| NN
,  ||| S:41626 E:41628 ||| ,
0.1  ||| S:41628 E:41632 ||| CD
M  ||| S:41632 E:41634 ||| NNP
piperazine-  ||| S:41634 E:41657 ||| NNP
N ||| S:41657 E:41658 ||| NNP
, ||| S:41658 E:41659 ||| ,
N ||| S:41659 E:41660 ||| NNP
'  ||| S:41660 E:41662 ||| POS
-bis ||| S:41662 E:41666 ||| JJ
( ||| S:41666 E:41667 ||| -LRB-
2-ethanesulfonic  ||| S:41667 E:41684 ||| NNP
acid ||| S:41684 E:41688 ||| NN
)  ||| S:41688 E:41690 ||| -RRB-
pH  ||| S:41690 E:41703 ||| JJ
6.4 ||| S:41703 E:41706 ||| CD
,  ||| S:41706 E:41708 ||| ,
0.4  ||| S:41708 E:41712 ||| CD
M  ||| S:41712 E:41714 ||| NNP
NaCl ||| S:41714 E:41718 ||| NNP
,  ||| S:41718 E:41720 ||| ,
and  ||| S:41720 E:41724 ||| CC
0.2  ||| S:41724 E:41728 ||| CD
mg ||| S:41728 E:41730 ||| CD
/ ||| S:41730 E:41731 ||| CD
ml  ||| S:41731 E:41734 ||| NN
of  ||| S:41734 E:41748 ||| IN
E.  ||| S:41748 E:41751 ||| NNP
coli  ||| S:41751 E:41756 ||| FW
tRNA  ||| S:41756 E:41761 ||| FW
( ||| S:41761 E:41762 ||| -LRB-
Sigma ||| S:41762 E:41767 ||| NNP
,  ||| S:41767 E:41769 ||| ,
St.  ||| S:41769 E:41773 ||| NNP
Louis ||| S:41773 E:41778 ||| NNP
,  ||| S:41778 E:41780 ||| ,
MO ||| S:41780 E:41782 ||| NNP
)  ||| S:41782 E:41794 ||| -RRB-
for  ||| S:41794 E:41798 ||| IN
2  ||| S:41798 E:41800 ||| CD
h  ||| S:41800 E:41802 ||| NN
at  ||| S:41802 E:41805 ||| IN
55°C  ||| S:41805 E:41810 ||| CD
with  ||| S:41810 E:41815 ||| IN
gentle  ||| S:41815 E:41822 ||| JJ
shaking ||| S:41822 E:41829 ||| NN
.  ||| S:41829 E:41831 ||| .
The  ||| S:41831 E:41835 ||| DT
hybridization  ||| S:41835 E:41859 ||| JJ
solution  ||| S:41859 E:41868 ||| NN
was  ||| S:41868 E:41872 ||| VBD
the  ||| S:41872 E:41876 ||| DT
same  ||| S:41876 E:41881 ||| JJ
as  ||| S:41881 E:41884 ||| IN
the  ||| S:41884 E:41888 ||| DT
prehybridization  ||| S:41888 E:41905 ||| JJ
solution  ||| S:41905 E:41924 ||| NN
but  ||| S:41924 E:41928 ||| CC
contained  ||| S:41928 E:41938 ||| VBD
10  ||| S:41938 E:41941 ||| CD
6cpm ||| S:41941 E:41945 ||| CD
/ ||| S:41945 E:41946 ||| CD
ml  ||| S:41946 E:41949 ||| NN
of  ||| S:41949 E:41952 ||| IN
the  ||| S:41952 E:41956 ||| DT
cCAF  ||| S:41956 E:41961 ||| JJ
probe  ||| S:41961 E:41967 ||| NN
or  ||| S:41967 E:41970 ||| CC
with  ||| S:41970 E:41975 ||| IN
the  ||| S:41975 E:41989 ||| DT
same  ||| S:41989 E:41994 ||| JJ
number  ||| S:41994 E:42001 ||| NN
of  ||| S:42001 E:42004 ||| IN
counts  ||| S:42004 E:42011 ||| NNS
of  ||| S:42011 E:42014 ||| IN
the  ||| S:42014 E:42018 ||| DT
vector  ||| S:42018 E:42025 ||| JJ
probe  ||| S:42025 E:42031 ||| NN
and  ||| S:42031 E:42035 ||| CC
incubated  ||| S:42035 E:42055 ||| NN
at  ||| S:42055 E:42058 ||| IN
55°C  ||| S:42058 E:42063 ||| CD
for  ||| S:42063 E:42067 ||| IN
48  ||| S:42067 E:42070 ||| CD
h  ||| S:42070 E:42072 ||| NN
with  ||| S:42072 E:42077 ||| IN
gentle  ||| S:42077 E:42084 ||| JJ
shaking ||| S:42084 E:42091 ||| NN
.  ||| S:42091 E:42093 ||| .
At  ||| S:42093 E:42096 ||| IN
the  ||| S:42096 E:42100 ||| DT
end  ||| S:42100 E:42104 ||| NN
of  ||| S:42104 E:42107 ||| IN
this  ||| S:42107 E:42122 ||| DT
period ||| S:42122 E:42128 ||| NN
,  ||| S:42128 E:42130 ||| ,
the  ||| S:42130 E:42134 ||| DT
cultures  ||| S:42134 E:42143 ||| NNS
were  ||| S:42143 E:42148 ||| VBD
washed  ||| S:42148 E:42155 ||| VBN
twice  ||| S:42155 E:42161 ||| RB
with  ||| S:42161 E:42166 ||| IN
2×  ||| S:42166 E:42169 ||| NNP
SSC  ||| S:42169 E:42173 ||| NNP
+  ||| S:42173 E:42175 ||| CD
0.1 ||| S:42175 E:42178 ||| CD
%  ||| S:42178 E:42190 ||| NN
Triton-X  ||| S:42190 E:42199 ||| JJ
100  ||| S:42199 E:42203 ||| CD
for  ||| S:42203 E:42207 ||| IN
1  ||| S:42207 E:42209 ||| CD
h  ||| S:42209 E:42211 ||| NNS
followed  ||| S:42211 E:42220 ||| VBN
by  ||| S:42220 E:42223 ||| IN
two  ||| S:42223 E:42227 ||| CD
more  ||| S:42227 E:42232 ||| JJR
washes  ||| S:42232 E:42239 ||| NN
with  ||| S:42239 E:42254 ||| IN
0.1×  ||| S:42254 E:42259 ||| NNP
SSC  ||| S:42259 E:42263 ||| NNP
+  ||| S:42263 E:42265 ||| CD
0.1 ||| S:42265 E:42268 ||| CD
%  ||| S:42268 E:42270 ||| NN
Triton-X  ||| S:42270 E:42279 ||| JJ
100 ||| S:42279 E:42282 ||| CD
,  ||| S:42282 E:42284 ||| ,
all  ||| S:42284 E:42288 ||| DT
at  ||| S:42288 E:42291 ||| IN
55°C  ||| S:42291 E:42296 ||| CD
in  ||| S:42296 E:42299 ||| IN
the  ||| S:42299 E:42303 ||| DT
shaker ||| S:42303 E:42309 ||| NN
.  ||| S:42309 E:42321 ||| .
The  ||| S:42321 E:42325 ||| DT
cultures  ||| S:42325 E:42334 ||| NNS
were  ||| S:42334 E:42339 ||| VBD
allowed  ||| S:42339 E:42347 ||| VBN
to  ||| S:42347 E:42350 ||| TO
dry ||| S:42350 E:42353 ||| VB
,  ||| S:42353 E:42355 ||| ,
then  ||| S:42355 E:42360 ||| RB
covered  ||| S:42360 E:42368 ||| VBN
with  ||| S:42368 E:42383 ||| IN
emulsion  ||| S:42383 E:42392 ||| NN
and  ||| S:42392 E:42396 ||| CC
processed  ||| S:42396 E:42406 ||| VBN
as  ||| S:42406 E:42409 ||| RB
described  ||| S:42409 E:42419 ||| VBN
previously  ||| S:42419 E:42430 ||| RB
[  ||| S:42430 E:42432 ||| -LRB-
6  ||| S:42432 E:42434 ||| CD
]  ||| S:42434 E:42446 ||| -RRB-
.  ||| S:42446 E:42479 ||| .
Author ||| S:42479 E:42485 ||| NN
's  ||| S:42485 E:42488 ||| POS
contributions  ||| S:42488 E:42510 ||| NNS
JEF  ||| S:42510 E:42514 ||| VBP
carried  ||| S:42514 E:42522 ||| VBN
out  ||| S:42522 E:42526 ||| RP
all  ||| S:42526 E:42530 ||| DT
studies  ||| S:42530 E:42538 ||| NNS
except  ||| S:42538 E:42545 ||| IN
for  ||| S:42545 E:42549 ||| IN
the  ||| S:42549 E:42553 ||| DT
TN  ||| S:42553 E:42556 ||| NNP
antisense  ||| S:42556 E:42574 ||| VBD
inhibition  ||| S:42574 E:42585 ||| JJ
experiment ||| S:42585 E:42595 ||| NN
.  ||| S:42595 E:42597 ||| .
LW  ||| S:42597 E:42600 ||| NNP
and  ||| S:42600 E:42604 ||| CC
QJL  ||| S:42604 E:42608 ||| NNP
initials  ||| S:42608 E:42617 ||| VBD
carried  ||| S:42617 E:42625 ||| VBN
out  ||| S:42625 E:42629 ||| RP
the  ||| S:42629 E:42641 ||| DT
TN  ||| S:42641 E:42644 ||| NNP
antisense  ||| S:42644 E:42654 ||| NN
studies ||| S:42654 E:42661 ||| NNS
.  ||| S:42661 E:42663 ||| .
MMG  ||| S:42663 E:42667 ||| NNP
initials  ||| S:42667 E:42676 ||| VBD
conceived  ||| S:42676 E:42686 ||| VBN
and  ||| S:42686 E:42690 ||| CC
designed ||| S:42690 E:42698 ||| VBN
,  ||| S:42698 E:42708 ||| ,
with  ||| S:42708 E:42713 ||| IN
JEF ||| S:42713 E:42716 ||| NNP
,  ||| S:42716 E:42718 ||| ,
the  ||| S:42718 E:42722 ||| DT
studies ||| S:42722 E:42729 ||| NNS
,  ||| S:42729 E:42731 ||| ,
and  ||| S:42731 E:42735 ||| CC
contributed  ||| S:42735 E:42747 ||| VBD
to  ||| S:42747 E:42750 ||| TO
manuscript  ||| S:42750 E:42769 ||| VB
preparation  ||| S:42769 E:42781 ||| NN
and  ||| S:42781 E:42785 ||| CC
submission ||| S:42785 E:42795 ||| NN
.  ||| S:42795 E:42805 ||| .
All  ||| S:42805 E:42809 ||| DT
authors  ||| S:42809 E:42817 ||| NNS
read  ||| S:42817 E:42822 ||| VBP
and  ||| S:42822 E:42826 ||| CC
approved  ||| S:42826 E:42835 ||| VBD
the  ||| S:42835 E:42839 ||| DT
final  ||| S:42839 E:42845 ||| JJ
manuscript ||| S:42845 E:42855 ||| NN
.  ||| S:42855 E:42879 ||| .
List  ||| S:42879 E:42884 ||| NN
of  ||| S:42884 E:42887 ||| IN
abbreviations  ||| S:42887 E:42901 ||| VBG
used  ||| S:42901 E:42914 ||| VBN
cCAF  ||| S:42914 E:42919 ||| JJ
chicken  ||| S:42919 E:42927 ||| NN
Chemotactic  ||| S:42927 E:42939 ||| NNP
and  ||| S:42939 E:42943 ||| CC
Angiogenic  ||| S:42943 E:42954 ||| NNP
Factor  ||| S:42954 E:42969 ||| NNP
CEFs  ||| S:42969 E:42974 ||| FW
chicken  ||| S:42974 E:42982 ||| FW
embryo  ||| S:42982 E:42989 ||| FW
fibroblasts  ||| S:42989 E:43009 ||| FW
Coll  ||| S:43009 E:43014 ||| FW
collagen  ||| S:43014 E:43031 ||| FW
ECM  ||| S:43031 E:43035 ||| FW
extracellular  ||| S:43035 E:43049 ||| FW
matrix  ||| S:43049 E:43064 ||| FW
FN  ||| S:43064 E:43067 ||| FW
fibronectin  ||| S:43067 E:43087 ||| FW
IL-8  ||| S:43087 E:43092 ||| FW
interleukin-8  ||| S:43092 E:43114 ||| FW
MCP-1  ||| S:43114 E:43120 ||| FW
monocyte  ||| S:43120 E:43129 ||| FW
chemotactic  ||| S:43129 E:43141 ||| FW
protein-1  ||| S:43141 E:43159 ||| FW
MGSA  ||| S:43159 E:43164 ||| FW
melanoma  ||| S:43164 E:43173 ||| FW
growth  ||| S:43173 E:43180 ||| FW
stimulatory  ||| S:43180 E:43192 ||| FW
activity  ||| S:43192 E:43209 ||| FW
MMP  ||| S:43209 E:43213 ||| FW
matrix  ||| S:43213 E:43220 ||| FW
metalloprotease  ||| S:43220 E:43244 ||| FW
PA  ||| S:43244 E:43247 ||| FW
plasminogen  ||| S:43247 E:43259 ||| FW
activator  ||| S:43259 E:43277 ||| FW
TGFβ1  ||| S:43277 E:43283 ||| FW
transforming  ||| S:43283 E:43296 ||| FW
growth  ||| S:43296 E:43303 ||| FW
factor  ||| S:43303 E:43310 ||| FW
β1  ||| S:43310 E:43321 ||| FW
TIMP  ||| S:43321 E:43326 ||| FW
tissue  ||| S:43326 E:43333 ||| FW
inhibitor  ||| S:43333 E:43343 ||| FW
of  ||| S:43343 E:43346 ||| FW
metalloprotease  ||| S:43346 E:43370 ||| FW
TN  ||| S:43370 E:43373 ||| FW
tenascin  ||| S:43373 E:43397 ||| FW
